Document:

EX-10.8

 Exhibit 10.8 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS
OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[*].” 
 EXECUTION COPY 

TECHNOLOGY LICENSING AGREEMENT 

This Technology Licensing Agreement (“Agreement”) is effective as of the Effective Date and is by and between Dow Global
Technologies Inc. and/or The Dow Chemical Company (hereinafter both are referred to as “Dow”), both Delaware corporations having their principal offices at either 2040 Dow Center, Midland, MI, 48674 USA or 2030 Dow Center, Midland, MI,
48674 USA and Pfenex Inc., a Delaware corporation (hereinafter “Pfenex”) having a principal place of business at 5501 Oberlin Drive, San Diego, CA. 

RECITALS 
 WHEREAS,
Dow owns the rights to a certain series of patents related to Pseudomonas fluorescens expression technology and made substantial patented and unpatented improvements to such technology, now generally known as “Pfenex Expression
TechnologyTM”; 
 WHEREAS, Dow has certain rights to a certain series of patents
related to RNA viruses; 
 WHEREAS, Dow has certain rights to a certain series of patents related to the use or transgenic plants for oral
immunization of animals; 
 WHEREAS, Dow owns the rights to a certain series of patents related to production techniques for proteins; 

WHEREAS, Dow has certain rights to a certain series of patents related to the ARC technology; 

WHEREAS, Pfenex desires to take a license to such intellectual property as further defined below. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as
follows: 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 1 - 

 EXECUTION COPY 
  

	ARTICLE 1	DEFINITIONS 

 1.01 Affiliates: “Affiliates” shall mean any entity that, directly
or indirectly through one or more intermediates, controls, is controlled by or is under common control with either Dow or Pfenex, where “controls”, “controlled by”, and “is under common control” means ownership,
directly or indirectly, of fifty percent (50%) or more of the voting equity interest in the entity or the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of that entity, whether
through ownership or voting securities, by contract or otherwise. 
 1.02 ARC Products: “ARC Products” shall mean any product or part of a
product, the making, using, importing or selling of which, absent the license set forth in Section 2.01, infringes a Valid Claim within the ARC Patents. 

1.03 ARC Patents. “ARC Patents” shall mean the Patents owned or Controlled by Dow or its Affiliates as of the Effective Date, or at anytime
during the Term, that are necessary or useful for the manufacture, use, or sale of ARC Products, including without limitation, the Gaertner patent as listed in Appendix D. 

1.04 Assets: “Assets” shall mean collectively the RNA Virus Patents, the Oral Immunization Patents, the Production Techniques Patents, the
ARC Patents and the rights granted to Pfenex under Section 2.01.05. 
 1.05 Control: “Control” in the context of intellectual property
rights, shall mean rights to intellectual property sufficient to grant the applicable license or sublicense under this Agreement without violating the terms of any written agreement with any Third Party in effect as of the Effective Date.
“Controlled” and “Controlling” shall have their correlative meanings. 
 1.06 Effective Date: “Effective Date” shall
mean November 30, 2009. 
 1.07 Field: “Field” shall mean any and all applications for therapeutic purposes in humans for any and all
indications, including, for the avoidance of doubt, vaccines. For 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 2 - 

 EXECUTION COPY 
  

 
the purposes of this definition, “therapeutic purposes” shall mean, with respect to a particular indication, human diagnostics, prophylaxis, cure, reduction, mitigation, prevention,
slowing or halting the progress of, or otherwise management of such indication. 
 1.08 Net Sales: “Net Sales” shall mean the sales
revenues actually received by Pfenex from sales of the applicable Product (as set forth in Article 3) to Third Party customers, less: (a) Customary trade, quantity or cash discounts, credits and rebates (including, without limitation, credits,
rebates and other discounts made or given with respect to Federal, state or foreign governmental programs (including, without limitation, Medicaid and Medicare) public or private hospitals and managed care entities or patient care organizations),
and non-affiliated brokers’ or agents’ commissions actually allowed and taken; (b) Amounts repaid or credited by reason of rejection or return, including chargebacks, refunds or rebates (including expenses related to disposal);
(c) Fees payable to purchasers, sales agents, distributors, group purchasing organizations or government agencies; (d) costs of insurance, packaging, storage and transportation from the place of manufacture to the customer’s premises;
(e) provisions for uncollectible accounts determined in accordance with generally accepted accounting practices, consistently applied to all products of Pfenex; and/or (f) Taxes levied on and/or other governmental charges made as to
production, import, export, sale, receipt, value-add, transportation, delivery, custom duties or use and paid by or on behalf of Pfenex for the RNA Virus Products, and less the sum of the following a) sales taxes, tariff duties and/or use taxes; b)
direct, external out-of-pocket expenses incurred by Pfenex; and c) amounts rebated, credited or refunded on returns for the Oral Immunization Products. 

1.09 Oral Immunization Products: “Oral Immunization Products” shall mean any product or part of a product, the making, using, importing or
selling of which, absent the license set forth in Section 2.01, infringes a Valid Claim within the Oral Immunization Patents. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 3 - 

 EXECUTION COPY 
  

 1.10 Oral Immunization Patents. “Oral Immunization Patents” shall mean the Patents owned or
Controlled by Dow or its Affiliates as of the Effective Date, or at anytime during the Term, that are necessary or useful for the manufacture, use, or sale of Oral Immunization Products, including without limitation, the Curtiss & Cardineau
patents as listed in Appendix B. 
 1.11 Parties: “Parties” shall mean collectively Pfenex and Dow. 

1.12 Party: “Party” shall mean either Pfenex or Dow as the case may be. 

1.13 Patents: “Patents” shall have the meaning set forth in the Technology Assignment Agreement. 

1.14 Product(s): “Product” shall mean individually the RNA Virus Products, the Oral Immunization Products, the Production Techniques Products
or the ARC Products, and “Products” shall mean collectively the RNA Virus Products, the Oral Immunization Products, the Production Techniques Products and the ARC Products. 

1.15 Production Techniques Products: “Production Techniques Products” shall mean any product or part of a product, the making, using,
importing or selling of which, absent the license set forth in Section 2.01, infringes a Valid Claim within the Production Techniques Patents. 
 1.16
Production Techniques Patents. “Production Techniques Patents” shall mean the Patents owned or Controlled by Dow or its Affiliates as of the Effective Date, or at anytime during the Term, that are necessary or useful for the
manufacture, use, or sale of Production Techniques Products, including without limitation, the patents related to production techniques for various proteins as listed in Appendix C. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 4 - 

 EXECUTION COPY 
  

 1.17 RNA Virus Products: “RNA Virus Products” shall mean any product or part of a product,
the making, using, importing or selling of which, absent the license set forth in Section 2.01, infringes a Valid Claim within the RNA Virus Patents. 

1.18 RNA Virus Patents. “RNA Virus Patents” shall mean the Patents owned or Controlled by Dow or its Affiliates as of the Effective Date, or
at anytime during the Term, that are necessary or useful for the manufacture, use, or sale of RNA Virus Products, including without limitation, the Ahlquist patents as listed in Appendix A. 

1.19 Third Party: “Third Party” shall mean any person, organization, firm, corporation, partnership or entity other than Pfenex, Dow and
their respective Affiliates. 
 1.20 Valid Claim: “Valid Claim” shall mean a claim of an issued, unexpired Patent within the RNA Virus
Patents, the Oral Immunization Patents, the Production Techniques Patents or the ARC Patents, as the case may be, which: (a) has not been held unpatentable, invalid or unenforceable by a court or other government agency of competent
jurisdiction in a decision from which no appeal can or has been taken; and (b) which has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 

1.21 All capitalized terms used in this Agreement that are not explicitly defined herein shall have the corresponding meanings set forth in the Contribution,
Assignment and Assumption Agreement, the Technology Assignment Agreement or the Grant-Back and Technology License Agreement.  
  

	ARTICLE 2	TRANSFER AND LICENSE OF ASSETS 

 2.01 Grant to Pfenex 

2.01.01 RNA Virus Patents: Dow hereby grants to Pfenex a worldwide royalty bearing license/sublicense, including the right to grant and
authorize sublicenses in accordance with Section 2.02, under the RNA Virus Patents to: (a) make, have made, use, sell, offer for sale and import RNA Virus Products; 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 5 - 

 EXECUTION COPY 
  

 
(b) practice any method, process or procedure in connection with its exercise of the activities described in clause (a) above; and (c) otherwise exploit the RNA Virus Patents. The
license/sublicense set forth in this Section 2.01.01 shall be exclusive (even as to Dow) in the Field. 
 2.01.02 Oral Immunization
Patents: Dow hereby grants to Pfenex a worldwide royalty bearing license/sublicense, including the right to grant and authorize sublicenses in accordance with Section 2.02, under the Oral Immunization Patents to: (a) make, have made,
use, sell, offer for sale and import Oral Immunization Products; (b) practice any method, process or procedure in connection with its exercise of the activities described in clause (a) above; and (c) otherwise exploit the Oral
Immunization Patents. The license/sublicense set forth in this Section 2.01.02 shall be exclusive (even as to Dow) in the Field. 

2.01.03 Production Techniques Patents: Dow hereby grants to Pfenex a worldwide fully paid up, non-exclusive royalty-free license in the
Field, including the right to grant and authorize sublicenses in accordance with Section 2.02, under the Production Techniques Patents to: (a) make, have made, use, sell, offer for sale and import Production Techniques Products;
(b) practice any method, process or procedure in connection with its exercise of the activities described in clause (a) above; and (c) otherwise exploit the Production Techniques Patents. 

2.01.04 ARC Patents: Dow hereby grants to Pfenex a worldwide fully paid up, royalty-free license, including the right to grant and
authorize sublicenses in accordance with Section 2.02, under the ARC Patents to: (a) make, have made, use, sell, offer for sale and import ARC Products; (b) practice any method, process or procedure in connection with its exercise of
the activities described in clause (a) above; and (c) otherwise exploit the ARC Patents. The license/sublicense set forth in this Section 2.01.04 shall be exclusive (even as to Dow) in the Field. 

2.01.05 To the fullest extent Dow has or may receive rights under Section 4.7 of the License Agreement between DGTI and Diversa
Corporation dated December 30, 2003 (“Diversa Agreement”), Dow hereby grants to Pfenex: 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 6 - 

 EXECUTION COPY 
  

 2.01.05.01 A perpetual, worldwide, royalty-free, non-exclusive license or
sublicense in the Field, as applicable, with the right to grant and authorize sublicenses in accordance with Section 2.02, under any DIVERSA patents or patent applications which have a priority date after December 19, 1997, and which are
listed in the Diversa Agreement as may be amended, and which contain teachings or claims which both i) are directed to Pseudomonas organisms and ii) include information derived from the use of the TDCC Technology and/or Sequestered
Information, in each case to: (a) make, have made, use, sell, offer for sale, import or otherwise exploit any product and (b) practice any method, process or procedure in connection with its exercise of the activities described in clause
(a) above. This license shall not include DIVERSA Genes, DIVERSA intellectual property directed to the functional applications of the protein or the use of the Gene with any other organism. 

2.01.05.02 A worldwide, royalty-free, immunity in the Field from suit under any DIVERSA patents as set forth in the Diversa
Agreement directed to the use of the genus Pseudomonas as an expression system. This immunity from suit does not extend to DIVERSA Genes, DIVERSA intellectual property directed to the functional applications of the proteins or the use of the
Gene with any genus other than Pseudomonas. 
 2.01.05.03 For the purposes of this Section 2.01.05 the terms
“DIVERSA,” “TDCC Technology,” “Sequestered Information,” “DIVERSA Genes” and “Gene” shall have the meanings set forth in the Diversa Agreement. 

2.01.05.04 Prior to, or shortly after the Closing Date, Dow shall use reasonable efforts to cause Dow AgroScience
(“DAS”) to obtain from Diversa (or its successor-in-interest) sufficient rights to effectuate the grant of rights from Dow to Pfenex in Sections 2.01.05.01 and 2.01.05.02, in writing, signed by the authorized representatives of the
applicable parties. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 7 - 

 EXECUTION COPY 
  

 2.02 Sublicensing Rights. 

2.02.01 Extension of Licenses to Affiliates. Pfenex may extend the rights under the licenses granted in Section 2.01 to
one (1) or more of its Affiliates; provided that Pfenex shall remain responsible for such Affiliate’s compliance with all obligations under this Agreement applicable to such Affiliate. 

2.02.02 Sublicenses. Provided Pfenex has the right to grant further sublicenses or extend other rights under any Assets, Pfenex may
grant and authorize sublicenses to Third Parties under the rights granted in Section 2.01 above. With respect to each sublicense granted by Pfenex to a Third Party, such sublicense shall include an explicit reference to this Agreement and
shall not conflict with, and shall be subordinate to, the terms and conditions of this Agreement. 
  

	ARTICLE 3	Royalties 

 3.01: RNA Virus Patents: Subject to the terms and conditions of this Agreement,
if Pfenex makes commercial sales of a RNA Virus Product, Pfenex shall pay Dow a running royalty of [*] of the Net Sales of such RNA Virus Product, wherein said royalties are due within 150 days of the end of each year in which such sale is made.

 3.02 Oral Immunization Patents: If Pfenex makes commercial sales of an Oral Immunization Product, Pfenex shall pay Dow the following to the extent
owed pursuant to the license agreement between Washington University and Agrigenetics dated December 30, 1996 (“Washington University ’96 Agreement”): 

3.02.01 A minimum payment due December 31st of each year of [*], such
payment obligation commencing at the end of the first full year during which Pfenex has made such commercial sales of an Oral Immunization Product. The payments made by Pfenex to Dow under this Section 3.02.01 shall be creditable against the
running royalty rate owed by Pfenex to Dow under Section 3.02.02. 
 3.02.02 A running royalty, which shall equal the
lesser of: (A) [*] of the Net Sales of such Oral Immunization Products or (B) the royalty percentage of the Net Sales of such Oral Immunization Products owed by Dow to Washington University pursuant to the Washington University ’96
Agreement; wherein such royalty payments shall be due December 31st of each year in which such sale is made. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 8 - 

 EXECUTION COPY 
  

 3.02.03 Within thirty (30) days after the end of each Contract Year
prior to First Commercial Sale (“Contract Year” and “First Commercial Sale” shall have the meanings ascribed to them in the Washington University ’96 Agreement), an annual maintenance royalty of [*] which will be fully
creditable against the royalties owed under Section 3.02.02. The payment obligation set forth in this section 3.02.03 shall commence in January 2010. 

3.02.04 Third Party Payments. If Pfenex, its Affiliate or sublicensee pays amounts to a Third Party under any agreement
to license or acquire intellectual property reasonably necessary for Pfenex, its Affiliate or sublicensee to develop or commercialize Products, then Pfenex may deduct [*] of such amounts from the amounts payable to Dow with respect to such Product
pursuant to this Article 3; provided that, in no event shall the amounts due to Dow be so reduced to less than [*] of the amount that would otherwise be payable to Dow under this Article 3.02.02. For clarity, any amounts not offset in a particular
period as a result of the cap in the preceding sentence shall be creditable in future periods. Subject to Section 3.02.02, in no event will the running royalty be less than [*]. 

3.03 Certain Terms. 
 3.03.01
Combination Product. In the event that a Product is sold in combination with another product, component or service for which no royalty would be due hereunder if sold separately, Net Sales from such combination product sales for purposes of
calculating the amounts payable by Pfenex under this Article 3 shall be calculated by multiplying the Net Sales of the combination product by the fraction A/(A + B), where “A” is the average gross selling price during the previous calendar
quarter of such Product sold separately and “B” is the gross selling price during the previous calendar quarter of the other product(s), component(s) or service(s). In the event that a substantial number of such separate sales of such
Product or such other product(s), 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 9 - 

 EXECUTION COPY 
  

 
component(s) or services(s) were not made during the previous calendar quarter, then the Net Sales shall be as reasonably allocated by Pfenex between such Product and such other product(s),
component(s) or service(s) based upon their relative importance and proprietary protection. 
 3.03.02 Single Royalty. No more than
the one royalty shall be due under this Agreement, as set forth in Section 3.01, with respect to the sale of a particular unit of any Product. No royalty shall be payable under this Article 3 with respect to sales of Products among Pfenex, its
Affiliates and its sublicensees for resale, nor shall a royalty be payable under this Article 3 with respect to any Products transferred for use in research or development, in clinical trials, in compassionate use programs, as donations to
non-profit institutions or government agencies, or as promotional free samples or the like. 
 3.03.03 Royalty Term. Pfenex’s
obligation to pay royalties under this Article 3 shall continue on a country-by-country and product-by-product basis until the expiration of the last Valid Claim in such country covering the sale of such Product. Thereafter, no further royalties
shall be due with respect to such Product in such country. 
 3.03.05 Royalty Reports and Payments. Commencing with the first
commercial sale of a Product by Pfenex hereunder, Pfenex shall provide to Dow a written report for each calendar quarter during the term of this Agreement, showing: (a) the gross sales of all Products sold by Pfenex during such calendar quarter
and the calculation of Net Sales of Products from such gross sales; (b) a calculation of total royalties, payable in United States Dollars, which have accrued under this Agreement based upon such Net Sales of the Products; and (c) any
reductions to or deductions from payments taken by Pfenex in accordance with this Agreement. If no royalties are due, Pfenex shall so report. Reports to be provided by Pfenex to Dow under this Section 3.03.05 shall be due sixty (60) days
following the end of each calendar quarter. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 10 - 

 EXECUTION COPY 
  

	ARTICLE 4	CONSIDERATION FOR THE ASSETS 

 4.01 In consideration for Dow’s license/sublicense under the
Assets and other intellectual property hereunder, Pfenex shall issue to Dow shares of Series A-1 Preferred Stock of Pfenex as set forth in that certain Contribution, Assignment and Assumption Agreement by and between Dow and Pfenex of even date
herewith. 
  

	ARTICLE 5	PFENEX REPRESENTATIONS AND WARRANTIES 

 5.01 Pfenex is a corporation duly organized and validly
existing under the laws of the State of Delaware. 
 5.02 Pfenex has all the necessary power and authority to execute deliver and perform this Agreement,
and no approvals or consents of anyone other than the signatories below are necessary in connection with the execution and delivery of this Agreement. 

5.03 This Agreement has been duly executed and delivered by Pfenex and constitutes a legal, valid and binding obligation of Pfenex enforceable in accordance
with its terms. 
 5.04 To the extent required of the licensee under the Washington University ’96 Agreement or under the Agreement between
Agrigenetics and University of Wisconsin dated December 23, 1982 (“Wisconsin Agreement”), Pfenex shall provide activity reports to Washington University under the Washington University ’96 Agreement or to University of Wisconsin
under the Wisconsin Agreement. Such activity reports shall comply with the format specified under the Washington University ’96 Agreement and shall include details about its activities and progress made, the status of any licensed products
under development and/or planned for development, the tasks necessary to develop or complete the development and introduction of products to market, the estimated time schedules for product development, clinical trials, market testing, and
regulatory approval, or the Wisconsin Agreement, as applicable. Upon delivery of such activity reports, Pfenex shall provide notice to Dow indicating that Pfenex has delivered the applicable activity report. Pfenex will use diligent efforts to bring
a product to market using the RNA Virus Patents and the Oral Immunization Patents. Failure to use diligent efforts may result in a loss of license to the RNA Virus Patents and the Oral Immunization Patents. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 11 - 

 EXECUTION COPY 
  

	ARTICLE 6	DOW REPRESENTATIONS AND WARRANTIES 

 6.01 The Dow Chemical Company and Dow Global Technologies
Inc. are corporations duly organized and validly existing under the laws of the State of Delaware. 
 6.02 The Dow Chemical Company and Dow Global
Technologies Inc. have all the necessary power and authority to execute deliver and perform this Agreement, and no approvals or consents of anyone (except certain additional Dow personnel) other than the signatories below are necessary in connection
with the execution and delivery of this Agreement. 
 6.03 To the best of its knowledge as of the Effective Date, Dow has all rights to grant the licenses
or sublicenses to the Assets, subject to Permitted Liens (as that term is defined in the Contribution, Assignment and Assumption Agreement and Schedule 1.17 therein) , and other performance promised to Pfenex under this Agreement and has good title
to all information and materials which are included in the rights and intellectual property transferred to Pfenex pursuant to this Agreement, free and clear of any liens, judgments, encumbrances or adverse claims. For clarity, Dow will not, during
the term of this Agreement, grant any rights to any Third Party that are inconsistent with the rights granted to Pfenex under this Agreement. 
 6.04 To the
best of its knowledge as of the Effective Date, Dow is not aware of any claims, demands or actions alleging that any of the Assets licensed or sublicensed in this document are invalid or unenforceable. This provision does not include a
representation or warrantee by Dow that any or all of the patent rights will grant or issue as valid patents. 
 6.05 To the best of its knowledge as of the
Effective Date, Dow has not received any notice claiming that the Assets violate or infringe any intellectual property rights of any Third Party. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 12 - 

 EXECUTION COPY 
  

 6.06 With regards to Third Party Agreements: 

6.06.01 As of the Effective Date, Exhibit 6.06.01 of this Agreement lists all the agreements between Dow and Third Parties pursuant to
which Dow has in licensed, has gained Control of or acquired any Patents within the Assets (each, a “Third Party Agreement”); 

6.06.02(i) Dow has previously provided to Pfenex a redacted (all material terms for the purposes of this Agreement have not been deleted) copy
of each Third Party Agreement as the same is in effect as of the Effective Date, (ii) each Third Party Agreement is in full force and effect as of the Effective Date and Dow shall maintain each Third Party Agreement in full force and effect and
enforce each Third Party Agreement to its fullest extent, in each case in accordance with its terms and conditions during the term of the Agreement subject to Section 5.04, (iii) as of the Effective Date, no notice of default or
termination has been received or given by Dow under any Third Party Agreement, and (iv) during the term of this Agreement, Dow shall not amend or otherwise modify any Third Party Agreement to license out such technology in the Field, or allow
any Third Party Agreement to be terminated, unless Pfenex fails to comply with the terms of such Third Party Agreement, without the prior consent of Pfenex; and 

6.06.03 In the event of any notice of breach by Dow or its Affiliates, as applicable, of any Third Party Agreement the termination of which
will or is likely to adversely affect Pfenex’s rights or obligations under this Agreement, Dow shall as promptly as reasonably practicable notify Pfenex in writing and Pfenex shall have the right, but not the obligation, to cure such breach on
behalf of Dow or its Affiliates, as applicable. In the event of any notice of breach by the counterparty of any Third Party Agreement in a manner that will or is likely to adversely affect Pfenex’s rights or obligations under this Agreement,
Dow shall immediately notify Pfenex. 
 6.07 Except for the express warranties in this article, Dow makes no representations or warranties, express or
implied, either in fact or by operation of law, regarding without limitation, the validity or scope of any patent rights conveyed or including, without limitation, performance, merchantability, fitness for a particular purpose, or the
non-infringement of third party intellectual property rights. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 13 - 

 EXECUTION COPY 
  

	ARTICLE 7	PATENT PROSECUTION AND ENFORCEMENT 

 7.01 Patent Prosecution and Maintenance. 

7.01.01 Control of Prosecution. As between the Parties, Dow shall control the Prosecution and Maintenance of all Assets.
Notwithstanding the foregoing, Dow agrees to: (i) provide Pfenex with copies of all patent applications, continuations, divisionals, re-examinations, reissues, any and all office actions and requests for patent term extensions and the like
including foreign counterparts thereof in existence as of the Effective Date within the Production Techniques Patents at least fifteen (15) business days before the due date for comment or with respect to foreign applications and office
actions, as soon as reasonably practicable before the due date for comment; and (ii) consult in good faith with Pfenex regarding such matters with respect to the Field. Such copies may be provided electronically. For the purposes of this
Section 7.01, “Prosecution and Maintenance” (including variations such as “Prosecute and Maintain”) shall mean, with respect to a Patent, the preparing, filing, prosecuting and maintenance of such Patent, as well as
continuations, divisionals, re-examinations, reissues and requests for patent term extensions and the like with respect to such Patent, together with the conduct of interferences, oppositions and other similar proceedings with respect to a Patent.

 7.01.02 In the event Dow decides to abandon an application or patent within the Production Techniques Patents that relates to the Field,
Dow shall provide Pfenex fifteen (15) business days notice in which Pfenex will have the right to Prosecute and Maintain any such application or patent at its own cost. For the purposes of 7.01.02, “abandon” will include abandoning
the Prosecution and Maintenance of a particular Patent without filing a divisional, continuation, continuation-in-part or foreign counterpart for such abandoned Patent. 

7.01.03 Cooperation. Both Parties shall cooperate with each other in connection with all activities relating to the Prosecution and
Maintenance of the Production Techniques Patents. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 14 - 

 EXECUTION COPY 
  

 7.02 Enforcement. 

7.02.01 Notice. In the event that either Party reasonably believes that any Oral Immunization Patents, Production Techniques Patents,
or ARC Patents are being infringed by a Third Party, or is subject to a declaratory judgment action arising from such infringement, in each case with respect to the manufacture, sale or use of a product for use within or outside the Field (an
“Infringing Product”), such Party shall promptly notify the other Party. 
 7.02.02 Initiating Enforcement Actions. Pfenex
and/or its Affiliates shall have the right (but not the obligation), at its own expense, to enforce the Oral Immunization Patents, Production Techniques Patents, or ARC Patents, or to defend any declaratory judgment action with respect to the Oral
Immunization Patents, Production Techniques Patents, or ARC Patents (each, an “Enforcement Action”) in cases where the Infringing Product is marketed and sold for use within the Field. Pfenex shall provide notice to Dow in writing after
taking any action to enforce, or threat to enforce, or defend any Enforcement Action and agrees to: (i) provide Dow with copies of and an opportunity to review and comment on all material communications, motions, filings, briefs, submissions
and the like regarding the validity, enforcement (including ownership) and scope (including claim construction) of any of the Oral Immunization Patents, Production Techniques Patents, or ARC Patents, at Dow’s expense, at least fifteen
(15) business days before the due date for filing or comment; and (ii) consider in good faith any comments provided by Dow regarding such matters. If Pfenex elects not to enforce or defend an Enforcement Action in a case where the
Infringing Product is marketed and sold solely for use in, and is used solely in, the Field, within ninety (90) days after its receipt of a request from Dow to do so, Dow shall thereafter have the right, at its own expense, to either initiate
and prosecute such action or to control the defense of such declaratory judgment action in its own name. Additionally, Dow shall have the right (but not the obligation), at its own expense, to enforce the Production Techniques Patents, or to defend
any declaratory judgment action with respect thereto, in all other cases, including in cases where the Infringing Product is marketed and sold solely for use outside, and is used solely outside, the Field. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 15 - 

 EXECUTION COPY 
  

 7.02.03 Cooperation. Without limiting any rights of comment and review in
Section 7.02.02, the Party initiating or defending any Enforcement Action pursuant to this Section 7.02 shall keep the other Party reasonably informed of the progress of any such Enforcement Action, and such other Party shall have the
right to participate with counsel of its own choice and at its own expense. Notwithstanding the foregoing right to participate in any Enforcement Action, the Parties shall assist one another and cooperate in any such Enforcement Action, as
reasonably requested by the Party initiating such Enforcement Action, at such Party’s expense. 
  

	ARTICLE 8	NOTICES 

 8.01 Any notice or other communication required or permitted to be given by either party
under this Agreement shall be given in writing and shall be effective when delivered, if delivered by hand, reputable courier service, facsimile with confirmation of transmission, email with confirmation of receipt or five days after mailing if
mailed by registered or certified mail, postage prepaid and return receipt requested, addressed to each party at the following addresses or such other address as may be designated by written notice by either Party: 

If to Pfenex: 
 Chief Executive Officer 

5501 Oberlin Drive 
 San Diego, CA 92121 

Fax: 858-352-4602 
 Email: [To be designated by written notice
to Dow] 
 If to Dow: 
 The Dow Chemical Company 

9330 Zionsville Road 
 Indianapolis, IN 46268 

Attention: General Patent Counsel 
 Fax: 317-337-4847 

Email: jkabramson@dow.com and mdlyons@dow.com 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 16 - 

 EXECUTION COPY 
  

	ARTICLE 9	TERM AND TERMINATION 

 9.01 Term. This Agreement shall commence on the Effective Date and,
unless terminated earlier as provided in this Article 9, shall continue in full force and effect until the last to expire of the Patents within the Assets. Upon the expiration (but not the earlier termination) of this Agreement in a given country in
accordance with this Article 9, the licenses and rights granted by Dow to Pfenex under this Agreement will continue on a fully paid-up, royalty-free and irrevocable basis in such country. 

9.02 Termination By Pfenex. Pfenex shall have the right to terminate this Agreement, in its entirety or on a Patent-by-Patent or a Product-by-Product
basis, in its sole discretion, upon thirty (30) days prior written notice to Dow. From and after the effective date of such termination under this Section 9.02 with respect to a particular patent or product, such patent or product shall
cease to be within the definition of the Patents within the Assets or Products, as applicable, for all purposes of this Agreement, and the rights and licenses granted by Dow to Pfenex under Article 2 shall terminate and all rights in the Assets
shall revert to Dow with respect to such patent or product. Upon termination of this Agreement in its entirety under this Section 9.02, all rights and obligations of the Parties shall terminate, except as provided in Section 9.03 below.
Notwithstanding the foregoing, Pfenex shall not terminate for a period of three (3) years following the Effective Date those licenses granted to Pfenex under this Agreement that are non-royalty bearing licenses. For clarity, Pfenex shall have
the right to terminate such non-royalty bearing licenses at any time after such three (3) year period as set forth in this Article 9 and shall at any time be permitted to terminate any royalty-bearing license granted hereunder. 

9.03 Effect of Expiration or Termination. Upon termination of this Agreement by Pfenex pursuant to Section 9.02, in its entirety or on a
Patent-by-Patent or a Product-by-Product basis, the applicable rights and licenses granted by Dow to Pfenex under Article 2 shall terminate and the applicable rights in the Assets shall revert to Dow, provided, however, that: 

9.03.01 Stock on Hand. Pfenex shall have the right to sell or otherwise dispose of all applicable Products in the process of
manufacture, testing, in use or in stock; subject to the obligation of Pfenex to pay royalties to Dow for such Products in accordance with Article 3. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 17 - 

 EXECUTION COPY 
  

 9.03.02 Sublicenses. Any applicable sublicense granted by Pfenex under
Section 2.02 prior to its receipt of the corresponding notice of such termination shall survive if the relevant sublicensee agrees in writing to be bound by the terms of this Agreement as such terms apply to such sublicensee (in which event,
such sublicensee will be deemed a direct licensee of Dow); provided that, any such sublicensee shall only be responsible for any payments that become due as a result solely of such sublicensee’s activities after the effective date of any such
termination and such sublicensee will be credited for any payments already paid by Pfenex prior to the effective date of any such termination as if such payment had been made by such sublicensee. 

9.03.03 Survival of Certain Obligations. Subject to Section 9.03, expiration or termination of this Agreement for any reason shall
not relieve either Party of any obligation accruing on or prior to such expiration or termination, or which is attributable to a period prior to such expiration or termination, nor preclude either Party from pursuing any rights and remedies it may
have under this Agreement, or at law or in equity, which accrued or are based upon any event occurring prior to such expiration or termination. The provisions of Articles 1-3, 5-7, 9 and 10 (in each case as may be applicable in the event of
termination on a Patent-by-Patent or a Product-by-Product basis) shall survive the expiration or termination of this Agreement for any reason. 
  

	ARTICLE 10	MISCELLANEOUS 

 10.01 Assignment: This Agreement and all rights herein may not be assigned
by Pfenex without the prior written consent of Dow; provided that Pfenex may assign, without the prior written consent of Dow, all or part of this Agreement to an Affiliate or to an entity acquiring all or substantially all of the assets and
business of a Pfenex to which this Agreement relates by merger, consolidation, public offering, or change of control, and such entity undertakes in writing all of the obligations and responsibilities of Pfenex under this Agreement. Dow may assign
this Agreement, in whole or in part, without the written consent of Pfenex; provided that, prior to such assignment, the assignee agrees in writing to be bound by the terms and conditions of this Agreement. The terms and

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 18 - 

 EXECUTION COPY 
  

 
conditions of this Agreement shall be binding on and inure to the benefit of the permitted successors and assigns of the Parties. Except for assignments expressly permitted under this
Section 10.01, any attempted assignment or transfer of this Agreement shall be null and void. 
 10.02 Severability: If any clause, provision,
or section of this Agreement, shall, for any reason, be held illegal, invalid or unenforceable, the Parties shall negotiate in good faith and in accordance with reasonable standards of fair dealing, a valid, legal, and enforceable substitute
provision or provisions that most nearly reflect the original intent of the Parties under this Agreement in a manner that is commensurate in magnitude and degree with the changes arising as a result of any such substitute provision or provisions.
All other provisions in this Agreement shall remain in full force and effect and shall be construed in order to carry out the original intent of the Parties as nearly as possible (consistent with the necessary reallocation of benefits) and as if
such invalid, illegal, or unenforceable provision had never been contained herein. 
 10.03 Merger of Understanding/Modification: This Agreement, the
Transaction Agreements and all Schedules and Exhibits attached thereto constitute the entire Agreement between the Parties regarding the subject matter hereof and all prior negotiations and understandings between the Parties are deemed to be merged
into this Agreement. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of each of the Parties. 

10.04 Force Majeure: Neither of the Parties shall be liable for any default or delay in performance of any obligation under this Agreement caused by
any of the following: Act of God, war, terrorism, riot, fire, explosion, accident, flood, sabotage, compliance with governmental requests, laws, regulations, orders or actions, national defense requirements or any other event beyond the reasonable
control of such Party; or labor trouble, strike, lockout or injunction (provided that neither of the Parties shall be required to settle a labor dispute against its own best judgment). The party invoking the provisions of this

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 19 - 

 EXECUTION COPY 
  

 
Section shall give the other Party written notice and full particulars of such force majeure event. Both Pfenex and Dow shall use reasonable business efforts to mitigate the effects of any force
majeure on their respective part. 
 10.05 Relationship of the Parties: This Agreement does not create a joint venture, partnership, or the
like, between the Parties. The Parties shall always remain independent contractors in its performance of this Agreement. No Party to this Agreement shall have any authority to employ any person as an employee or agent for or on behalf of the other
party to this Agreement for any purpose, and no Party to this Agreement, nor any person performing any duties or engaging in any work at the request of such Party, shall be deemed to be an employee or agent of the other Party to this Agreement. 

10.06 Choice of Law; Submission to Jurisdiction: All questions with respect to the construction of this Agreement and the rights and liabilities of the
Parties hereto shall be determined in accordance with the laws of the State of New York applicable to business arrangements entered into and performed entirely within the State of New York. The Parties hereto irrevocably (a) submit to the
exclusive personal jurisdiction of any state court or federal court in the State of New York in any suit, action or other legal proceeding relating to this Agreement; (b) agree that all claims in respect of any such suit, action or other legal
proceeding may be heard and determined in, and enforced in and by, any such court; and (c) waive any objection that they may now or hereafter have to venue in any such court or that such court is an inconvenient forum. 

10.07 Provisions Contrary to Law: In performing this Agreement, the Parties shall comply with all applicable laws and regulations. Nothing in this
Agreement shall be construed so as to require the violation of any law, and wherever there is any conflict between any provision of this Agreement and any law the law shall prevail, but in such event the affected provision of this Agreement shall be
affected only to the extent necessary to bring it within the applicable law. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 20 - 

 EXECUTION COPY 
  

 10.08 Remedies: Except as otherwise expressly stated in this Agreement, the rights and remedies of a
party set forth herein with respect to failure of the other to comply with the terms of this Agreement (including, without limitation, rights of full termination of this Agreement) are not exclusive, the exercise thereof shall not constitute an
election of remedies and the aggrieved party shall in all events be entitled to seek whatever additional remedies may be available in law or in equity. 

10.09 Fees: Except as otherwise provided herein, each Party shall bear its own legal fees incurred in connection with the transactions contemplated
hereby, provided, however, that if any Party to this Agreement seeks to enforce its rights under this Agreement by legal proceedings or otherwise, the non-prevailing Party shall pay all costs and expenses incurred by the prevailing party, including,
without limitation, all reasonable attorneys’ fees. 
 10.10 Headings: Headings herein are for convenience of reference only and shall in no way
affect interpretation of this Agreement. 
 10.11 Counterparts: This Agreement may be executed in any number of counterparts with the same effect as
if all parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. 

10.12 Appendices: The appended Appendices and Exhibits and any modifications or amendments thereof form an integral part of this Agreement. 

10.13 Waiver: Neither Party may waive or release any of its rights or interests in this Agreement except in writing. The failure of either Party to
assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. No waiver by either Party of
any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 21 - 

 EXECUTION COPY 
  

 10.14 Confidentiality of the Agreement. Except as expressly permitted herein, this Agreement,
including the terms set forth herein, shall be maintained in confidence by the Parties and shall not be provided or disclosed to Third Parties. Notwithstanding the foregoing, each Party shall have the right to disclose this Agreement, including the
terms set forth herein, to its (i) tax advisors, accountants, legal counsel, investors, banks and financial sources and its advisors, or potential business partners or other Third Parties who are under an obligation of confidentiality, and
(ii) in confidence, in connection with the sale of substantially all the business assets to which this Agreement relates, so long as, in the case of a disclosure under (i) or (ii) hereof, the person or entity to which disclosure is
made is bound under confidentiality provisions that are reasonable and customary under the applicable circumstances. In addition, and notwithstanding anything to the contrary herein, Dow and Pfenex may disclose this Agreement, including the terms
set forth herein, as required to comply with applicable law, regulations, court orders, or tax or securities filings (including any of the rules and regulations of a relevant stock exchange or other governing body, specifically including the
Securities & Exchange Commission (SEC)). 
 10.15 Provisional Remedies: Nothing in this Agreement shall limit the right of either Party to
seek to obtain in any court of competent jurisdiction any equitable or interim relief or provisional remedy, including injunctive relief, that may be necessary to protect the rights or property of that Party. Specifically, the Parties acknowledge a
breach of this Agreement may result in irreparable harm to either Party, and either Party will be entitled to seek injunctive and other equitable relief to prevent any breach or the threat of any breach of this Agreement by the other Party without
showing or proving actual damages. Notwithstanding, seeking or obtaining such equitable or interim relief or provisional remedy in a court shall not be deemed a waiver of the agreement to arbitrate. For clarity, any such equitable remedies shall be
cumulative and not exclusive and are in addition to any other remedies that either Party may have under this Agreement or applicable law. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 22 - 

 EXECUTION COPY 
  

 10.16 Dispute Resolution: In the event any Dispute (as that term is defined in the Grant-Back and
Technology License Agreement) arises between the Parties, the Parties shall resolve such Dispute utilizing the dispute resolution procedures set forth in Section 10.13 of the Grant-Back and Technology License Agreement; provided that, each
reference to the term “Agreement” in such Section 10.13 of the Grant-Back and Technology License Agreement shall be deemed to be references to this Agreement; provided further that, the reference to “Section 10.14” shall be
replaced with “Section 10.15” of this Agreement, and the reference to “Section 10.13” shall be replaced with “Section 10.16” of this Agreement. 

[REMAINDER OF THIS PAGE LEFT BLANK INTENTIONALLY] 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 23 - 

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, the Parties hereto have understood, agreed to and caused this Agreement
to be executed in duplicate originals by their duly authorized representatives as of the Effective Date. 
  

			
	THE DOW CHEMICAL COMPANY
		
	By:	 	 /s/ Fernando Ruiz

		
	Name:	 	 Fernando Ruiz

		
	Title:	 	 Corporate Vice President and Treasurer

	
	DOW GLOBAL TECHNOLOGIES INC.
		
	By:	 	 /s/ Mark A. Whiteman

		
	Name:	 	 Mark A. Whiteman

		
	Title:	 	 President

	
	PFENEX INC.
		
	By:	 	 /s/ Albert Hansen

		
	Name:	 	 Albert Hansen

		
	Title:	 	 President

 [Signature Page to Technology License Agreement] 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 24 - 

 EXECUTION COPY 
  

 Appendix A 

RNA Virus Patents: 
  

							
	Ahlquist	  	 MODIFIED PLUS STRAND RNA VIRUSES; (from Univ Wisconsin)
	  	2/14/1984	  	US5173410
				
	Ahlquist	  	 Subgenomic promoter
	  	3/7/1985	  	US5466788
				
	Ahlquist	  	 RNA transformation vector
	  	3/7/1985	  	US5500360
				
	Ahlquist	  	 Hybrid RNA virus
	  	2/9/1987	  	US5602242
				
	Ahlquist	  	 Hybrid RNA virus
	  	2/9/1987	  	US5627060
				
	Ahlquist	  	 Plant tissue comprising a subgenomic promoter
	  	8/25/1994	  	US5633447
				
	Ahlquist	  	 Subgenomic promoter
	  	8/25/1994	  	US5670353
				
	Ahlquist	  	 Plasmid encoding hybrid RNA virus
	  	2/9/1987	  	US5804439
				
	Ahlquist	  	 RNA transformation vector
	  	3/7/1985	  	US5846795

 and any foreign counterpart thereof. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 25 - 

 EXECUTION COPY 
  

 Appendix B 

Oral Immunization Patents: 
  

							
	Curtiss & Cardineau	  	 Oral Immunization By Transgenic Plants
	  		  	US5654184
				
	Curtiss & Cardineau	  	 Oral Immunization By Transgenic Plants
	  		  	US5679880
				
	Curtiss & Cardineau	  	 Oral Immunization By Transgenic Plants
	  		  	US5686079

 and any foreign counterpart thereof. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 26 - 

 EXECUTION COPY 
  

 Appendix C 

Production Techniques Patents: 
  

									
	62339A	  	 PCT
 PCT
	  	OVER-EXPRESSION OF EXTREMOZYME GENES IN PSEUDOMONADS AND CLOSELY RELATED BACTERIA	  	2/13/2002	    	 WO2003068926 WO2003068948

PCT/US02/004294

		  	USA	  		  	10/504,505	    	
		  	Australia	  		  	2003215197	    	
		  	Brazil	  		  	PI0307630	    	
		  	Canada	  		  	2475926	    	
		  	China	  		  	03808240.3	    	
		  	EPO	  		  	03711011.1	    	[Validation in progress]
		  	India	  		  	1766/2004	    	
		  	Japan	  		  	2003-568041	    	
		  	Mexico	  		  	PA/A/04/007886	    	
					
	61727A	  	USA	  	LOW-COST PRODUCTION OF PEPTIDES	  	5/22/2002	    	 US20050227321
 PCT/US03/12407

		  	PCT	  		  		    	
		  	Australia	  		  	2003228637	    	
		  	Canada	  		  	2482995	    	
		  	China	  		  	03814541.3	    	
		  	EPO	  		  	03726398.5	    	[Validated in GB, FR, DE, NL, CH]
		  	India	  		  	261/2004	    	
		  	Japan	  		  	2003-586175	    	
		  	S. Korea	  		  	2004-7017047	    	
					
	61957A	  	PCT	  	PROCESS FOR REMOVING WATER FROM AQUEOUS SOLUTIONS OF PROTEINS	  	2/27/2004	    	WO2005092915
		  	USA	  		  	10/590095	    	
		  	EPO	  		  	05713770.5	    	Validated in GB, DE, FR,
					
	62644A	  	PCT	  	METHOD FOR THE EXTRACTION OF INTRACELLULAR PROTEINS FROM A FERMENTATION BROTH	  	2/27/2004	    	 WO2005087791
 PCT/US05/005309

		  	USA	  		  	60/548403	    	
		  	EPO	  		  	05723333.0	    	
		  	USA	  		  	10/590185	    	
	65217	  	USA	  	CONTINUOUS OSMOTIC SHOCK PROCESS FOR RELEASE OF PROTEINS FROM BACTERIA	  	1/12/2007	    	US Application No: 12/013042

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 27 - 

 EXECUTION COPY 
  

									
		  	AU	  		  	2008205632	  	
		  	CA	  		  	PCT/US08/000426	  	
		  	CH	  		  	PCT/US08/000426	  	
		  	EP	  		  	08724501.5	  	
		  	IN	  		  	PCT/US08/000426	  	
		  	JP	  		  	PCT/US08/000426	  	
		  	SINGAPORE	  		  	200904693-9	  	
		  	SOUTH KOREA	  		  	PCT/US08/000426	  	

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 28 - 

 EXECUTION COPY 
  

 Appendix D 

ARC Patent 
 US Patent No: 7,338,794 entitled
“Amended recombinant cells for the production and delivery of gamma interferon as an antiviral agent, adjuvant and vaccine accelerant” and any foreign counterpart thereof. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 CONFIDENTIAL - Do not
share without permission 
 - 29 - 

 EXECUTION COPY 
  

 Exhibit 6.06.01 

Third Party Agreements 
 1. License
Agreement between Mycogen Corporation and The Dow Chemical Company dated January 1, 2001. 
 2. Agreement between Agrigenetics and University of
Wisconsin dated December 23, 1982. 
 3. License Agreement between Washington University and Agrigenetics dated December 30, 1996. 

4. ARC Technology License Agreement between Dow Global Technologies Incorporated and Dow AgroSciences LLC dated November 30, 2009. 

5. Agreement between DAS and Dow granting rights under Section 4.7 of the Diversa Agreement. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

  
 CONFIDENTIAL - Do not
share without permission 
 - 30 -EX-10.12

 Exhibit 10.12 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS
OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[*].” 
  

 
 SUBCONTRACT AGREEMENT 

FIRM FIXED PRICE COMMERCIAL ITEMS (GOVERNMENT 
  

			
	SUBCONTRACTOR:	 	SUBCONTRACT #: P010022290
	The Dow Chemical Company	 	MODIFICATION #: NA
	ADDRESS: 2030 Dow Center Midland, MI 48674	 	DPAS RATING: NA
		 	 TYPE: FIRM FIXED PRICE
 COMMERCIAL
ITEMS (GOVERNMENT)

		 	VALUE: $336,800.00

 INTRODUCTION 

This Subcontract Agreement, effective September 11, 2009 is made between SCIENCE APPLICATIONS INTERNATIONAL CORPORATION (hereinafter known as
“Buyer”), a Delaware corporation with principal offices in San Diego, California, and The Dow Chemical Company (hereinafter known as “Seller”), a Delaware corporation with principal offices in Midland, MI. The effort to be
performed by Seller under this Subcontract will be part of Buyer’s Prime Contract # N01-AI-05421 which has been issued by National Institutes of Allergy and Infectious Diseases (NIAID). The work, defined in Attachment I (Statement of Work and
Schedule) will be performed on a Firm Fixed-Price basis, in accordance with Schedule A (Specific Terms and Conditions), and any referenced documents listed in 17.0 Order of Precedence section of this agreement, 

SCHEDULE A 
 SPECIFIC
TERMS AND CONDITIONS 
  

	1.0	PRICE 

 The total firm fixed price for the work to be performed under this Subcontract is $336,800. This
Subcontract is fully funded in the amount of $336,800 including profit. 
  

	1.1	DELIVERY 

 The goods and services required by this subcontract shall be delivered in accordance with the
delivery schedule contained in this agreement. The time of delivery stated is of the essence of this Subcontract. The date specified for delivery is the required delivery date at Buyer’s plant, unless otherwise specifically noted herein. All
items furnished under this subcontract shall be delivered FOB Destination, unless specified otherwise in writing by the Buyer’s contractual representative. Delivery shall not be deemed complete until the goods have been actually received
and accepted by Buyer, notwithstanding delivery to any carrier, or until orders for services have been performed, received, and accepted by Buyer. 
  

	1.2	INSPECTION 

 All goods supplied and services performed pursuant hereto shall be subject to inspection and
test by buyer and its agents and by its customers at all times and places, whether during or after manufacture as to goods, or performance as to services, and notwithstanding the terms of delivery or payment or, as to goods, that title has not yet
passed to Buyer or to its customers. In the event that goods supplied are not performed in accordance with the specifications and instructions of Buyer, Buyer may require prompt correction thereof, or as to services, require that the services be
rendered again at Seller’s expense. Buyer may terminate the subcontract for default if such defects exist and if Seller is unable or refuses to replace the goods or render the services again promptly. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 1 of
9             
 #9-932-072 Commercial Items [Government] (rev. 9/25/2006)

 

 
  
  

	1.3	INVOICES 

 Invoices shall be prepared in duplicate and contain the following information; subcontract
number, subproject number, Stage #. Invoices will be mailed to: 
 Science Applications International Corporation 

Attention: Gina B. McGeehan 
 5202
Presidents Court, Suite 110 
 Frederick, Maryland 21703 

Invoices shall clearly reference a unique invoice number on each invoice, and the date of the invoice. Invoices shall include the “Amount Previously
Billed,” the “Amount of this Invoice,” and the “Total Amount Billed to Date.” 
  

	1.4	PAYMENT 

 For each Stage of work there will be two invoices each totaling 50 % of the price for each
Stage of Work, an initial invoice upon commencement of the Stage and a final invoice upon acceptance of the final report for each Stage. Payment terms will be Net 45 days from date of invoice. Upon receipt of invoice Buyer shall within five
(5) business days review the invoice and determine if the invoice is acceptable. If Buyer reasonable deems the invoice unacceptable Buyer shall contact Seller and Seller shall reissue a conforming invoice with a new date of invoice. If
(1) Buyer does not pay on time or (2) Buyer’s financial responsibility becomes unsatisfactory (S&P rating below BBB- or Moody’s rating below Baa3) to Seller and Seller deems itself insecure, Seller may accelerate the
due date and demand immediate payment on any outstanding invoice for Product, or may require cash payments or satisfactory security for future deliveries and for payment of all sums owed under this Agreement. Buyer agrees to pay all costs and
expenses, including reasonable attorney’s fees, incurred by Seller in the collection of any sum payable by Buyer to Seller, or in the exercise of any remedy. Dow may charge Prime +2% on all overdue amounts. 

 

	1.5	WARRANTY 

 BUYER UNDERSTANDS AND ACKNOWLEDGES THAT MATERIAL IS EXPERIMENTAL AND BY PROVIDING MATERIAL
SELLER MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AS TO ANY MATTER, INCLUDING WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS OF THE MATERIAL PROVIDED HEREUNDER FOR ANY
PARTICULAR PURPOSE OTHER THAN AS REQUIRED BY THE STATEMENT OF WORK OR THAT THE USE OF THE MATERIAL OR ANY PRODUCT OR PROCESS DERIVED OR PRODUCED THEREFROM WILL NOT INFRINGE ANY PATENT, COPYRIGHT OR OTHER RIGHTS OF THIRD PARTIES. BUYER HEREBY AGREES
THAT IN NO EVENT SHALL SELLER BE LIABLE FOR ANY DIRECT, INDIRECT OR CONSEQUENTIAL DAMAGES, RESULTING FROM ANY USE BY BUYER OF THE MATERIAL AND ALL DERIVATIVES THEREOF OUTSIDE OF THE SCOPE OF THIS AGREEMENT. ADDITIONALLY, THE SELLER WARRANTS THE
PRICE CHARGED FOR THE GOODS AND/OR SERVICES PURCHASED PURSUANT HERETO SHALL BE NO HIGHER THAN SELLER’S CURRENT PRICE TO ANY OTHER CUSTOMER FOR THE SAME QUALITY AND QUANTITY OF SUCH GOODS OR SERVICES. 

 

	2.0	TECHNICAL AND CONTRACTUAL REPRESENTATIVES 

 The following authorized representatives are hereby
designated for this Subcontract 
  

											
	SELLER:	  		  		  	BUYER:	  		  	
		  	TECHNICAL:	  	 Silvia Chang
	  		  	TECHNICAL:	  	 Steve Huang

		  	CONTRACTUAL:	  	 Patrick Lucy
	  		  	CONTRACTUAL:	  	 Gina B. McGeehan

  

	2.1	CONTACTS 

 Contacts with Buyer that affect the subcontract prices, schedule, statement of work, and
subcontract terms and conditions shall be made with the authorized contractual representative. No changes to this Subcontract shall be binding upon Buyer unless incorporated in a written modification to the Subcontract and signed by Buyer’s
contractual representative. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 2 of
9             
 #9-932-072 Commercial Items [Government] (rev. 9/25/2006)

 

 
  
  

	2.2	CHANGES 

 Buyer may, by reasonable written notice to Seller make changes within the general scope of this
Order in any one or more of the following (a) drawings, designs or specifications; (b) quantity; (c) time or place of delivery; (d) method of shipment or packing; and (e) the quantity of Buyer furnished property. Upon
Buyer’s written notice, Buyer may, for any reason, direct Seller to suspend, in whole or in part, delivery of goods or performance of services hereunder for such period of time as may be determined by Buyer in its sole discretion. If any such
change or suspension causes a material increase or decrease in the cost of, or the lime required for the performance of any part of the Service under this Order, the parties will jointly determine an equitable adjustment in the Order price or
delivery schedule, or both No such adjustment or any other modification of the terms of this Order will be allowed unless authorized by both parties by means of a written modification to the Order. Failure to agree to any adjustment shall be a
dispute under the Disputes clause of this subcontract. However, Seller shall proceed with the work as changed without interruption and without awaiting settlement of any such claim. 

 

	3.0	DISCLOSURE 

 Seller shall not disclose information concerning work under this Subcontract to any third
party, unless such disclosure is necessary for the performance of the subcontract effort. No news releases, public announcement, denial or confirmation of any part of the subject matter of this Subcontract or any phase of any program hereunder shall
be made without prior written consent of Buyer. The restrictions of this paragraph shall continue in effect upon completion or termination of this Subcontract for such period of time as may be mutually agreed upon in writing by the parties. In the
absence of a written established period, no disclosure is authorized. Failure to comply with the provisions of this Clause may be cause for termination of this subcontract 
  

	4.0	KEY PERSONNEL 

  

	(a)	For purposes of this clause, Buyer and Seller define “Key Personnel” as those individuals who are mutually recognized as essential to the successful completion and execution of this Subcontract.

  

	(b)	Personnel designated as “Key Personnel” shall be assigned to the extent necessary for the timely completion of the task to which assigned. Any substitution or reassignment involving Seller’s “Key
Personnel” assigned to this work shall be made only with persons of equal abilities and qualifications and is subject to prior approval of Buyer, in writing which will not be unreasonably withheld. 

 

	(c)	Buyer reserves the right to request the removal and Seller shall endeavor to remove any individual assigned to this Subcontract if individual is deemed not qualified, or performs at an unacceptable level, or is
requested by its client to do so. If Buyer is not satisfied with how the issue is resolved by Seller, Buyer may resolve the issue according to Section 10 of this Subcontract or alternatively may terminate this Subcontract according to
Section 11 of this Subcontract at Buyers sole discretion. 

  

	(d)	Seller’s Key Personnel are: Diane Retallack, Ph.D., Lawrence Chew, Ph.D. and Jeffrey Allen, Ph.D. 

  

	5.0	ASSIGNMENTS AND SUBCONTRACTS 

 With a proper 30-day advance notification to Buyer, Dow shall have the
right to assign this Agreement in connection with the reorganization, consolidation, spin-off, sale or transfer of assets related to that portion of its business pertaining to the subject matter of this Agreement, either alone or in conjunction with
other Dow businesses. In addition, Dow shall have the right to assign its respective rights or obligations and delegate its performance hereunder, in whole or in part, to any of its Affiliates with the prior written consent of Buyer which will not
be unduly withheld. Further, Seller agrees to obtain Buyer’s approval before subcontracting this Order or any substantial portion thereof; provided, however, that this limitation shall not apply to the purchase of standard commercial supplies
or raw materials. 
  

	6.0	INSURANCE PROVISION FOR PROCUREMENT CONTRACTS 

 Without prejudice to Seller’s liability to indemnify
Buyer as stated in any Indemnification provision contained in this Agreement, Seller shall procure at its expense and maintain for the duration of this Agreement the insurance policies required below with financially responsible insurance companies,
and with policy limits not less than those indicated below. 
  

	(a)	Workers’ Compensation: Coverage for statutory obligations imposed by laws of any State in which the work is to be performed, including where applicable, coverage under the United States Longshoremen’s
and Harbor Workers’ Act (USL&H), the Jones Act, and the Defense Base Act (DBA). In addition, the policy shall be endorsed to waive the insurer’s rights of subrogation in favor of Buyer. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 3 of
9             
 #9-932-072 Commercial Items [Government] (rev. 9/25/2006)

 

 
  
  

	(b)	Employer’s Liability: Coverage for injuries to employees not covered by workers’ compensation with limits of at least $1,000,000 each accident, $1,000,000 each employee by disease and $1,000,000 policy
limit by disease. In addition, the policy shall be endorsed to waive the insurer’s rights of subrogation in favor of Buyer. 

  

	(c)	Commercial General Liability: Coverage for third party bodily injury and property damage, personal injury, products and completed operations, contractual liability, and independent contractors’ liability
with limits not less than $1,000,000 per occurrence and $2,000,000 in the aggregate. Buyer, its officers and employees, and Buyer’s customer where required by Buyer’s Agreement with its customer, shall be named as Additional Insured and a
waiver of subrogation shall be provided in favor of Buyer. 

  

	(d)	Business Automobile Liability: Coverage for use of all owned, non-owned, and hired vehicles with limits of not less than $1,000,000 per occurrence combined single limit for bodily injury and property damage
liability. Buyer, its officers and employees, and Buyer’s customer where required by Buyer’s Agreement with its customer, shall be named as Additional Insured and a waiver of subrogation shall be provided in favor of Buyer.

  

	(e)	Professional Liability: If seller is performing any professional services, coverage for damages (including financial loss) caused by any acts, errors and omissions arising out Seller’s performance of
professional services with limits of not less than $1,000,000 per claim and $2,000,000 in the aggregate. 

  

	(f)	All-Risk Property Insurance: Coverage to repair or replace property, including supplies covered by this Agreement, of Buyer and/or Buyer’s customer which may be in the possession or control of Seller. Buyer
shall be named as a Loss Payee with respect to loss or damage to said property and/or supplies furnished by Buyer. Further, Seller assumes the risk of loss or destruction of or damage to any of its property and its employees’ property, whether
owned, hired, rented, borrowed, or otherwise. Seller waives and shall ensure that its employees waive all rights of recovery against Buyer and Buyer’s customer and their respective employees for any loss, destruction of or damage to any such
property. 

 The required insurance coverages above shall be primary and non-contributing with respect to any other insurance that may be
maintained by Buyer and notwithstanding any provision contained herein, the Seller, and its employees, agents, representatives, consultants, subcontractors and suppliers, are not insured by Buyer, and are not covered under any policy of insurance
that Buyer has obtained or has in place. 
 Any self-insured retentions, deductibles and exclusions in coverage in the policies required under this Article
shall be assumed by, for the account of, and at the sole risk of Seller or the subcontractor which provides the insurance and to the extent applicable shall be paid by Seller or such subcontractor. In no event shall the liability of Seller or any
subcontractor be limited to the extent of any of insurance or the minimum limits required herein. 
 Prior to commencement of any work, and within 15 days
of any policy renewal that occurs while any work is on-going under this Agreement, Seller shall provide Buyer certificates of insurance evidencing the insurance policies above, including evidence of additional insured status and waivers of
subrogation where required. Buyer reserves the right to refuse to accept policies from companies with an A.M. Best Rating of less than A- VII. Seller, or its insurers, shall provide 30 days advance written notice to Buyer in the event of
cancellation or material modification of any policy. Failure of Buyer to demand such certificates or to identify any deficiency in the insurance provided shall not be construed as or deemed to be a waiver of Seller’s, or its
subcontractors’, obligations to maintain the above insurance coverages. 
  

	7.0	INDEMNIFICATION 

  

	(a)	Seller shall indemnify, defend and hold SAIC and SAIC’s customer, NIAID, specifically related to Prime Contract # N01-AI-05421 harmless from and against any and all damages, losses, liabilities and expenses arising
out of or relating to any claims, causes of action, lawsuits or other proceedings, regardless of legal theory, that result, from Seller’s (or any of Seller’s subcontractors, suppliers, employees, agents or representatives):
(i) intentional misconduct, negligence, or fraud, (ii) breach of any representation, warranty or covenant made herein, or (iii) products or services including, without limitation, any claims that such products or services infringe any
United States patent, copyright, trademark, trade secret or any other proprietary right of any third party except to the extent such claim arises solely from the use of the Buyer Technology or Buyer Materials. Buyer will give prompt notice of any
such claim and, with respect to claims described in clause above, Seller will control the defense, settlement or compromise of such claim, provided, however, that Seller shall berequired to obtain the prior written consent of Buyer before entering
into any settlement or compromise that would not relieve Buyer from any liability for past infringement or otherwise would limit the ability of Buyer to realize the full benefit of the Services. 

 

	(b)	Buyer shall indemnify Seller (including its officers, directors and employees) for all third party claims arising from the use by Buyer (or on behalf of Buyer) of samples of products, documentation, or technology
received from Seller under this Order, except for any claim for which Seller is required to indemnify Buyer above or any claim arising as a result of the negligence or willful misconduct of Seller. Seller will give prompt notice of any such claim
and Buyer will control the defense, settlement or compromise of such claim. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 4 of
9             
 #9-932-072 Commercial Items [Government] (rev. 9/25/2006)

 

 
  
  

	8.0	INFRINGEMENT INDEMNITY 

  

	(a)	Seller warrants that it is not aware of any patent, intellectual property, or industrial property rights of any third party that would be infringed by virtue of Seller performing Services, except to the extent arising
solely from the use of Buyer Technology or Buyer Materials. Also, Seller shall indemnify Buyer (including its officers, directors, employees, and SAIC’s customer, NIAID, specifically related to Prime Contract # N01-AI-05421 for all third party
claims arising in connection with a patent infringement resulting from or related to the performance of the Services, except to the extent such claim arises solely from the use of the Buyer Technology or Buyer Materials. Buyer will give prompt
notice of any such claim and, with respect to claims described above, Seller shall control the defense, settlement or compromise of such claim, provided, however, that Seller shall be required to obtain the prior written consent of Buyer before
entering into any settlement or compromise that would not relieve Buyer from any liability for past infringement or otherwise would limit the ability of Buyer to realize the full benefit of the Services. 

 

	(b)	Buyer shall indemnify Seller against liability incurred by Seller in connection with a patent infringement claim by a third party arising as a result of the use by Seller of Buyer Technology or Buyer materials in
connection with the performance of the Services. Seller will give prompt notice of any such claim and Buyer will control the defense, settlement or compromise of such claim. As used herein, “Buyer Technology” means all proprietary and/or
confidential technical and other information not known to Seller relating to PRODUCT (“PRODUCT” shall mean a full length CSP) and materials in connection with this Order, for which Buyer has intellectual property ownership or patent rights
or which Buyer is otherwise authorized to use. 

  

	(c)	Notwithstanding the foregoing paragraph, when this order is performed under the Authorization and Consent of the U.S. Government to infringe U.S. Patents, Seller’s liability for infringement of such Patents in such
performance shall be limited to the extent of the obligation of Buyer to indemnify the U.S. Government. 

  

	9.0	CONFIDENTIALITY AND USE OF BUYER FURNISHED ITEMS/INFORMATION 

 Both parties agree to maintain the
other’s Confidential Information in confidence with the same degree of care each holds its own confidential information. Neither party will use the Confidential Information of the other party except for the performance of the Service described
in the Purchase Order. Both parties will disclose the Confidential Information only to its officers, consultants and employees directly concerned with the Service, but will neither disclose the Confidential Information to any third party nor use the
Confidential Information for any other purpose. Upon completion of this Order, and at the disclosing parties request, the other party will return all Confidential Information, except that each party may retain one copy of such papers, records or
other documents for the sole purpose of determining its continuing obligations under this Order. The parties’ obligation of nondisclosure and the limitations upon the right to use the other party’s Confidential Information, samples and
test results shall not apply to the extent that either can demonstrate that the Confidential Information: (a) was in its possession prior to the time of disclosure; or (b) is or becomes public knowledge through no fault or omission of the
recipient of the Confidential Information; or (c) is obtained by the recipient from a third party under no obligation of confidentiality to the disclosing party; or (d) if such party is required to disclose the Confidential Information in
connection with a legal or administrative proceeding, such party will give the other party prompt notice of such request The disclosing party may seek an appropriate protective order or other remedy or waive compliance or both with the provisions of
this Order. If such party seeks a protective order or other remedy, the other party will cooperate. If such party fails to obtain a protective order or waive compliance with the relevant provisions of this Order, the other party will disclose only
that portion of the Confidential Information which its legal counsel determines it is required to disclose, after consultation with the other party’s attorneys. 

Seller agrees that it will keep confidential and not disclose, disseminate or publish the features of any equipment, tools, gauges, patterns, designs,
drawings, engineering data, computer programs and software or other technical or proprietary information furnished, loaned or bailed by Buyer hereunder (hereinafter collectively referred to as “Items/Information”, and use such
Items/Information only in the performance of this Subcontract or, if authorized, other orders from Buyer and not otherwise, without Buyer’s prior written consent. Notwithstanding any other provision herein, Buyer and Seller shall each retain
ownership of, and all right, title and interest in and to, their respective pre-existing Intellectual Property. 
 Both Parties agree that the Expression
Strains and Production Strain(s) represent Confidential Information from both Parties. Neither Party shall have the right to utilize, license or commercialize the Expression Strains and/or the Production Strain(s) beyond the scope of activities in
this agreement without the consent of the other Party. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 5 of
9             
 #9-932-072 Commercial Items [Government] (rev. 9/25/2006)

 

 
  
 All such items furnished, loaned or bailed by Buyer
hereunder, or fabricated, manufactured, purchased, or otherwise acquired by Seller for the performance of this Subcontract and specifically charged to Buyer, are the property of Buyer. 

Upon completion, expiration or termination of this Subcontract, Seller shall return all such Items in good condition, reasonable wear only excepted, together
with all spoiled and surplus Items to Buyer, or make such other disposition thereof as may be directed or approved by Buyer. Seller agrees to replace, at its expense, all such Items not so returned. Seller shall make no charge for any storage,
maintenance or retention of such Items. Seller shall bear all risk of loss for all such Items in Seller’s possession. 
 Seller also agrees to use any
designs or data contained or embodied in such Items in accordance with any restrictive legends placed on such Items by the Buyer or any third party. If Buyer furnishes any material for fabrication hereunder, Seller agrees: (i) not to substitute
any other material for such fabrication without Buyer’s prior written consent, and (ii) that title to such material shall not be affected by incorporation in or attachment to any other property. 

Materials (“Materials” shall mean cell lysates provided by Seller to Buyer under this Order and any constituents, and any tangible materials that
incorporate the foregoing) sent to Buyer under this Order (hereinafter defined as Buyer Materials) shall not be used in human clinical studies. Samples of Materials sent to Seller by Buyer under this Order (hereinafter defined as Seller Materials)
shall be used by Seller solely for the purpose of providing the Services for Buyer as set forth herein, and for no other purpose, and shall not be transferred to any other person by Seller. 

 

	10.0	DISPUTES 

 Any dispute not disposed of in accordance with the “Disputes Clause” of Schedule B,
if any, shall be determined in the following manner. 
  

	(a)	Buyer and Seller agree to enter into Negotiation to resolve any dispute. Both parties agree to negotiate in good faith to reach a mutually agreeable settlement within a reasonable amount of time. 

 

	(b)	If negotiations are unsuccessful, Buyer and Seller agree to enter into binding Arbitration except for intellectual property issues. The American Arbitration Association (AAA) Commercial Arbitration Rules (most recent
edition) are to govern this Arbitration. The Arbitration shall take place in the County of San Diego, State of California. The Arbitrator shall be bound to follow the applicable subcontract provisions and California law in adjudicating the dispute.
It is agreed by both parties that the Arbitrator’s decision is final, and that no party may take any action, judicial or administrative, to overturn this decision. The judgment rendered by the Arbitrator may be entered in any court having
jurisdiction thereof. 

 Pending any decision, appeal or judgment referred to in this provision or the settlement of any
dispute arising under this Subcontract, Seller shall proceed diligently with the performance of this Subcontract. 
  

	11.0	DEFAULT 

  

	(a)	The Buyer may, by written notice of default to the Seller, terminate the whole or any part of this Subcontract in any one of the following circumstances: (i) if Seller fails to make delivery of the supplies or to
perform the services within the time specified herein or any extension thereof; or (ii) if Seller fails to perform any of the other provisions of this Subcontract in accordance with its terms, and in either of these two circumstances does not
cure such failure within a period of 10 days (or such longer period as Buyer may authorize in writing) after receipt of notice from the Buyer specifying such failure; or (iii) Seller becomes insolvent or the subject of proceedings under any law
relating to bankruptcy or the relief of debtors or admits in writing its inability to pay its debts as they become due. 

  

	(b)	If this Subcontract is so terminated, Buyer may procure or otherwise obtain, upon such terms and in such manner as Buyer may deem appropriate, supplies or services similar to those terminated, Seller, subject to the
exceptions set forth below, shall be liable to Buyer for any excess costs of such similar supplies or services. 

  

	(c)	Seller shall continue performance of this Subcontract to the extent not terminated. Buyer shall have no obligations to Seller with respect to the terminated part of this Subcontract except as herein provided. In case of
Seller’s default, Buyer’s rights as set forth herein shall be in addition to Buyer’s other rights although not set forth in this Subcontract. 

  

	(d)	Seller shall not be liable for damages resulting from default due to causes beyond the Seller’s control and without Seller’s fault or negligence, provided, however, that if Seller’s default is caused by
the default of a subcontractor or supplier, such default must arise out of causes beyond the control of both Seller and subcontractor or supplier, and without the fault or negligence of either of them and, provided further, the supplies or services
to be furnished by the subcontractor or supplier were not obtainable from other sources. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 6 of
9             
 #9-932-072 Commercial Items [Government] (rev. 9/25/2006)

 

 
  
  

	(e)	Seller agrees to immediately notify Buyer in writing of any actual or potential delay in Sellers performance under this Order. Such notice shall, at a minimum, describe the cause, effect, duration and corrective action
proposed by Seller to address the problem. Seller shall give prompt written notice to the Buyer of all changes to such conditions 

  

	(f)	Notwithstanding the foregoing, Seller shall not be liable for any default or delay in performance of any obligation under this Order caused by any of the following: Act of God, war, riot, fire, explosion, accident,
flood, sabotage and any other event beyond the reasonable control of Seller; or labor trouble, strike, lockout or injunction (provided that Seller shall not be required to settle a labor dispute against its own best judgment). 

 

	12.0	GENERAL RELATIONSHIP 

 The Subcontractor is not an employee of SAIC for any purpose whatsoever. Seller
agrees that in all matters relating to this Subcontract it shall be acting as an independent contractor and shall assume and pay all liabilities and perform all obligations imposed with respect to the performance of this Subcontract. Seller shall
have no right, power or authority to create any obligation, expressed or implied, on behalf of Buyer and/or the Government and shall have no authority to represent Buyer as an agent. 

 

	13.0	NON-WAIVER OF RIGHTS 

 The failure of Buyer to insist upon strict performance of any of the terms and
conditions in the Subcontract, or to exercise any rights or remedies, shall not be construed as a waiver of its rights to assert any of the same or to rely on any such terms or conditions at any time thereafter. The invalidity in whole or in part of
any term or condition of this subcontract shall not affect the validity of other parts hereof. 
  

	14.0	APPLICABLE STATE LAW AND COMPLIANCE 

 This Subcontract shall be governed by and construed in accordance
with the laws of the State of Delaware. Seller agrees to comply with the applicable provisions of any federal, state or local law or ordinance and all orders, rules and regulations issued there under. 

 

	15.0	EXPORT CONTROL COMPLIANCE FOR FOREIGN PERSONS 

 The subject technology of this Subcontract (together
including data, services, and hardware provided hereunder) may be controlled for export purposes under the International Traffic in Arms Regulations (ITAR) controlled by the U.S. Department of State or the Export Administration Regulations
(“EAR”) controlled by the U.S. Department of Commerce. ITAR controlled technology may not be exported without prior written authorization and certain EAR technology requires a prior license depending upon its categorization, destination,
end-user and end-use. Exports or re-exports of any U.S. technology to [any destination under U.S. sanction or embargo are forbidden. 
 Access to certain
technology (“Controlled Technology”) by Foreign Persons (working legally in the U.S.), as defined below, may require an export license if the Controlled Technology would require a license prior to delivery to the Foreign Person’s
country of origin. SELLER is bound by U.S. export statutes and regulations and shall comply with all U.S. export laws. SELLER shall have full responsibility for obtaining any export licenses or authorization required to fulfill its obligations under
this Subcontract. 
 SELLER hereby certifies that all SELLER employees who have access to the Controlled Technology are U.S. citizens, have permanent U.S.
residency or have been granted political asylum or refugee status in accordance with 8 U.S.C. 1324b(a)(3). Any non-citizens who do not meet one of these criteria are “Foreign Persons” within the meaning of this clause, but have been
authorized under export licenses to perform their work hereunder. 
  

	16.0	STANDARDS OF BUSINESS ETHICS & CONDUCT 

 SAIC believes in fair and open competition and is
committed to conducting its business fairly, impartially and in an ethical and proper manner. SAIC is owned and controlled by its employee owners. These characteristics make it imperative that SAIC employees adhere to a particularly high ethical
standard. Employee ownership both demands and fosters highly ethical conduct because SAIC can be successful only when employees look after long-term interests of the company and resist pressures to compromise SAIC standards. Buyer’s expectation
is that Seller also will conduct its business fairly, impartially and in an ethical and proper manner. If Seller has cause to believe that Buyer or any employee or agent of Buyer has acted improperly or unethically under this agreement/order, Seller
shall report such behavior to the SAIC Ethics Hotline (800) 435-4234. Copies of The Science Applications International Corporation (SAIC) code of Ethics and contacts for such reports are available on www.saic.com under Corporate
Governance. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 7 of
9             
 #9-932-072 Commercial Items [Government] (rev. 9/25/2006)

 

 
  
  

	17.0	ORDER OF PRECEDENCE 

 The documents listed below are hereby incorporated by reference. In the event of an
inconsistency or conflict between or among the provisions of this Subcontract, the inconsistency shall be resolved by giving precedence in the following order: 
  

	1.	Attachment I: Statement of Work and Schedule dated July 2009. 

  

	2.	Schedule A: Specific Terms and Conditions Form 9-932-072 (Rev. 9/25/06). 

  

	3.	Schedule B: U.S. Government Terms and Conditions, Part III — FAR Clauses Form 9-932-082 (Rev. 07/25/07). 

  

	4.	Attachment C (Enclosure 2; (Rev. 4/2009) Property Administration Requirements For Subcontractors With An Adequate System Or Requisite Internal Controls 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 8 of
9             
 #9-932-072 Commercial Items [Government] (rev. 9/25/2006)

 

 
  
  

	18.0	ENTIRE AGREEMENT 

 The parties hereby agree that this Subcontract, including all documents incorporated
herein by reference, shall constitute the entire agreement and understanding between the parties hereto and shall supersede and replace any and all prior or contemporaneous representations, agreements or understandings of any kind, whether written
or oral, relating to the subject matter hereof. 
 In witness whereof, the duly authorized representatives of Buyer and the Seller have executed this
Subcontract on the Dates shown. 
  

									
	THE DOW CHEMICAL COMPANY	 		 	SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
			
	 /s/ Bart Waters
	 		 	 /s/ Gina B. McGeehan

	(Signature)	 		 	(Signature)
					
	Name:	 	 Bart Waters
	 		 	Name:	 	 Gina B. McGeehan

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 R&D Director
	 		 	Title:	 	 Senior Subcontracts Administrator

					
	Date:	 	 9 Sep 2009
	 		 	Date:	 	 9-14-09

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 9 of
9             
 #9-932-072 Commercial Items [Government] (rev. 9/25/2006)

 

 
 STATEMENT OF WORK 

Evaluation of Malaria CSP Expression in Pfenex Expression TechnologyTM 

And Process Manufacturing 

Malaria Vaccine Production and Support Services 

July 2009 
  

	1.	Background 

 Science Applications International Corporation (SAIC) serves as the prime
contractor for the Malaria Vaccine Production and Support Services (MVPSS) contract awarded by the Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID). SAIC develops and supports
malaria vaccine candidate manufacturing for clinical use as part of DMID’s malaria program. 
 Currently, the most advanced and
efficacious malaria vaccine employed thus far is the RTS,S/AS02 vaccine developed by GlaxoSmithKline, which contains a consensus amino acid sequence for the C-terminal half of the malaria parasite P. falciparum (Pf) circumsporozoite protein
(CS) molecule. Administered alone, this vaccine has shown -~50% efficacy in infants in Phase II trials in Africa. Further, primate study data indicated that heterologous prime boosting with an
adenovirus-based CS vaccine candidate may increase the antigen’s efficacy by enhancing and maintaining the T-cell response (CD8+ and CD4+). Additionally, other studies have been performed which indicate the N-terminal portion of CS may further
improve a CS-based vaccine. 
 The manufacture of a full length CS has been refractory to recombinant expression efforts thus far. This is in
large part due to the malaria parasite’s extremely A/T-rich genome with many lysine and arginine repeats, and frequent disulfide bonds. Further, these parasites lack the N-linked glycosylation machinery. Consequently, the expression,
purification, and scale-up of many potential recombinant subunit vaccine candidates have beenunsuccessful.Attention must be paid to potential aberrant post-translational modifications and correct folding when expressing and purifying these as
recombinant proteins. Thus, SAIC seeks to overcome these manufacturing hurdles of full length CS through the Malaria Vaccine Production and Support Services contract to explore an alternative expression platform and screening services. 

 

	2.	Scope of Work 

 Independently and not as an agent of SAIC, Dow shall furnish all of the
necessary services, qualified personnel, materials, equipment, facilities, and travel not otherwise provided under the terms of this agreement as needed for the proof-of-principle evaluation of functional, full-length CSP expression utilizing
Pfēnex Expression TechnologyTM. Optional requirements are also included for Fermentation Optimization and a Technology Transfer package for Fermentation Processes. As part of this support, Dow shall be required to provide summary
reports related to the development and manufacturing process, other documentation as required in the deliverables, bacterial cell lysates and reagent-grade CSprotein. 

SAIC will provide the following information and materials: 
  

	 	2.1.	Background literature/references relating to CSP. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  
  

	 	2.2.	An aliquot of reagent grade CSP antigen (for use as an analytical reference standard) 

  

	 	2.3.	CSP-specific antibody suitable for Western blot analysis 

  

	 	2.4.	Shipping instructions for filtered lysate 

  

	3.	Period of Performance 

 The period of performance (POP) for this effort is upon award
through April 2011. 
  

	4.	Technical Requirements 

  

	 	4.1.	Milestone 1: Evaluation of CSP expression in Pfēnex Expression TechnologyTM 

  

	 	4.1.1.	[*] 

  

	 	4.1.1.1.	[*] 

  

	 	4.1.1.2.	Dow shall transform the resulting plasmids into a strain of Dow’s Pfenex Expression TechnologyTM and plate onto selective medium. 

 

	 	4.1.1.3.	Dow shall select a series of positive clones from assorted vectors and verify correct coding sequences of insert. 

  

	 	4.1.2.	Dow shall assess the expression of CSP in Pfēnex Expression TechnologyTM at [*] mL scale in a minimum of [*] unique strains 

 

	 	4.1.2.1.	Dow shall transform the resulting plasmids into up to [*] host strains. (A minimum of 280 unique Expression Strains) 

  

	 	4.1.2.2.	Dow shall perform [*] as a primary screen. 

  

	 	4.1.2.3.	Dow shall perform a [*] on selected samples. 

  

	 	4.1.3.	Dow shall issue a final report of milestone 1 efforts. 

  

	 	4.1.3.1.	Report shall include an executive summary, brief description of test method with a reference to corresponding SOP, test results (i.e. small scale growth, expression, analytical), and conclusion. Copies of raw data
including sequencing data shall be included as an appendix. 

  

	 	4.2.	Milestone 2 [OPTIONAL]: Fermentation Assessment of CSP in Pfēnex Expression TechnologyTM 

  

	 	4.2.1.	Dow shall screen multiple fermentation conditions at the [*] scale using [*] Expression Strains to evaluate protein quality and expression levels 

 

	 	4.2.1.1.	Execute experiments to screen multiple fermentation conditions in mini-bioreactors for protein expression and protein quality. [*] fermentations per strain) 

 

	 	4.2.1.2.	Dow shall perform [*] analysis on samples from each of the fermentations. 

  

	 	4.2.1.3.	Dow shall perform [*] analysis 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 

 

 
  
  

	 	4.2.2.	Dow shall confirm selected conditions used at the [*] and verify conditions are suitable at the high cell density fermentation [*] scale to evaluate protein quality and expression levels of selected strains chosen based
on data generated in 4.2.1.3. 

  

	 	4.2.2.1.	Dow shall confirm selected conditions and strains identified in the screening experiments in a scalable high cell density fermentation process in multiplex fermentors for protein expression and protein quality.

  

	 	4.2.2.2.	Dow shall collect multiple time point samples for evaluation of protein expression levels and quality 

  

	 	4.2.2.3.	Dow shall utilize a [*] as appropriate to prepare samples from the best fermentation of each expression strain for supply to SAIC. 

4.2.2.3.1. Dow shall transfer to SAIC samples of the filtered whole cell lysate or periplasmic release extract and cell free
broth for further in vitro analysis. 
 4.2.2.3.2. Dow shall perform [*] on samples from each fermentation. 

4.2.2.3.3. Dow shall perform [*] and CSP specific assay on selected samples. 

4.2.2.3.4. Dow shall perform [*] analysis on selected samples. 

 

	 	4.2.3.	Dow shall issue a final report of milestone 2 efforts. 

  

	 	4.2.3.1.	Report shall include an executive summary, brief description of test methods with associated reference to SOPs, data (i.e. small scale growth, expression, analytical), and conclusion. Copies of raw data shall be
included as an appendix. 

  

	 	4.3.	Milestone 3 [OPTIONAL]: Preparation and Characterization of a Pseudomonas-CSP Research Cell Bank (RCB) 

Dow shall prepare a non-GMP Research Cell Bank (RCB). 
  

	 	4.3.1.	DOW shall generate [*] vials of RCB 

  

	 	4.3.2.	DOW will store the RCB a temperature-controlled [*] freezer which has a monitoring system. 

  

	 	4.3.3.	A [*] scale fermentation run shall performed to confirm productivity 

  

	 	4.3.3.1.	Dow shall harvest and prepare filtered lysate from the [*] fermentation ([*] working volume) 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

3 

 

 
  
  

	 	4.3.3.2.	Plasmid retention shall be evaluated using viable count plating of the samples on selective and non-selective media. 

  

	 	4.3.3.3.	Structural stability be evaluated using plasmid restriction digests. 

  

	 	4.3.4.	Dow shall perform a characterization analysis of the generated Pseudomonas-CSP RCB 

  

	 	4.3.4.1.	Phenotype of the strain shall be determined by [*] 

  

	 	4.3.4.2.	Culture purity analysis shall be performed on the RCB. 

  

	 	4.3.4.3.	[*] shall be confirmed by [*] 

  

	 	4.3.4.4.	Dow shall confirm the [*] 

  

	 	4.3.5.	Dow shall issue a final report of milestone 3 efforts. 

  

	 	4.3.5.1.	Report shall include, but no be limited to, an executive summary, description of cell banking methods and materials used, with associated reference to SOPs, characterization data, raw material certificates of analysis,
and copies of raw data. 

  

	 	4.3.5.2.	A draft report shall be submitted to SAW two weeks following completion of task and a final copy submitted one week following SAIC comments. 

 

	5.	Quality Requirements 

 Dow shall maintain a Quality System that meets scientific
expectations of traceability, reliability and control. Dow is responsible for the development and demonstration of suitability of contracted deliverables as well as providing reports and managing this project in a manner that meets scientific
expectations of traceability, reliability and control ensuring that the filtered whole cell lysate or periplasmic release extract and cell free broth produced and analyzed in the developed process and assays have the quality, and identity they
purport. 
  

	6.	Meeting and Conference Requirements 

 Unless an alternative directive is provided;
meeting, conference, and audit support shall include the following: 
  

	 	6.1.	Dow shall schedule a kickoff meeting via on-site meeting at Dow’s facilities with SAIC within 7 days of award. The agenda shall be provided by Dow in advance. The purpose of the kickoff meeting is formal
introduction of key staff and project management, technical and contractual discussions, and initial action items required to initiate contract work. 

  

	 	6.2.	Dow shall participate in biweekly meetings and/or teleconferences with SAIC. Such meetings may include, but are not limited to, meetings to discuss the technical (e.g., assay designs and critical reagents), quality,
schedule, regulatory, and contractual aspects of the program and site visits to Dow’s facilities. All visits to Dow’s facility shall be prearranged. Dow shall be responsible for preparing meeting agendas and summaries. Meeting minutes
shall be captured by Dow and are due to SAIC within 7 days after the completion of a biweekly teleconference. 

  

	 	6.3.	Dow also shall be available for ad hoc support (e.g., phone calls and e-mails) to SAIC as required for project communications. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

4 

 

 
  
  

	7.	Reporting Requirements 

  

	 	7.1.	Monthly Technical and Business Progress Report: A monthly TPR shall be submitted to the SAIC management point of contact by the eighth of each month during subcontract POP. 

 

	 	7.1.1.	The TPR shall cover the work accomplished as well as issues and proposed resolutions that occur during each reporting period. 

  

	 	7.1.2.	Each TPR also shall contain an updated monthly project management schedule to indicate work completed and any change in schedule. Deliverables shall be incorporated into the schedule. 

 

	 	7.2.	Reports should include an updated inventory log to include cell banks, samples, and SAIC provide materials, and a notice of any temperature deviations of equipment storing SAIC material. The report shall also document
any changes made to methods and procedures utilized for the CSP expression efforts. 

  

	 	7.2.1.	Report shall include invoicing information for work performed during each reporting period and anticipated work activities. 

  

	 	7.3.	Documentation to Support an IND or Amendment: Data generated under this subcontract may be incorporated into an MA submission. Dow shall provide a list of relevant SOPs or other control, development and testing
documents as requested. 

  

	8.	Subcontract Deliverables 

 Table 3 summarizes documents and other deliverables due
to SAIC at the indicated timelines. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

5 

 

 
  
 Table 3. Deliverables to SAIC

  

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	Form
		  		  		  		  	
	1	  	Project Management	  	Final Project Schedule	  	To be submitted within 1 week of kickoff meeting; schedule to be baselined within 3 weeks of award	  	1 electronic file, Preferably .mmp format
					
	 2
	  	Meeting Requirement	  	Meeting Agenda	  	1 day prior to regular meetings, 3 days prior to kickoff	  	1 electronic Word document or email
					
	 3
	  	Meeting Requirement	  	Meeting Summaries	  	7 days after meetings	  	1 electronic Word document
					
	 4
	  	Technical Requirement	  	Milestone 1 Report	  	Draft: 2 weeks following completion of procedure Final: 2 weeks after receipt of SAIC comments	  	 Draft: Word Document
 Final: Signed
PDF

					
	5	  	Technical Requirement	  	Milestone 2 Report [If Funded]	  	Draft: 2 weeks following completion of testing. Final: 2 weeks after receipt of SAIC comments	  	 Draft: Word Document
 Final: Signed
PDF

					
	 6
	  	Technical Requirement	  	Milestone 2 Fermentation samples [If Funded]	  	1 week following successful fermentation run.	  	Sent to SAIC designee in proper shipping containers
					
	 7
	  	Technical Requirement	  	 Milestone 3
 Cell Bank Report [If

Funded]
	  	Draft: 2 weeks following completion of requirement. Final: 2 weeks after receipt of SAIC comments	  	 Draft: Word Document
 Final: Signed
PDF

					
	 8
	  	Technical Requirement	  	Milestone 3 Lysate from 20 L fermentation [If Funded]	  	2 weeks following completion of requirement.	  	Sent to SAIC designee in proper shipping containers

	*	Days = Calendar days; SAIC shall provide comment within 1 week. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

6 

 

 
 SCHEDULE B - U.S. GOVERNMENT TERMS AND CONDITIONS 

Applicable to all U.S. Government “Commercial Items” Subcontracts 

PART III - FAR CLAUSES 
  

	1.	DEFINITIONS 

 In all such clauses, unless the context of the clause requires otherwise, the term
“Contractor” shall mean Seller, the term “Contract” shall mean this Order, and the terms “Government,” “Contracting Officer” and equivalent phrases shall mean Buyer and Buyer’s Purchasing Representative,
respectively. It is intended that the referenced clauses shall apply to Seller in such manner as is necessary to reflect the position of Seller as a subcontractor to Buyer, to insure Seller’s obligations to Buyer and to the United States
Government, and to enable Buyer to meet its obligations under its Prime Contract or Subcontract. 
 The following definitions apply unless otherwise
specifically stated: 
 “Buyer” - the legal entity issuing this Order. 

“Commercial Item” — as defined by FAR 2-101 

“FAR” - the Federal Acquisition Regulation. 

“Prime Contract” - the Government contract under which this Order is issued. 

“Purchasing Representative” - Buyer’s authorized representative. 

“Seller” - the legal entity which contracts with the Buyer. 

“This Order” - this contractual instrument, including changes. 
  

	2.	IDENTIFICATION OF CONTRACT NUMBERS 

 Government contract numbers shown on this Order shall be included in
subcontracts and purchase orders issued by Seller hereunder. 
  

	3.	COMMERCIAL ITEMS 

 By FAR 2-101, “Commercial item” means— 

(1) Any item, other than real property, that is of a type customarily used by the general public or by non-governmental entities for purposes
other than governmental purposes, and— 
 (i) Has been sold, leased, or licensed to the general public; or 

(ii) Has been offered for sale, lease, or license to the general public; 

(2) Any item that evolved from an item described in paragraph (1) of this definition through advances in technology or performance and
that is not yet available in the commercial marketplace, but will be available in the commercial marketplace in time to satisfy the delivery requirements under a Government solicitation; 

(3) Any item that would satisfy a criterion expressed in paragraphs (1) or (2) of this definition, but for—
(i) Modifications of a type customarily available in the commercial marketplace; or 
 (ii) Minor modifications of a type not
customarily available in the commercial marketplace made to meet Federal Government requirements. “Minor modifications” means modifications that do not significantly alter the nongovernmental function or essential physical characteristics
of an item or component, or change the purpose of a process. Factors to be considered in determining whether a modification is minor include the value and size of the modification and the comparative value and size of the final product. Dollar
values and percentages may be used as guideposts, but are not conclusive evidence that a modification is minor; 
 (4) Any combination of
items meeting the requirements of paragraphs (1), (2), (3), or (5) of this definition that are of a type customarily combined and sold in combination to the general public; 

(5) Installation services, maintenance services, repair services, training services, and other services if— (i) Such services are
procured for support of an item referred to in paragraph (1), (2), (3), or (4) of this definition, regardless of whether such services are provided by the same source or at the same time as the item; and 

(ii) The source of such services provides similar services contemporaneously to the general public under terms and conditions similar to those
offered to the Federal Government; 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 1 of 5 

 

 
  
 (6) Services of a type offered and
sold competitively in substantial quantities in the commercial marketplace based on established catalog or market prices for specific tasks performed or specific outcomes to be achieved and under standard commercial terms and conditions. This does
not include services that are sold based on hourly rates without an established catalog or market price for a specific service performed or a specific outcome to be achieved. For purposes of these services— 

(i) “Catalog price” means a price included in a catalog, price list, schedule, or other form that is regularly maintained by the
manufacturer or vendor, is either published or otherwise available for inspection by customers, and states prices at which sales are currently, or were last, made to a significant number of buyers constituting the general public; and 

(ii) “Market prices” means current prices that are established in the course of ordinary trade between buyers and sellers free to
bargain and that can be substantiated through competition or from sources independent of the offerors. 
  

	4.	DISPUTES 

 (a) Notwithstanding any provisions herein to the contrary: 

 

	 	(1)	If a decision relating to the Prime Contract is made by the Contracting Officer and such decision is also related to this Order, said decision, if binding upon Buyer under the Prime Contract shall in turn be binding
upon Buyer and Seller with respect to such matter; provided, however, that if Seller disagrees with any such decision made by the Contracting Officer and Buyer elects not to appeal such decision, Seller shall have the right reserved to Buyer under
the Prime Contract with the Government to prosecute a timely appeal in the name of Buyer, as permitted by the contract or by law, Seller to bear its own legal and other costs. If Buyer elects not to appeal any such decision, Buyer agrees to notify
Seller in a timely fashion after receipt of such decision and to assist Seller in its prosecution of any such appeal in every reasonable manner. If Buyer elects to appeal any such decision of the Contracting Officer, Buyer agrees to furnish Seller
promptly with a copy of such appeal. Any decision upon appeal, if binding upon Buyer, shall in turn be binding upon Seller. Pending the making of any decision, either by the Contracting Officer or on appeal, Seller shall proceed diligently with
performance of this Order. 

  

	 	(2)	If, as a result of any decision or judgment which is binding upon Seller and Buyer, as provided above, Buyer is unable to obtain payment or reimbursement from the Government under the Prime Contract for, or is required
to refund or credit to the Government, any amount with respect to any item or matter for which Buyer has reimbursed or paid Seller, Seller shall, on demand, promptly repay such amount to Buyer. Additionally, pending the final conclusion of any
appeal hereunder, Seller shall, on demand, promptly repay any such amount to Buyer. Buyer’s maximum liability for any matter connected with or related to this Order which was properly the subject of a claim against the Government under the
Prime Contract shall not exceed the amount of Buyer’s recovery from the Government. 

  

	 	(3)	If this Order is issued by Buyer under a Government Subcontract rather than a Prime Contract, and if Buyer has the right under such Subcontract to appeal a decision made by the Contracting Officer under the Prime
Contract in the name of the Prime Contractor (or if Buyer is subject to any arbitrator’s decision under the terms of its subcontract), and said decision is also related to this Order, this Disputes Clause shall also apply to Seller in a manner
consistent with its intent and similar to its application had this Order been issued by Buyer under a Prime Contract with the Government. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 2 of 5 

 

 
  
  

	 	(4)	Seller agrees to provide certification that data supporting any claim made by Seller hereunder is made in good faith and that the supporting data is accurate and complete to the best of Seller’s knowledge or
belief, all in accordance with the requirements of the Contract Disputes Act of 1978 (41USC601-613) and implementing regulations. If any claim of Seller is determined to be based upon fraud or misrepresentation, Seller agrees to defend, indemnify
and hold Buyer harmless for any and all liability, loss, cost or expense resulting therefrom. 

 (b) Any dispute not addressed in paragraph
(a) above, will be subject to the disputes clause of Schedule A of this subcontract agreement. 
  

	5.	OTHER GOVERNMENT PROCUREMENT 

 Nothing contained herein shall be construed as precluding the Seller from
producing items for direct sale to the Government, utilizing therefore all hardware and/or software, including designs, drawings, engineering data or other technical or proprietary information furnished Seller by Buyer, provided the Government has
the unrestricted right to permit the use thereof for such purpose. 
  

	6.	TERMINATION FOR CONVENIENCE 

 The Buyer may terminate performance of work under this subcontract in
whole, or in part if the Purchasing Representative determines that a termination is in the Buyer’s interest. The Buyer shall terminate by delivering to the Seller a Notice of Termination specifying the extent of termination and the effective
date. In the event of such termination, the Seller shall immediately stop all work hereunder and shall immediately cause any and all of its suppliers and subcontractors to cease work. Subject to the terms of this order, the Seller shall be paid a
percentage of the contract price reflecting the percentage of the work performed prior to the notice of termination, plus reasonable charges the Seller can demonstrate to the satisfaction of the Buyer using its standard record keeping system, have
resulted from the termination. The Seller shall not be required to comply with the cost accounting standards or cost principles for this purpose. The Seller shall not be paid for any work performed or costs incurred which reasonably could have been
avoided. 
  

	7.	ANTI-KICKBACK ACT OF 1986 

 By accepting this Order, Seller certifies that it has not offered, provided,
or solicited and will not offer, provide, or solicit any kickback in violation of the Anti-Kickback Act of 1986 (41 USC §§ 51-58). “Kickback” means any money, fee, commission, credit, gift, gratuity, thing of value, or
compensation of any kind that is provided, directly or indirectly, for the purpose of improperly obtaining or rewarding favorable treatment in connection with a prime contract or a subcontract relating to a prime contract. Seller agrees to
indemnify, defend, and hold Buyer harmless from and against any losses, liabilities, offsets and expenses (including reasonable attorney’s fees) arising out of or relating to Seller’s failure to comply with the provisions of the
Anti-Kickback Act. 
  

	8.	FAR CLAUSES APPLICABLE TO THIS ORDER 

 The clauses in FAR Subpart 52.2 referenced in subparagraph (a),
the clauses applicable in subparagraph (b), and those referenced and checked in subparagraph (c) below, in effect on the date of this Order, are incorporated herein and made a part of this Order. To the extent that an earlier version of any
such clause is included in the Prime Contract or Subcontract under which this Order is issued, the date of the clause as it appears in such Prime Contract or Subcontract shall be controlling and said version shall be incorporated herein. The extent
of the flow down shall be as required by the clause. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 3 of 5 

 

 
  
 (a) The following clauses are applicable to this
order: 
  

			
	 Clause & FAR
 Ref.
	  	Title of Clause
	52.219-8	  	Utilization of Small Business Concerns [15 U.S.C. 637(d)(2) and (3)] In all subcontracts that offer further subcontracting opportunities. If the subcontract (except subcontracts to small business concerns) exceeds $550,000
($1,000,000 for construction of any public facility), the subcontractor must include 52.219-8 in lower tier subcontracts that offer subcontracting opportunities.
	52.222-26	  	Equal Opportunity (E.O. 11246)
	52.222-35	  	Equal Opportunity for Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (38 U.S.C. 4212)
	52.222-36	  	Affirmative Action for Workers with Disabilities (29 U.S.C. 793)
	52.222-39	  	Notification of Employees Rights Concerning Payment of Union Dues or Fees (E.O. 13201)
	52.222-41	  	Service Contract Act of 1965, as Amended (41 U.S.C. 351, et. Seq.)
	52.247-64	  	Preference for Privately-Owned U.S. Flag Commercial Vessels (46 U.S.C. Appendix 1241(b) and 10 U.S.C. 2631)
	52.227-11	  	Patent Rights June 1997

 (b) The Seller shall comply with the FAR clauses in this paragraph (b) that the Buyer has indicated as being incorporated
into this order by reference to implement provisions of law or Executive orders applicable to acquisitions of commercial items: 
  

					
	 	  	 Clause &
 FAR Ref.
	  	Title of Clause
	 ̈	  	52.203-6	  	Restrictions on Subcontractor Sales to the Government, with Alternate I (41 U.S.C. 253g and 10 U.S.C. 2402) (If order exceeds $100,000)
	 ̈	  	52.219-9	  	Small Business Subcontracting Plan [15 U.S.C. 637(d)(4)] (if order to a large business and exceeds $550,000)
	 ̈	  	52.219-9	  	Alternate I
	 ̈	  	52.219-9	  	Alternate II
	 ̈	  	52.219-16	  	Liquidated Damages-Subcontracting Plan (15 U.S.C. 637(d)(4)(F)(i)) (If FAR 52.219-9 is incorporated)
	 ̈	  	52.222-3	  	Convict Labor (E.O. 11755)
	 ̈	  	52.222-19	  	Child Labor-Cooperation with Authorities and Remedies (E.O. 13126)
	 ̈	  	52.222-21	  	Prohibition of Segregated Facilities
	 ̈	  	52.222-37	  	Employment Reports on Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (38 U.S.C. 4212)
	 ̈	  	52.225-1	  	Buy American Act - Supplies (41 U.S.C. 10a-10d)
	 ̈	  	52.225-3	  	Buy American Act - Free Trade Agreements - Israeli Trade Act (41 U.S.C. 10a-10d, 19 U.S.C. 3301 note, 19 U.S.C. 2112 note, Pub. L. 108-77, 108-78, 108-286 & 109-53)
	 ̈	  	52.225-3	  	Alternate I
	 ̈	  	52.225-3	  	Alternate II
	 ̈	  	52.225-5	  	Trade Agreements (19 U.S.C. 2501, et. seq., 19 U.S.C. 3301 note)
	 ̈	  	52.225-13	  	Restrictions on Certain Foreign Purchases (E.O.s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury)
	 ̈	  	52.239-1	  	Privacy or Security Safeguards (5 U.S.C. 552a)

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 4 of 5 

 

 
  
 (c) The Seller shall comply with the FAR clauses in
this paragraph (c), applicable to commercial services, which the Buyer has indicated as being incorporated in this Order by reference to implement provisions of law or execute orders applicable to acquisitions of commercial items: 

 

					
	 	  	 Clause &
 FAR Ref.
	  	Title of Clause
	 ̈	  	52.222-42	  	Statement of Equivalent Rates for Federal Hires (29 U.S.C. 206 and 41 U.S.C. 351 et. seq.)
	 ̈	  	52.222-43	  	Fair Labor Standards Act and Service Contract Act - Price Adjustment (Multiple Year and Option Contracts) (29 U.S.C. 206 and 41 U.S.C. 351 et. seq.)
	 ̈	  	52.222-44	  	Fair Labor Standards Act and Service Contract Act - Price Adjustment (29 U.S.C. 206 and 41 U.S.C. 351 et. seq.)

 (d) In addition to the clauses listed in paragraphs (a), (b) and (c) above, if this order will contain Government
property, the below listed clauses as checked, are applicable: 
  

					
	 	  	 Clause &
 FAR Ref.
	  	Title of Clause
	 ̈	  	52.245-1	  	Government Property
	 ̈	  	52.245-2	  	Government Property Installation Operation Services
	 ̈	  	52.245-9	  	Use & Charges (When FAR 52.245-1 is incorporated)

 (e) In addition to the clauses listed in paragraphs (a) (b) (c) and (d) above, if this order will be
performed under any order issued by an agency of the Department of Defense, the below listed clauses are applicable: 
  

					
	 	  	 Clause &
 FAR Ref.
	  	Title of Clause
	 ̈	  	252.219-7003	  	Small Business Subcontracting Plan (DoD Contracts) (15 U.S.C. 637)
	 ̈	  	252.219-7004	  	Small Business Subcontracting Plan (Test Program) (15 U.S.C. 637 note)
	 ̈	  	252.225-7001	  	Buy American Act and Balance of Payments Program (41 U.S.C. 10a-10d, E.O. 10582)
	 ̈	  	252.225-7012	  	Preference for Certain Domestic Commodities (10 U.S.C. 2533a) (If order exceeds $100,000)
	 ̈	  	252.225-7014	  	Preference for Domestic Specialty Metals, Alternate I (10 U.S.C. 2241 note)
	 ̈	  	252.225-7015	  	Restriction on Acquisition of Hand or Measuring Tools (10 U.S.C. 2533a)
	 ̈	  	252.225-7021	  	Trade Agreements (19 U.S.C. 2501-2518 and 19 U.S.C. 3301 note)
	 ̈	  	252.225-7036	  	Buy American Act—Free Trade Agreements—Balance of Payments Program (41 U.S.C. 10a-10d and 19 U.S.C. 3301 note)
	 ̈	  	252.226-7001	  	Utilization of Indian Organizations, Indian-Owned Economic Enterprises, and Native Hawaiian Small Business Concerns (Section 8021 of Public Law 107-248 and similar sections in subsequent DoD appropriations acts) (If order exceeds
$500,000)
	 ̈	  	252.227-7015	  	Technical Data-Commercial Item
	 ̈	  	252.237-7019	  	Training for Contractor Personnel Interacting with Detainees (Section 1092 of Public Law 108-375)
	 ̈	  	252.246-7003	  	Notification of Potential Safety Issues
	 ̈	  	252.247-7023	  	Transportation of Supplies by Sea (10 U.S.C. 2631)
	 ̈	  	252.247-7024	  	Notification of Transportation of Supplies by Sea (10 U.S.C. 2631)

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 5 of 5 

 

 
 SUBCONTRACT AGREEMENT 

FIRM FIXED PRICE COMMERCIAL ITEMS (GOVERNMENT) 
  

					
	SUBCONTRACTOR:	  	SUBCONTRACT #:	  	P010022290
			
	Pfenex Inc.	  	MODIFICATION #:	  	1
			
	ADDRESS:	  	DPAS RATING:	  	NA
			
	 5501 Oberlin Dr.
  

San Diego, CA 92121
	  	TYPE:	  	 FIRM FIXED PRICE COMMERCIAL
  

ITEMS (GOVERNMENT)

			
		  	VALUE:	  	$336,800.00

 Modification No. 1 to Subcontract No. P010022290 is issued to assign Subcontract No. P010022290 from The Dow Chemical
Company to Pfenex Inc. (Pfenex). 
  

	1.0	MODIFICATION EFFECTIVE DATE 

 This Modification No. 1 to Subcontract No. P010022290 is effective
December 1, 2009. 
  

	2.0	ASSIGNMENTS 

 In accordance with Subcontract No. P010022290 Section 5.0, Assignments and
Subcontracts, and the Novation Agreement signed by Science Applications International Corporation (SAIC), The Dow Chemical Company, and Pfenex, attached hereto, Subcontract No. P010022290 is assigned from The Dow Chemical Company to Pfenex. 

 

	3.0	PRICE 

 The total not-to-exceed price of Subcontract No. P010022290 remains $336,800.00. Of this amount,
at the time of assignment of this Subcontract total payments to The Dow Chemical Company are $62,282.50. The remaining Subcontract price available to be paid to Pfenex is $274,317.50. 

 

	4.0	TECHNICAL AND CONTRACTUAL REPRESENTATIVES 

 Pfenex (SELLER) Technical and Contractual representatives
are: 
  

					
	TECHNICAL:	  	 Charles H. Squires, Ph.D.
	  	
			
	CONTRACTUAL:	  	 Patrick Lucy
	  	
		
	SAIC (BUYER) Technical and Contractual representatives remain:	  	
			
	TECHNICAL:	  	 Steve Huang
	  	
			
	CONTRACTUAL:	  	 Gina B. McGeehan
	  	

 ** 

All other Subcontract terms and conditions, 

including Key Personnel and Statement of Work, remain unchanged. 

** 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 1 of 2 

 

 
  
 Modification No. 1 Attachment: Agreement
of Assignment and Assumption, effective December 1, 2009 
 In witness whereof, the duly authorized representatives of Buyer and Seller have executed
this Subcontract modification No. 1 on the dates shown. 
  

									
	PFENEX, INC.	 		 	SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
			
	  
	 		 	 /s/ Janet E. Lilly

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick Lucy
	 		 	Name:	 	 Janet E. Lilly

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Senior Subcontracts Administrator

					
	Date:	 	  
	 		 	Date:	 	 January 20, 2010

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 2 of 2 

 AGREEMENT OF ASSIGNMENT AND ASSUMPTION 

THIS AGREEMENT is made and entered into effective December 1, 2009 by and among The Dow Chemical Company, a Delaware corporation
(“Transferor); Pfenex, Inc., a Delaware corporation (“Transferee”), and Science Applications International Corporation (“SAIC”), a Delaware corporation. 

RECITALS 
 A. SAIC has
entered into a certain contract with Transferor, namely: Subcontract Agreement No. P010022290 (the “Contract”). The term “Contract”; as used in this Agreement, means the above contract including all modifications thereto made
between SAIC and Transferor prior to the effective date of this Agreement. 
 B. As of December 1, 2009 Transferor has transferred to
Transferee all the assets of Transferor’s biopharmaceuticals business. 
 C. The parties hereto desire that SAIC consent to the
assignment of the Contract to Transferee. 
 D. NOW, THEREFORE, for and in consideration of the premises and other good and
sufficient consideration, the parties hereto agree as follows: 
 1. Transferor confirms to SAIC the full and complete assignment of the
Contract to Transferee (the “Assignment”) and waives any claims and rights against SAIC that it now has or may have in the future in connection with the Contract. 

2. Transferee represents to SAIC that by virtue of the Assignment, Transferee has acquired from Transferor all of the assets of the Transferor
relating to the Contract, and that Transferee is in a position to fully perform all of the obligations of the Transferor under the Contract. 

3. SAIC agrees to be bound by and to perform the Contract in accordance with the conditions contained in the Contract. Transferee assumes all
obligations and liabilities of, and all claims against, Transferor under the Contract as if Transferee were the original party to the Contract. 

4. Transferee ratifies all previous actions taken by Transferor with respect to the Contract, with the same force and effect as if the action
had been taken by Transferee. 
 5. SAIC recognizes Transferee as Transferor’s successor in interest in and to the Contract. Transferee
by this Agreement becomes entitled to all rights, titles, and interests of Transferor in and to the Contract as if Transferee were the original party to the Contract. 

6. Except as expressly provided in this Agreement, nothing in this Agreement shall be construed as a waiver of any rights of SAIC against
Transferor for Transferor’s performance or failure to perform prior to the effective date of this Assignment. SAIC reserves any and all claims that it may have against Transferor to Transferor’s performance or failure to perform the
Contract up to the date of this Assignment, including, but not limited to, any further claim of the Government, no such claim(s) being known or anticipated at this time. 

7. All payments and reimbursements previously made by Transferor to SAIC, and all other previous actions taken by SAIC under the Contract,
shall be considered to have discharged those parts of SAIC’s obligations under the Contract. 
 8. Payment of any and all proper
invoices under the Contract submitted by SAIC to Transferor prior to the date this Agreement is fully executed shall be paid to SAIC by Transferee. Thereafter, all payments under the Contract after the date this Agreement is fully executed by all
the parties hereto shall be made by Transferee. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

1 

 

 
  
 9. The Transferor will complete all
Contract closeout actions specified in Subcontract Agreement No. P010022290 as necessary and requested by SAIC 
 10. SAIC shall be
responsible for no costs as a result of this Agreement. 
 11. This Agreement shall be governed by and interpreted in accordance with the
laws of the State of California. 
 12. Transferor waives notice of, and consents to, any further modifications of the Contract. 

13. The Contract shall remain in full force and effect, except as modified by this Agreement. Each party has executed this Agreement as of the
day and year first above written. 
 IN WITNESS WHEREOF, the parties have executed this assignment effective as of the date first written
above on the dates indicated below. 
  

									
	TRANSFEROR:	 		 	TRANSFEREE:
	The Dow Chemical Company	 		 	Pfenex Inc.
	2030 Dow Center	 		 	5501 Oberlin Drive
	Midland, MI 48674	 		 	San Diego, CA 92121
					
	By:	 	 /s/ Authorized Person
	 		 	By:	 	 /s/ Authorized Person

					
	Title:	 	 Business R&D Director
	 		 	Title:	 	 V.P. Business Development

					
	Date:	 	 December 22, 2009
	 		 	Date:	 	 January 7, 2010

				
	SCIENCE APPLICATIONS INTERNATIONAL CORPORTATION	 		 		 	
	5202 Presidents Court, Suite 110	 		 		 	
	Frederick, MS 21703	 		 		 	
					
	By:	 	 /s/ Janet E. Lilly
	 		 		 	
					
	Title:	 	 Sr. Subcontracts Admin
	 		 		 	
					
	Date:	 	 January 20, 2010
	 		 		 	

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 

 

 
 SUBCONTRACT AGREEMENT 

FIRM FIXED PRICE COMMERCIAL ITEMS (GOVERNMENT) 
  

							
	SUBCONTRACTOR:	  	SUBCONTRACT #:	  	P010022290
			
	Pfenex Inc.	  	MODIFICATION #:	  	2
			
	ADDRESS:	  	DPAS RATING:	  	NA
			
	301 Newbury Street PMB 251, Danvers, MA 01923	  	TYPE:	  	 FIRM FIXED PRICE
  

COMMERCIAL ITEMS
  

(GOVERNMENT)

		  	VALUE:	  	$486,800.00

 Modification No. 2 to Subcontract No. P010022290 is issued to Pfenex Inc. (Pfenex) to add funding and
Statement of Work for the Production of additional filtered lysates, and purified full-length CSP expressed in Pfēnex Expression TechnologyTM. As part of this support, Pfenex shall be required to provide summary reports related to
the development and manufacturing process, other documentation as required in the deliverables, bacterial cell lysates and reagent- grade CS protein of 80-85% purity.. 
  

	 	1.0	MODIFICATION EFFECTIVE DATE 

 This Modification No. 2 to Subcontract No. P010022290
is effective May 24, 2010. 
  

	 	2.0	PRICE 

 The total not-to-exceed price of Subcontract No. P010022290 is increased by
$150,000.00 from $336,800.00.00 to $486,800.00. Of this amount, at the time of assignment of this Subcontract total payments to The Dow Chemical Company were $62,282.50 thus the remaining Subcontract price available to be paid to Pfenex is
$424,517.50. 
  

	 	3.0	INVOICES 

 Invoices shall be prepared in duplicate and contain the following information;
subcontract number, subproject number, Stage #. Invoices will be mailed to: 
 Science Applications International Corporation 

Attention: Earleen K. Smith 
 5202
Presidents Court, Suite 110 
 Frederick, Maryland 21703 

Earleen.k.smith@saic.com 
  

	 	3.0	TECHNICAL AND CONTRACTUAL REPRESENTATIVES 

 Pfenex (SELLER) Technical and Contractual
representatives are: 
  

							
		 	TECHNICAL:	  	 Charles H. Squires, Ph.D.
	  	
		 	CONTRACTUAL:	  	 Patrick Lucy
	  	

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 1 of 2 

 

 
  
 SAIC (BUYER) Technical and
Contractual representatives remain: 
  

							
		 	TECHNICAL:	  	 Steve Huang
	  	
		 	CONTRACTUAL:	  	 Earleen K. Smith
	  	

 4.0 Statement of Work entitled “Evaluation of Malaria CSP Expression in Pfēnex Expression
TechnologyTM, and Process Manufacturing, Malaria Vaccine Production and Support Services, May 4, 2010, Subcontract Modification 2” is herein incorporated into and made part of Subcontract No. P010022290. 

*** 
 All other Subcontract terms
and conditions remain unchanged. 
 *** 
 In
witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract modification No. 2 on the dates shown. 
  

									
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Earleen K. Smith

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick Lucy
	 		 	Name:	 	 Earleen K. Smith

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

					
	Date:	 	 05/24/10
	 		 	Date:	 	 5/24/10

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 2 of 2

 STATEMENT OF WORK 

Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM 

and Process Manufacturing 

Malaria Vaccine Production and Support Services 

May 4, 2010 

Subcontract Modification 2 
  

	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all of
the necessary services, qualified personnel, materials, equipment, facilities, and travel not otherwise provided under the terms of this agreement as needed for the production of additional filtered lysates, and purified full-length CSP expressed in
Pfēnex Expression TechnologyTM. As part of this support, Pfenex shall be required to provide summary reports related to the development and manufacturing process, other documentation as required in the deliverables, bacterial cell
lysates and reagent-grade CS protein of [*]. 
 SAIC will provide the following information and materials: 

 

	 	1.1.1.	Background literature/references relating to Circumsporozoite Protein (CSP). 

  

	 	1.1.2.	Additional anti-CSP mAbs and control CSP, if required. 

  

	 	1.1.3.	Shipping instructions for filtered lysates and purified CSP protein 

  

	2.	Technical Requirements 

  

	 	2.1.	Milestone 1: Provide filtered lysates to SAIC 

  

	 	2.1.1.	Pfenex shall use [*] to prepare filtered lysates starting from [*] cell paste from the best fermentation performed in Stage 2 for each of the three strains [*]. 

 

	 	2.1.2.	Pfenex shall ship the filtered lysates to a contractor designated by SAIC. 

  

	 	2.2.	Milestone 2: [*] protein to SAIC 

  

	 	2.2.1.	Pfenex shall evaluate up to four [*] to capture CSP protein using batch binding experiments in 96-well plate format. 

  

	 	2.2.2.	Pfenex shall conduct small scale [*] runs using up to two selected [*] to evaluate purification of CSP protein. 

  

	 	2.2.3.	Pfenex shall conduct small scale secondary chromatography runs using up to two selected [*] using elution pool from the primary capture column runs. 

 

	 	2.2.4.	Pfenex shall evaluate up to two [*] for reduction of [*]. 

  

	 	2.2.5.	Pfenex shall analyze the final purified proteins and the filtered lysate using analytical methods including [*] 

  

	 	2.2.5.1.	Pfenex shall assess the difference in endotoxin level between filtered lysate and purified CSP. 

  

	 	2.2.5.2.	Pfenex shall also assess [*] 

  

	 	2.2.6.	Pfenex shall ship the resulting purified CSP protein (approximately 10 mg) to SAIC. 

 Note: The
purification activities are designed to result in 10 mg of purified CSP protein. Pfenex will carry out the activities as described above, however if additional activities are required to achieve the 10 mg deliverable an additional scope of work
under a new contract modification may be necessary. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

1 

	 	2.3.	Pfenex shall issue a final report of milestone 1 and 2 efforts. 

  

	 	2.3.1.	Report shall include an executive summary, brief description of methods, results and conclusions, inventory of reagents provided by SAIC, and raw data in PDF format. 

 

	3.	Deliverables to SAIC 

  

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	 Form

	 1
	  	Technical	  	 [*]
	  	Within a week of completion	  	Sent to SAIC designee in proper shipping containers with a temperature monitor
					
	 2
	  	Technical	  	 [*]
	  	Within a week of completion	  	Sent to SAIC designee in proper shipping containers with a temperature monitor
					
	 3
	  	Technical	  	Unused reagents provided by SAIC	  	Within 2 week2 of SAIC request	  	Sent to SAIC designee in proper shipping containers
					
	 4
	  	Reporting	  	Weekly Email Update	  	COB Friday	  	Email
					
	 5
	  	Reporting	  	Final Report	  	Draft: 2 weeks following completion Final: 2 weeks after receipt of SAIC comments	  	Draft: Word Document
Final: Signed Pdf

  

	*	Days = Calendar days; SAIC shall provide comment within 1 week. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 

 

 
 SUBCONTRACT AGREEMENT 

FIRM FIXED PRICE COMMERCIAL ITEMS (GOVERNMENT) 
  

					
	SUBCONTRACTOR:	 	SUBCONTRACT #:	  	P010022290
			
	Pfenex Inc.	 	MODIFICATION #:	  	3
			
	ADDRESS:	 	DPAS RATING:	  	Not Rated
			
	301 Newbury Street PMB 251, Danvers, MA 01923	 	TYPE:	  	 FIRM FIXED PRICE COMMERCIAL
  

ITEMS (GOVERNMENT)

		 	VALUE:	  	$486,800.00

 Modification No. 3 to Subcontract No. P010022290 is issued to Pfenex Inc. (Pfenex) to update the payment terms
with regard to the funding added as part of Modification #2. 
  

	Article 1.4	PAYMENT – is amended to read as follows: 

 (a) Original Subcontract Award: For each Stage of work
there will be two invoices each totaling 50 % of the price for each Stage of Work, an initial invoice upon commencement of the Stage and a final invoice upon acceptance of the final report for each Stage. 

(b) Subcontract Modification #2: For each of the two Milestones in the Statement of Work dated May 4, 2010 (modification #2) there will be two invoices
each totaling 50% of the price for each Milestone, an initial invoice upon commencement of the Milestone and a final invoice upon acceptance of the final report and associated deliverables for each Milestone. 

(c) Payment terms will be Net 45 days from date of invoice. Upon receipt of invoice Buyer shall within five (5) business days review the invoice and
determine if the invoice is acceptable. “If Buyer reasonable deems the invoice unacceptable Buyer shall contact Seller and Seller shall reissue a conforming invoice with a new date of invoice. If (1) Buyer does not pay on time or
(2) Buyer’s financial responsibility becomes unsatisfactory (S&P rating below BBB- or Moody’s rating below Baa3) to Seller and Seller deems itself insecure, Seller may accelerate the due date and demand immediate payment on any
outstanding invoice for Product, or may require cash payments or satisfactory security for future deliveries and for payment of all sums owed under this Agreement. Buyer agrees to pay all costs and expenses, including reasonable attorney’s
fees, incurred by Seller in the collection of any sum payable by Buyer to Seller, or in the exercise of any remedy. Seller may charge Prime +2% on all overdue amounts. 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract modification No. 3 on the dates shown. 

 

									
	PFENEX INC.	 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Earleen K. Smith

	(Signature)	 	(Signature)
					
	Name:	 	 Patrick Lucy
	 		 	Name:	 	 Earleen K. Smith

	(Type or Print)	 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

					
	Date:	 	 June 14, 2010
	 		 	Date:	 	 6/15/10

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 1 of 1

 

 
  
 SUBCONTRACT AGREEMENT 

FIRM FIXED PRICE COMMERCIAL ITEMS (GOVERNMENT) 
  

					
	SUBCONTRACTOR:	  	SUBCONTRACT #:	  	P010022290
			
	Pfenex Inc.	  	MODIFICATION #:	  	4
			
	ADDRESS:	  	DPAS RATING:	  	Not Rated
			
	301 Newbury Street PMB 251, Danvers, MA 01923	  	TYPE:	  	 FIRM FIXED PRICE COMMERCIAL
  

ITEMS (GOVERNMENT)

		  	VALUE:	  	$721,800.00

 Modification No. 4 to Subcontract No, P010022290 Is issued to Pfenex Inc, (Pfenex) to add funding and
Statement of Work for the Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM and Process Manufacturing. 
  

	Article 1.0	PRICE is amended to read as follows: 

 The total not-to-exceed price of Subcontract No. P010022290 is
increased by $235,000.00 from $486,800.00 to $721,800.00 including profit. 
  

	Article 1.4	PAYMENT – is amended to read as follows: 

 (a) Original Subcontract Award: For each Stage of work
there will be two invoices each totaling 50 % of the price for each Stage of Work, an initial invoice upon commencement of the Stage and a final invoice upon acceptance of the final report for each Stage. 

 

	(b)	Subcontract Modification #2: For each of the two Milestones in the Statement of Work dated May 4, 2010 (modification #2) there will be two invoices each totaling 50% of the price for each Milestone, an Initial
Invoice upon commencement of the Milestone and a final invoice upon acceptance of the final report and associated deliverables for each Milestone. 

Subcontract Modification #4: For each of the two Milestones in the Statement of Work dated November 15, 2010 (modification #4) there
will be two Invoices each totaling 50% of the price for each Milestone, an Initial invoice upon commencement of the Milestone and a final invoice upon acceptance of the final report and associated deliverables for each Milestone. 

(c) Payment terms will be Net 45 days from date of invoice. Upon receipt of invoice Buyer shall within five (5) business days review the Invoice and
determine if the invoice is acceptable. If Buyer reasonable deems the Invoice unacceptable Buyer shall contact Seller and Seller shall reissue a conforming Invoice with a new date of invoice. If (1) Buyer does not pay on time or
(2) Buyer’s financial responsibility becomes unsatisfactory (S&P rating below BBB- or Moody’s rating below Baa3) to Seller and Seller deems itself insecure, Seller may accelerate the due date and demand immediate payment on any
outstanding invoice for Product, or may require cash payments or satisfactory security for future deliveries and for payment of all sums owed under this Agreement. Buyer agrees to pay all costs and expenses, including reasonable attorney’s
fees, incurred by Seller in the collection of any sum payable by Buyer to Seller, or in the exercise of any remedy. Dow may charge Prime +2% on all overdue amounts. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 1 of 2

 

 
  
  

	Article 17.0	ORDER OF PRECEDENCE – is amended to road as follows: 

 The documents listed below are hereby
incorporated by reference. In the event of an inconsistency or conflict between or among the provisions of this Subcontract, the inconsistency shall be resolved by giving precedence in the following order: 

1. Attachment I: Statement of Work and Schedule dated July 2009, and Subcontract Modification #2 dated May 4, 2010 and Subcontract Modification #4
dated November 15, 2010. 
  

	2.	Schedule A: Specific Terms and Conditions Form 9-932-072 (Rev. 9/25/06). 

  

	3.	Schedule B: U.S. Government Terms and Conditions, Part III — FAR Clauses Form 9-932-082 (Rev. 07/25/07). 

  

	4.	Attachment C (Enclosure 2; (Rev. 4/2009) Property Administration Requirements For Subcontractors With An Adequate System Or Requisite Internal Controls 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract modification No. 2 on the dates shown. 

 

									
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Earleen K. Smith

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick Lucy
	 		 	Name:	 	 Earleen K. Smith

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

					
	Date:	 	 12/15/10
	 		 	Date:	 	 12/15/10

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 2 of 2

 

 
 STATEMENT OF WORK 

Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM 

and Process Manufacturing 

Malaria Vaccine Production and Support Services 

November 15, 2010 

Subcontract Modification 4 
  

	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all of
the necessary services, qualified personnel, materials, equipment, and facilities for the purification of SAIC EP533-036/C5533-129 CS protein expressed in Pfēnex Expression TechnologyTM. As part of this project, Pfenex is
required to provide related meeting support, reports, and deliverables as listed in Table 1. 
  

	 	1.1.	SAIC will provide the following information and materials: 

  

	 	1.1.1.	Background literature/references relating to Circumsporozoite Protein (CSP). 

  

	 	1.1.2.	Additional anti-CSP mAbs and control CSP, if required, 

  

	 	1.1.3.	Shipping instructions for purified CSP protein 

  

	2.	Technical Requirements 

 As a follow-on to the successful production, testing, and
selection of a CS protein expressing cell line under the original subcontract and Mod 2 which composed of : (i)-Evaluation of CSP expression (Stage 1), (ii)-Fermentation assessment of CSP (Stage 2), (iii)-CSP purification (Stage 2A/Mod 2) and
(iv)-Preparation and characterization of Pseudumonas-CSP Research Cell Bank (RCB) (Stage 3), SAIC requires Pfenex to provide [*] using the process established in Stage 2A. 
  

	 	2.1.	Stage 3A: Protein purification 

  

	 	2.1.1.	Pfenex shall provide [*] of purified CSP from clone [*] 

  

	 	2.1.1.1.	Pfenex shall use the [*] working fermentation already available from Stage 3 plus additional fermentation if needed. Pfenex shall use the process established in Stage 2A for the protein purification efforts.

  

	 	2.1.2.	The purified CSP should have purity greater than [*]% and endotoxin level suitable for [*] 

  

	 	2.1.3.	The final product shall be at [*] 

  

	 	2.1.4.	Pfenex shall calculate % of CSP in starting, intermediate, and final materials in the process and include the data in the final report. 

 

	 	2.1.5.	Pfenex shall conduct analytical testing of the purified CSP including but not limited to [*] 

  

	 	2.1.5.1.	[*] 

  

	 	2.1.6.	[*] 

  

	 	2.1.7.	Pfenex shall ship the purified CSP to a SAIC designated facility. 

  

	 	2.1.8.	Pfenex shall issue a final report of the purification efforts. Report shall include an executive summary, brief description of methods, results and conclusions, inventory of reagents provided by SAIC, and raw data in
PDF format. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

1 

 

 
  
  

	3.	Table 1 Deliverables to SAIC 

  

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	 Form

	1	  	Technical	  	[*]	  	Within a week of completion	  	Sent to SAIC designee in proper shipping containers with a temperature monitor
	2	  	Technical	  	Unused reagents provided by SAIC	  	Within 2 week2 of SAIC request	  	Sent to SAIC designee in proper shipping containers
	3	  	Reporting	  	Weekly Email Update	  	COB Friday	  	Email
	4	  	Reporting	  	Final Report	  	 Draft: 2 weeks following completion
 Final: 2
weeks after receipt of SAIC comments
	  	 Draft: Word Document
 Final: Signed
Pdf

  

	*	Days = Calendar days; SAIC shall provide comment within 1 week. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 

 

 
 SUBCONTRACT AGREEMENT 

FIRM FIXED PRICE COMMERCIAL ITEMS (GOVERNMENT) 
  

					
	SUBCONTRACTOR:	  	SUBCONTRACT #:	  	P010022290
			
	Pfenex Inc.	  	MODIFICATION #:	  	5
			
	ADDRESS:	  	DPAS RATING:	  	Not Rated
			
	5501 Oberlin Drive San Diego, CA 92121	  	TYPE:	  	 FIRM FIXED PRICE COMMERCIAL
  

ITEMS (GOVERNMENT)

		  	VALUE:	  	$3,093,173.00

 Modification No. 5 to Subcontract No. P010022290 is issued to Pfenex Inc. (Pfenex) to add subcontract value, incremental
funding and a Statement of Work dated December 23, 2010 for the Evaluation of Malaria CSP Expression in Pfenex Expression TechnologyTM and Process Manufacturing. 

Article 1.0 PRICE is amended to read as follows: 
 The
total not-to-exceed price of Subcontract No. P010022290 is increased by $2,371,373.00 from $721,800.00 to $3,093,173.00 including profit. This subcontract is incrementally funded for work to be performed through September 21, 2011. The total
FUNDING of Subcontract No. P010022290 is increased by $1,591,328.02 from $721,800.00 to $2,313,128.02 including profit 
 Article 1.4 PAYMENT –
is amended to read as follows: 
 (a) Original Subcontract Award: For each Stage of work there will be two invoices each totaling 50 % of the price
for each Stage of Work, an initial invoice upon commencement of the Stage and a final invoice upon acceptance of the final report for each Stage. 

Subcontract Modification #2: For each of the two Milestones in the Statement of Work dated May 4, 2010 (modification #2) there will be two invoices each
totaling 50% of the price for each Milestone, an initial invoice upon commencement of the Milestone and a final invoice upon acceptance of the final report and associated deliverables for each Milestone. 

Subcontract Modification #4: For each of the two Milestones in the Statement of Work dated November 15, 2010 (modification #4) there will be two invoices
each totaling 50% of the price for each Milestone, an initial invoice upon commencement of the Milestone and a final invoice upon acceptance of the final report and associated deliverables for each Milestone. 

Subcontract Modification #5: The following table shall be utilized for Milestone Invoice dates of submission and Invoice Amounts for the Milestones defined
in the Statement of Work dated December 13, 2010 (modification #5). There will be two invoices each totaling 50% of the price for each Milestone, an initial invoice upon commencement of the Milestone and a final invoice upon acceptance of the
final report and associated deliverables for each Milestone. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 1 of 3

 

 
  
  

															
	 Milestone
	  	 Stage
	  	Dollar
Amount	 	 	 	  	 Expected Invoice

date
	  	Expected invoice
amount	 
	 Milestone 2.1
	  	Stage 4	  	 	[*	] 	 	Start	  	1/17/11	  	$	[*	] 
		  		  				 	Finish	  	4/19/11	  	$	[*	] 
	 Milestone 2.2
	  	Stage 5	  	 	[*	] 	 	Start	  	3/22/11	  	$	[*	] 
		  		  				 	Finish	  	9/16/11	  	$	[*	] 
	 Milestone 2.3
	  	Stage 6	  	 	[*	] 	 	Start	  	1/17/11	  	$	[*	] 
		  		  				 	Finish	  	5/24/11	  	$	[*	] 
	 Milestone 2.4
	  	Stage 7	  	 	[*	] 	 	Start	  	8/19/11	  	$	[*	] 
		  		  				 	Finish	  	2/3/12	  	$	[*	] 
	 Milestone 2.5
	  	Stage 8	  	 	[*	] 	 	Start	  	1/10/12	  	$	[*	] 
		  		  				 	Finish	  	6/3/12	  	$	[*	] 
	 Milestone 2.6
	  	Stage 9	  	 	[*	] 	 	Start	  	11/18/11	  	$	[*	] 
		  		  				 	Finish	  	2/7/12	  	$	[*	] 
	 Milestone 2.7
	  	Report	  	 	[*	] 	 	Start	  	5/3/12	  	$	[*	] 
		  		  				 	Finish	  	5/24/12	  	$	[*	] 

 (b) Payment terms will be Net 45 days from date of invoice. Upon receipt of invoice Buyer shall within five
(5) business days review the invoice and determine if the invoice is acceptable. If Buyer reasonable deems the invoice unacceptable Buyer shall contact Seller and Seller shall reissue a conforming invoice with a new date of invoice. If
(1) Buyer does not pay on time or (2) Buyer’s financial responsibility becomes unsatisfactory (S&P rating below BBB- or Moody’s rating below Baa3) to Seller and Seller deems itself insecure, Seller may accelerate the due date
and demand immediate payment on any outstanding invoice for Product, or may require cash payments or satisfactory security for future deliveries and for payment of all sums owed under this Agreement. Buyer agrees to pay all costs and expenses,
including reasonable attorney’s fees, incurred by Seller in the collection of any sum payable by Buyer to Seller, or in the exercise of any remedy. Pfenex may charge Prime +2% on all overdue amounts. 

Article 17.0 ORDER OF PRECEDENCE — is amended to read as follows: 

The documents listed below are hereby incorporated by reference. In the event of an inconsistency or conflict between or among the provisions of this
Subcontract, the inconsistency shall be resolved by giving precedence in the following order: 
  

	 	1.	Attachment Statement of Work and Schedule dated December 23, 2010 

  

	 	2.	Schedule A: Specific Terms and Conditions Form 9-932-072 (Rev. 9/25/06). 

  

	 	3.	Schedule B: U.S. Government Terms and Conditions, Part III — FAR Clauses Form 9-932-082 (Rev. 07/25/07). 

  

	 	4.	Attachment C (Enclosure 2; (Rev. 4/2009) Property Administration Requirements For Subcontractors With An Adequate System Or Requisite Internal Controls 

5. Attachment II: Statement of Work and Schedule dated July 2009, Subcontract Modification #2 dated May 4, 2010, and Subcontract
Modification #4 dated November 15, 2010. 
 Article 19.0 SURVIVAL — Is added to the Subcontract to read as follows: 

19.0 SURVIVAL 
 If this Subcontract expires, is
completed, or is terminated, Seller shall not be relieved of those obligations contained in the following articles: 1.0, 1.5, 3.0, 7.0, 8.0, 9.0, 10.0, 12.0, 14.0, 15.0, and 17.0. 

All other Subcontract terms and conditions remain unchanged. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 2 of 3

 

 
  
 In witness whereof, the duly authorized
representatives of Buyer and Seller have executed this Subcontract modification No. 5 on the dates shown. 
  

									
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Earleen K. Smith

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick Lucy
	 		 	Name:	 	 Earleen K. Smith

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

					
	Date:	 	 1/10/11
	 		 	Date:	 	 1/10/11

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 3 of 3

 Statement of Work 

Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM 

and Process Manufacturing 

Malaria Vaccine Production and Support Services 

December 23, 2010 

Subcontract Modification 5 
  

	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all of
the necessary services, qualified personnel, materials, equipment, and facilities for the full development of a manufacturing process for the SAIC Circumsporozoite Protein (CSP) expressed from C5533-129 clone using Pfēnex Expression
TechnologyTM and technical transfer of the process to a SAIC designated facility. The process shall be suitable for a scale up, at a minimum, of a [*] fermentation scale and follow-on purification, upon transfer. As part of this project, Pfenex
is required to provide related meeting support, reports, and deliverables as listed in Table 1. 
 1.1. SAIC will provide the
following information and materials: 
  

	 	•	 	Background literature/references relating to CSP. 

  

	 	•	 	Additional anti-CSP monoclonal antibodies (mAbs) and control CSP, if required. 

  

	 	•	 	Shipping instructions for purified CSP protein and other materials. 

  

	2.	Technical Requirements 

 As a follow-on to the successful production, testing, and
selection of a CSP expressing cell line under the original subcontract and Mod 2 which was composed of: (i)-Evaluation of CSP expression (Stage 1), (ii)-Fermentation assessment of CSP (Stage 2),
(iii)-CSP purification (Stage 2A/Mod 2) and (iv)-Preparation and characterization of Pseudomonas-CSP Research Cell Bank (RCB) (Stage 3); SAIC now requires Pfenex to develop a manufacturing process
suitable for a scale up, at a minimum, of a [*] fermentation scale and follow-on purification for the SAIC selected clone CS533-129 and technical transfer of the process to a SAIC designated facility. 

2.1. Stage 4: Fermentation Optimization of cell line CS533-129  

 

	 	•	 	Pfenex shall optimize fermentation parameters for protein expression utilizing the RCB. 

  

	 	•	 	The optimized fermentation shall be confirmed at the [*] scale. 

  

	 	•	 	The optimized fermentation shall produce material which can be subsequently purified to meet product quality and safety specifications required for human use when produced under cGMP conditions. 

 

	 	•	 	Pfenex shall submit the optimized fermentation procedure/protocol to SAIC for review and approval. 

  

	 	•	 	Document shall also contain, at a minimum, in process parameters examined, rational for parameters selected, and copies of the raw data. 

2.2. Stage 5: Purification Process Development 
  

	 	•	 	Pfenex shall examine, choose, and optimize a final method for [*] 

  

	 	•	 	The primary recovery procedure shall produce material which can be subsequently purified to meet product quality and safety specifications required for human use when produced under cGMP conditions. 

 

	 	•	 	Pfenex shall select and submit an optimal method to SAIC for review and approval. 

  

	 	•	 	Document shall also contain, at a minimum, methods examined, rational for method selected, and copies of the raw data. 

  

	 	•	 	Pfenex shall develop a downstream purification process based on lessons learned from Stage 2A (CSP research-grade purification strategy). 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

1 

	 	•	 	In-process recovery of CSP shall be calculated and monitored. 

  

	 	•	 	Pfenex shall utilize a buffer system that is suitable for the solubility and stability of the purified CSP; and that the buffer system shall meet product quality and safety specifications required for human use when
produced under cGMP conditions. 

  

	 	•	 	Pfenex shall summit the developed purification process procedures and protocols to SAIC for review and approval before moving forward to engineering run (Stage 7). 

 

	 	•	 	Document shall also contain, at a minimum, processes examined, rational for processes selected, and copies of the raw data. 

  

	 	•	 	Pfenex shall ship all purified CSP generated during development to a SAIC designated facility; however, Pfenex may retain up to 10% of the material produced if necessary. 

2.3. Stage 6: Product Specific Analytical Method Development  
  

	 	•	 	Pfenex shall develop and qualify product specific in-process and final product analytical methods and provide standard operating procedures (SOPs) for each method. 

 

	 	•	 	For release testing of bulk drug substance, the testing shall include but not be limited to, [*] 

  

	 	•	 	For characterization of bulk drug substance, the testing shall include but not limited to [*] 

  

	 	•	 	Pfenex shall establish acceptance criteria and specifications in consultation with SAIC, where applicable, that will be the basis for release and stability monitoring. The specifications shall be appropriate for a phase
1 clinical product. 

  

	 	•	 	Pfenex shall recommend and submit the developed analytical and characterization testing, including procedures, protocols, and their results, to SAIC for review and approval. 

2.4. Stage 7: Engineering Run 
  

	 	•	 	Pfenex shall perform [*] to ensure reproducibility of previously drafted procedures. 

  

	 	•	 	Pfenex shall develop master batch production records (BPRs) for the first engineering run that cover all of upstream and downstream process, and identifies where the in-process tests occur and what volume is removed for
testing. SAIC will be provided copies of the master BPRs for review and approval prior to use. 

  

	 	•	 	Pfenex shall develop master BPRs for the second engineering run that cover all of upstream and downstream process and identifies where procedures are modified, if any. SAIC will be provided copies of the master BPRs for
review and approval prior to use. 

  

	 	•	 	Pfenex shall submit the completed BPRs to SAIC upon the completion of each engineering run. 

  

	 	•	 	Pfenex shall execute the release and characterization testing as accomplished in Stage 6 for the engineering run material. 

  

	 	•	 	Pfenex shall set aside aliquots for the stability program described below, and ship the remaining purified CSP from the engineering runs to a SAIC designated facility in aliquots to be determined at a later
timepoint. 

 2.5. Stage 8: Stability Program  

 

	 	•	 	Pfenex shall conduct a non-GMP stability monitoring of the purified CSP. Pfenex shall submit the stability monitoring plans for both engineering runs to SAIC for review and approval. 

 

	 	•	 	The stability of purified CSP from the engineering runs shall be evaluated for stability at conditions of [*] 

  

	 	•	 	Stability monitoring assessment shall include, at minimum, [*] 

  

	 	•	 	A stability report shall be submitted to SAIC at each stability timepoint and include, at minimum, assays utilized with associated SOP, test results in table format, conclusion, trending data, and copies of raw
data. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 

 2.6. Stage 9: Process Training and Transfer 

 

	 	•	 	Pfenex shall train SAIC’s clinical contract manufacture organization (CMO) on the manufacturing process and shall transfer the BPRs (master and completed) and analytical method SOPs. 

 

	 	•	 	As part of the process training and transfer Pfenex shall conduct at least one successful training run. 

  

	 	•	 	The process yield from the process training run shall be within acceptable scientific variation from the 2 engineering runs performed in Stage 7. The purified CSP shall have purity [*] 

 

	 	•	 	The process training run shall demonstrate reproducibility in all up- and down-stream processes including, but not limited to, growth rate in fermentation, quantity and quality of CSP in lysate, in primary recovery, in
each process step, and in final product. 

  

	 	•	 	Pfenex shall provide to SAIC and to SAIC designated CMO the RCS and a full process transfer package with all information necessary for the transfer of the manufacturing process. 

 

	 	•	 	The full process transfer package shall be applicable for a scale up, at a minimum, [*] and follow-on purification, upon transfer. 

  

	 	•	 	The full process transfer package shall include, but is not limited to, the following items: 

  

	 	•	 	Bill of materials and suggested suppliers 

  

	 	•	 	Detailed fermentation and purification process procedures (master BPRs) 

  

	 	•	 	Listing of instruments/equipment 

  

	 	•	 	Detailed testing procedures (SOPs) 

  

	 	•	 	Technical specification for the bulk drug substance 

  

	 	•	 	Health/Safety/Environment assessment of all materials and process 

  

	 	•	 	Detailed characterization of purified protein/buffer and intermediates 

  

	 	•	 	Stability testing plan and final report 

  

	 	•	 	Research cell bank growth parameters and technical information 

  

	 	•	 	Construct expression information and test results 

  

	 	•	 	The process transfer and associated training records for the transfer to the clinical CMO shall be well documented and be provided to SAIC in the final report. 

2.7. Final Report 
  

	 	•	 	Pfenex shall issue a final report covering all of the process development and process transfer efforts. The report shall include an executive summary, brief description of methods, results, and conclusions pertaining to
all process development activities, technical transfer training records and report, inventory of reagents provided by SAIC, and raw data in PDF format. 

  

	 	•	 	The final report shall also contain sufficient data for use in the CMC section of the IND submission including, but not limited to, details of the cloning and development of the expression strain CS533-129.

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

3 

	3.	Quality Requirements 

 In addition to the Quality Requirements stated in the SOW, Pfenex
shall execute a Quality Management Plan suitable for process development and technical transfer (see Section 10). 
  

	 	3.1.	Pfenex shall provide a scientific, technical, and administrative infrastructure to ensure quality control of all process development and technical transfer activities. 

 

	 	3.2.	The quality management plan shall include use of any materials, instruments/equipment, methods, procedures utilized in the process development and technical transfer. 

 

	 	3.3.	At a minimum, Pfenex shall ensure: 

  

	 	•	 	Facilities in which SAIC’s materials are maintained in a safe and secure manner and allow limited access. 

  

	 	•	 	Personnel have the necessary education and training in all procedures relevant to work assignments; training and qualifications are verified by leadership of Pfenex. 

 

	 	•	 	SOPs will be used to document policies and procedures. SOPs will be version controlled and approved by key personnel. 

  

	 	•	 	An effective tracking/tracing system or procedure is in place for all materials and equipment used in this contract. 

  

	 	•	 	Equipment calibration and maintenance are performed as required and are documented. 

  

	 	3.4.	The Quality management plan shall govern Pfenex’s commitment to quality and ensure that procedures addressing the following requirements are in place. 

 

	 	•	 	SOPs 

  

	 	•	 	Document/version control 

  

	 	•	 	Equipment maintenance and repair 

  

	 	•	 	Training: adherence of staff to required schedules 

  

	 	•	 	Data management 

  

	 	•	 	Record management system 

  

	 	•	 	Safety plan 

  

	 	•	 	Asset tracking and management 

  

	 	•	 	Building and facility monitoring 

  

	 	•	 	Adherence to Federal or other applicable regulatory requirements appropriate for work on this contract 

  

	 	•	 	Operational deviations and failures will be investigated through root cause analysis, which will be documented. 

  

	 	3.5.	Cold/frozen and controlled temperature storage chambers have continuous monitors with alarms or are monitored at least every 4 hours by security staff. Any deviations will be immediately reported to Pfenex staff.

  

	 	3.6.	Effective cold chain management practices are in place for the handling of materials, products and samples. 

  

	 	3.7.	Investigation are initiated upon incident discovery (excursion from written procedure, policy, or protocol). Upon request, copies results of investigations are submitted to SAIC for review. 

 

	 	3.8.	SAIC may schedule in-plant and other visits at Pfenex to audit quality of activities conducted in this contract. 

  

	4.	Record Management Requirements 

 Pfenex shall maintain a record management system
suitable for process development and technical transfer (see Section 10, Quality Management Plan). 
  

	 	4.1.	Pfenex shall have a record management system that permits detailed records to be made concurrently with the performances of each process development activity. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

4 

	 	4.2.	Records and documents shall be created and maintained in a manner that allows version control, handling steps, tests, retests, investigations, data, and results. 

 

	 	4.3.	Record and document security systems shall be adequate to ensure confidentiality and privacy of proprietary information. Confidential or proprietary information shall be restricted to staff with a need for access
and inspectors from regulatory agencies. Records shall be readily accessible for inspection by authorized personnel from SAIC. 

  

	 	4.4.	Records and documents shall be maintained for a minimum of 5 years after the completion of process development and technical transfer. SAIC shall be contacted for disposal or transfer instructions at the end of a
records storage period or at the end of the subcontract POP. 

  

	 	4.5.	Electronic records shall be backed up daily on a separate server or network. Weekly backups shall be stored on an appropriate media, e.g., CD, tape, and stored off-site. 

 

	 	4.6.	Corrections or changes in a record shall be made in accordance with a quality monitoring procedures suitable for managing process development and technical transfer. 

 

	 	4.7.	Unless alternate agreements are made, all raw data and laboratory notebooks related to this subcontract shall be made available to SAIC upon request. 

 

	5.	Table 1. Deliverables to SAIC 

  

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	 Form

	1	  	Technical	  	purified CSP from process development	  	Within a week of completion	  	Sent to SAIC designee in proper shipping containers with a temperature monitor
	2	  	Technical	  	purified CSP from engineering and training runs	  	Within a week of completion	  	Sent to SAIC designee in proper shipping containers with a temperature monitor
	3	  	Technical	  	Unused reagents provided by SAIC	  	Within 2 weeks of SAIC request	  	Sent to SAIC designee in proper shipping containers
	4	  	Technical	  	fermentation	  		  	
	5	  	Technical	  		  		  	
	6	  	Technical	  		  		  	PDF or Word document
	7	  	Technical	  		  		  	PDF or Word document
	8	  	Technical	  		  		  	PDF or Word document
	9	  	Technical	  		  		  	PDF or Word document
	10	  	Technical	  		  		  	PDF or Word document
	11	  	Technical	  		  		  	PDF or Word document
	12	  	Technical	  		  		  	PDF or Word document
	13	  	Technical	  		  		  	PDF or Word document
	14	  	Technical	  		  		  	PDF or Word document
	15	  	Reporting	  		  		  	Telecom
	16	  	Reporting	  		  		  	PDF or Word document

  

	*	Days = Calendar days 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

5 

 

 
 SUBCONTRACT AGREEMENT 

FIRM FIXED PRICE COMMERCIAL ITEMS (GOVERNMENT) 

Modification 06 
  

					
	SUBCONTRACTOR:	 	SUBCONTRACT #:	  	P010022290
			
	Pfenex Inc.	 	MODIFICATION #:	  	06
			
	ADDRESS:	 	DPAS RATING:	  	Not Rated
			
	10790 Roselle Street San Diego, CA 92121	 	TYPE:	  	 FIRM FIXED PRICE COMMERCIAL
  

ITEMS (GOVERNMENT)

		 	 VALUE:
 FUNDED:
	  	 $4,055,873.00

$2,640,928.02

 The purpose of this modification is to add subcontract value, incremental funding and a Statement of Work, dated May 2,
2011, entitled “Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM and Process Manufacturing. The modification results from Pfenex Inc’s proposal, dated May 11, 2011. As a result, the award value is
increased from $3,093,173.00 by $962,700.00 to $4,055,873.00. 
 Article 1.0 PRICE is modified to read as follows: 

The total not-to-exceed PRICE of Subcontract No. P010022290 is increased by $962,700.00 from $3,093,173.00 to $4,055,873.00 including profit. This
subcontract is incrementally funded for work to be performed through September 21, 2011. The total FUNDING of Subcontract No. P010022290 is increased by $327,800.00 from $2,313,128.02 to $2,640,928.02 including profit. 

Article 1.3 INVOICES is modified to read as follows: 

Invoices shall contain the following information: subcontract number, subproject number, Stage #. Invoices may be mailed or emailed to: 

Science Applications International Corporation 

Attention: Michael A. Younkins 

5202 Presidents Court, Suite 110 

Frederick, Maryland 21703 

Michael.A.Younkins@saic.com 
 Article
2.0 TECHNICAL AND CONTRACTUAL POINTS OF CONTACT is modified to replace Earleen Smith with the following: 
 SAIC (BUYER): 

Contractual: Michael A. Younkins  

Article 1.4 PAYMENT — is modified to read as follows: 

(a) Original Subcontract Award: For each Stage of work there will be two invoices each totaling 50 % of the price for each Stage of Work, an initial
invoice upon commencement of the Stage and a final invoice upon acceptance of the final report for each Stage. 
 Subcontract Modification #2: For each of
the two Milestones in the Statement of Work dated May 4, 2010 (modification #2) there will be two invoices each totaling 50% of the price for each Milestone, an initial invoice upon commencement of the Milestone and a final invoice upon
acceptance of the final report and associated deliverables for each Milestone. 
 Subcontract Modification #4: For each of the two Milestones in the
Statement of Word dated November 15, 2010 (modification #4) there will be two invoices each totaling 50% of the price for each Milestone, an initial invoice upon commencement of the Milestone and a final invoice upon acceptance of the final
report and associated deliverables for each Milestone. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 1 of 5

 

 
  
  

Subcontract Modification #5: The table shown in Mod #5 shall be utilized for Milestone Invoice dates of submission and Invoice Amounts for the Milestones
defined in the Statement of Work dated December 13, 2010 (modification #5). There will be two invoices each totaling 50% of the price for each Milestone, an initial invoice upon commencement of the Milestone and a final invoice upon acceptance
of the final report and associated deliverables for each Milestone. 
 Subcontract Modification #6: The following table shall be utilized for Milestone
Invoice submission: 
 (see next page) 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	 Page 2 of 5

 

 
  
  

							
	 Milestone
	  	 Payment
	  	 Amount
	  	 Duration

				
	Antigen 1 & Antigen 2 Milestone 1	  	 50% upon

commencement
	  	$[*]	  	 Approximately 8 weeks from

receipt of synthetic genes

	  
 Antigen 1 & Antigen 2 Milestone 1
	  	  
 50% upon delivery of

report
	  	$[*]	  
				
	Antigen 1 Milestone 2 [OPTIONAL]: Fermentation Assessment of [*] in Pfēnex Expression TechnologyTM	  	 50% upon

commencement
	  	$[*]	  	 Approximately 6 weeks from

receipt of written

authorization to proceed

	  
 Antigen 1 Milestone 2 [OPTIONAL]: Fermentation Assessment of
[*] in Pfēnex Expression TechnologyTM
	  	  
 50% upon delivery of

report
	  	$[*]	  
				
	Antigen 2 Milestone 2 [OPTIONAL]: Fermentation Assessment of [*] in Pfēnex Expression TechnologyTM	  	 50% upon

commencement
	  	$[*]	  	 Approximately 6 weeks from

receipt of written

authorization to proceed

	  
 Antigen 2 Milestone 2 [OPTIONAL]: Fermentation Assessment of
[*] in Pfēnex Expression TechnologyTM
	  	  
 50% upon delivery of

report
	  	$[*]	  
				
	Antigen 1 Milestone 2A [Optional]: [*] pure [*] protein from 3 selected [*] clones respectively to SAIC	  	 50% upon

commencement
	  	$[*]	  	 Approximately 7 weeks from

receipt of written

authorization to proceed

	  
 Antigen 1 Milestone 2A [Optional]: [*] pure
[*] protein from 3 selected [*] clones respectively to SAIC
	  	  
 50% upon delivery of

report
	  	$[*]	  
	  
 Antigen 2 Milestone 2A [Optional]: [*] pure
[*] protein from 3 selected [*] clones respectively to SAIC
	  	  
 50% upon

commencement
	  	$[*]	  
	  
 Antigen 2 Milestone 2A [Optional]: [*] pure
[*] protein from 3 selected [*] clones respectively to SA IC
	  	  
 50% upon delivery of

report
	  	$[*]	  
				
	Antigen I Milestone 3 [OPTIONAL]: Preparation and Characterization of a P. fluorescens-[*] Research Cell Bank (RCB)	  	 50% upon

commencement
	  	$[*]	  	 Approximately 4 weeks from

receipt of written

authorization to proceed

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	 Page 3 of 5

 

 
  

							
	Antigen 1 Milestone 3 [OPTIONAL]: Preparation and Characterization of a P. fluorescens-[*] Research Cell Bank (RCB)	  	 50% upon delivery of

report
	  	$[*]	  	
				
	Antigen 2 Milestone 3 [OPTIONAL]: Preparation and Characterization of a P. fluorescens-[*] Research Cell Bank (RCB)	  	 50% upon

commencement
	  	$[*]	  	 Approximately 4 weeks from

receipt of written

authorization to proceed

	  
 Antigen 2 Milestone 3 [OPTIONAL]: Preparation and Characterization of
a P. fluorescens- [*] Research Cell Bank (RCB)
	  	 50% upon delivery of

report
	  	$[*]	  

 (b) Payment terms will be Net 45 days from date of invoice. Upon receipt of invoice Buyer shall within five (5) business
days review the invoice and determine if the invoice is acceptable. If Buyer reasonable deems the invoice unacceptable Buyer shall contact Seller and Seller shall reissue a conforming invoice with a new date of invoice. If (1) Buyer does not
pay on time or (2) Buyer’s financial responsibility becomes unsatisfactory (S&P rating below BBB- or Moody’s rating below Baa3) to Seller and Seller deems itself insecure, Seller may accelerate the due date and demand immediate
payment on any outstanding invoice for Product, or may require cash payments or satisfactory security for future deliveries and for payment of all sums owed under this Agreement. Buyer agrees to pay all costs and expenses, including reasonable
attorney’s fees, incurred by Seller in the collection of any sum payable by Buyer to Seller, or in the exercise of any remedy. Pfenex may charge Prime +2% on all overdue amounts. 

Article 17.0 ORDER OF PRECEDENCE — is modified to read as follows: 

The documents listed below are hereby incorporated by reference. In the event of an inconsistency or conflict between or among the provisions of this
Subcontract, the inconsistency shall be resolved by giving precedence in the following order: 
  

	1.	Attachment I: Statement of Work and Schedule dated May 11, 2011 

  

	2.	Schedule A: Specific Terms and Conditions Form 9-932-072 (Rev. 9/25/06). 

  

	3.	Schedule B: U.S. Government Terms and Conditions, Part III — FAR Clauses Form 9-932-082 (Rev. 07/25/07). 

  

	4.	Attachment C (Enclosure 2; (Rev. 4/2009) Property Administration Requirements For Subcontractors With An Adequate System Or Requisite Internal Controls 

 

	5.	Attachment II: Statement of Work and Schedule dated July 2009, Subcontract Modification #2 dated May 4, 2010, Subcontract Modification #4 dated November 15, 2010 and Subcontract Modification #5 dated
January 1, 2011. 

 All other Subcontract terms and conditions remain unchanged. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	 Page 4 of 5

 

 
  
 In witness whereof, the duly authorized
representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 
  

									
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Michael A. Younkins

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick Lucy
	 		 	Name:	 	 Michael A. Younkins

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

					
	Date:	 	 May 25, 2011
	 		 	Date:	 	 6/1/2011

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	 Page 5 of 5

 STATEMENT OF WORK 

Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM 

And Process Manufacturing 

Malaria Vaccine Production and Support Services 

May 2, 2011 

Subcontract Modification 6 
  

	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfēnex shall
furnish all of the necessary services, qualified personnel, materials, equipment, facilities, and travel not otherwise provided under the terms of this agreement as needed for the proof-of-principle evaluation of expressing full-length and
functional [*], suitable for use with [*] in combination vaccines, utilizing Pfēnex Expression TechnologyTM. Pfēnex shall provide antigens, cell banks, and reports and other documentation related to the development and
manufacturing process, as required in the deliverables (Table 1). Milestones in this subcontract modification include: 
  

			
	 Antigen
	  	 Milestone

		
	CeITOS	  	Milestone 1: Evaluation of [*] expression in Pfēnex Expression TechnologyTM
	  	  
 Milestone 2 [OPTIONAL]: Fermentation Assessment of [*] in
Pfēnex Expression TechnologyTM

	  	  
 Milestone 2A [Optional]: Provide [*] pure [*] protein from 3
selected [*] clones respectively to SAIC

	  	  
 Milestone 3 [OPTIONAL]: Preparation and Characterization of a
Pseudomonas-[*] Research Cell Bank (RCB)

		
	TRAP	  	Milestone 1: Evaluation of [*] expression in Pfēnex Expression TechnologyTM
	  	  
 Milestone 2 [OPTIONAL]: Fermentation Assessment of [*] in
Pfēnex Expression TechnologyTM

	  	  
 Milestone 2A [Optional]: Provide [*] pure [*] protein from 3
selected [*] clones respectively to SAIC

	  	  
 Milestone 3 [OPTIONAL]: Preparation and Characterization of a
Pseudomonas-[*] Research Cell Bank (RCB)

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

1 

 SAIC will provide the following information and materials: 

 

	 	1.1.	Background literature/references relating to [*]. 

  

	 	1.2.	Suitable reference materials and sera relating to [*] if available. 

  

	2.	Period of Performance 

 The period of performance (POP) for this effort is upon award
through September 2014. 
  

	3.	Technical Requirements 

  

	 	3.1.	Milestone 1: Evaluation of [*] expression in Pfēnex Expression TechnologyTM 

  

	 	3.1.1.	Pfēnex shall clone and express a synthesized full-length [*] gene sequences (minus the GPI sequence) in Pfēnex Expression TechnologyTM. 

 

	 	3.1.1.1.	The coding region for the [*] from Pf strain [*] shall be optimized, synthesized, and cloned into a minimum of [*] different Pfēnex expression vectors. 

 

	 	3.1.1.2.	Pfenex shall transform the resulting plasmids into a strain of Pfēnex Expression TechnologyTM and plate onto selective medium. 

 

	 	3.1.1.3.	Pfēnex shall select a series of positive clones from assorted vectors and verify correct coding sequences of insert. 

  

	 	3.1.2.	Pfēnex shall assess the expression of [*] in Pfēnex Expression TechnologyTM at [*] scale in a minimum of [*] unique strains 

 

	 	3.1.2.1.	Pfēnex shall transform the resulting plasmids into up to [*] selected host strains. (A minimum of [*] unique Expression Strains) 

 

	 	3.1.2.2.	Pfēnex shall perform [*] as a primary screen. 

  

	 	3.1.2.3.	Pfēnex shall verify the target band on [*] (if antibody is available), and [*]. 

  

	 	3.1.3.	Pfēnex shall issue a final report of milestone 1 efforts. 

  

	 	3.1.3.1.	Report shall include an executive summary, brief description of test method with a reference to corresponding SOP, test results (i.e. small scale growth, expression, analytical), and conclusion. Copies of raw data
including sequencing data shall be included as an appendix. 

  

	 	3.2.	Milestone 2 [OPTIONAL]: Fermentation Assessment of [*] in Pfēnex Expression TechnologyTM 

  

	 	3.2.1.	Pfēnex shall screen multiple fermentation conditions at the [*] scale using [*] Expression Strains to evaluate protein quality and expression levels 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 

	 	3.2.1.1.	Execute experiments to screen multiple fermentation conditions in mini-bioreactors for protein expression and protein quality. ([*] fermentations per strain) 

 

	 	3.2.1.2.	Pfēnex shall perform [*] analysis on samples from each of the fermentations. 

  

	 	3.2.1.3.	Pfēnex shall verify the target band and its solubility on [*] 

  

	 	3.2.2.	Pfēnex shall confirm selected conditions used at the [*] scale and verify conditions are suitable at the high cell density fermentation [*] scale to evaluate protein quality and expression levels of selected
strains chosen based on data generated in 3.2.1.3. 

  

	 	3.2.2.1.	Pfēnex shall confirm selected conditions and strains identified in the screening experiments in a scalable high cell density fermentation process in multiplex fermentors for protein expression and protein
quality. 

  

	 	3.2.2.2.	Pfēnex shall collect multiple time point samples for evaluation of protein expression levels and quality 

  

	 	3.2.2.3.	Pfēnex shall utilize a [*] method as appropriate to prepare samples from the best fermentation of each expression strain for supply to SAIC. 

3.2.2.3.1. Pfēnex shall transfer to SAIC samples of the filtered whole cell lysate or periplasmic release extract
and cell free broth for further in vitro analysis. 
 3.2.2.3.2. Pfēnex shall perform [*] on samples
from each fermentation. 
 3.2.2.3.3. Pfēnex shall verify the target band and its solubility on [*] 

 

	 	3.2.3.	Pfēnex shall issue a final report of milestone 2 efforts. 

  

	 	3.2.3.1.	Report shall include an executive summary, brief description of test methods with associated reference to SOPs, data (i.e. small scale growth, expression, analytical), and conclusion. Copies of raw data shall be
included as an appendix. 

  

	 	3.3.	Milestone 2A [Optional]: Provide [*] pure [*] protein from [*] selected [*] clones respectively to SAIC 

  

	 	3.3.1.	Pfenex shall evaluate up to four [*] to capture [*] protein using batch binding experiments in 96-well plate format. 

  

	 	3.3.2.	Pfenex shall conduct small scale capture chromatography runs using up to two selected [*] to evaluate purification of [*] protein. 

  

	 	3.3.3.	Pfenex shall conduct small scale secondary chromatography runs using up to two selected [*] using elution pool from the primary capture column runs. 

 

	 	3.3.4.	Pfenex shall evaluate up to [*] for reduction of [*]. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

3 

	 	3.3.5.	Pfenex shall analyze the final purified proteins and the filtered lysate using analytical methods including [*] 

  

	 	3.3.5.1.	Pfenex shall assess the difference in endotoxin level between filtered lysate and purified [*] 

  

	 	3.3.5.2.	Pfenex shall also assess the conformational integrity of the purified [*] 

  

	 	3.3.6.	If the quality and purity of purified protein is deemed acceptable by SAIC for R&D non-clinical studies, Pfenex shall ship the resulting purified [*] protein ([*]) from [*] selected [*] clones to SAIC.

  

	 	3.4.	Pfenex shall issue a final report of purification efforts. 

  

	 	3.4.1.	Report shall include an executive summary, brief description of methods, results and conclusions, inventory of reagents provided by SAIC, and raw data in PDF format. 

 

	 	3.5.	Milestone 3 [OPTIONAL]: Preparation and Characterization of a Pseudomonas-[*] Research Cell Bank (RCB) 

Pfenex shall prepare a non-GMP Research Cell Bank (RCB). 
  

	 	3.5.1.	Pfēnex shall generate [*] vials of RCB 

  

	 	3.5.2.	Pfēnex shall store the RCB a temperature-controlled -80°C freezer which has a monitoring system. 

  

	 	3.5.3.	A [*] scale fermentation run shall performed to confirm productivity 

  

	 	3.5.3.1.	Pfēnex shall harvest and prepare filtered lysate from the [*] fermentation ([*] working volume) 

  

	 	3.5.3.2.	Plasmid retention shall be evaluated using viable count plating of the samples on selective and non-selective media. 

  

	 	3.5.3.3.	Structural stability shall be evaluated using plasmid restriction digests. 

  

	 	3.5.4.	Pfēnex shall perform a characterization analysis of the generated Pseudomonas-[*] 

  

	 	3.5.4.1.	Phenotype of the strain shall be determined by plating on [*] 

  

	 	3.5.4.2.	Culture purity analysis shall be performed on the RCB. 

  

	 	3.5.4.3.	[*] 

  

	 	3.5.4.4.	Pfēnex shall confirm the [*] 

  

	 	3.5.5.	Pfenex shall issue a final report of milestone 3 efforts. 

  

	 	3.5.5.1.	Report shall include, but no be limited to, an executive summary, description of cell banking methods and materials used, with associated reference to SOPs, characterization data, raw material certificates of analysis,
and copies of raw data. 

  

	 	3.5.5.2.	A draft report shall be submitted to SAIC two weeks following completion of task and a final copy submitted one week following SAIC comments. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

4 

	4.	Quality Requirements 

 Pfenex shall maintain a Quality System that meets scientific
expectations of traceability, reliability and control. Pfenex shall be responsible for the development and demonstration of suitability of contracted deliverables as well as providing reports and managing this project in a manner that meets
scientific expectations of traceability, reliability and control ensuring that the filtered whole cell lysate or periplasmic release extract and cell free broth produced and analyzed in the developed process and assays have the quality, and identity
they purport. 
  

	5.	Meeting and Conference Requirements 

 Unless an alternative directive is provided;
meeting, conference, and audit support shall include the following: 
  

	 	5.1.	Pfēnex shall schedule a kickoff meeting via on-site meeting with SAIC within 7 days of award. The agenda shall be provided by Pfenex in advance. The purpose of the kickoff meeting is formal introduction of key
staff and project management, technical and contractual discussions, and initial action items required to initiate contract work. 

  

	 	5.2.	Pfēnex shall participate in biweekly meetings and/or teleconferences with SAIC. Such meetings may include, but are not limited to, meetings to discuss the technical (e.g., assay designs and critical reagents),
quality, schedule, regulatory, and contractual aspects of the program and site visits to Pfenex’s facilities. All visits to Pfēnex’s facility shall be prearranged. Pfēnex shall be responsible for preparing meeting agendas and
summaries. Meeting minutes shall be captured by Pfēnex and are due to SAIC within 7 days after the completion of a biweekly teleconference. 

  

	 	5.3	Pfēnex also shall be available for ad hoc support (e.g., phone calls and e-mails) to SAIC as required for project communications. 

 

	6.	Reporting Requirements 

  

	 	6.1.	Monthly Technical and Business Progress Report: A monthly TPR shall be submitted to the SAIC management point of contact by the eighth of each month during subcontract POP. 

 

	 	6.1.1.	The TPR shall cover the work accomplished as well as issues and proposed resolutions that occur during each reporting period. 

  

	 	6.1.2.	Each TPR also shall contain an updated monthly project management schedule to indicate work completed and any change in schedule. Deliverables shall be incorporated into the schedule. 

 

	 	6.2.	Reports should include an updated inventory log, and a notice of any temperature deviations of equipment storing SAIC material. The report shall also document any changes made to methods and procedures utilized for the
cloning and expression efforts. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

5 

	 	6.2.1.	Report shall include invoicing information for work performed during each reporting period and anticipated work activities. 

  

	 	6.3.	Documentation to Support an IND or Amendment: Data generated under this subcontract may be incorporated into an FDA submission. Pfenex shall provide a list of relevant SOPs or other control, development and testing
documents as requested. 

  

	7.	Subcontract Deliverables 

 Table 3 summarizes documents and other deliverables due
to SAIC at the indicated timelines. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

6 

 Table 1. Deliverables to SAIC 

 

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	 Form

	1	  	Project 
Management	  	 Final Project 

Schedule
	  	To be submitted within 1 week of kickoff meeting; schedule to be baselined within 3 weeks of award	  	1 electronic file, Preferably .mmp
format
	2	  	Meeting 
Requirement	  	 Meeting

Agenda
	  	1 day prior to regular meetings, 3 days prior to kickoff	  	 1 electronic Word 

document or
 email

	3	  	Meeting 
Requirement	  	 Meeting

Summaries
	  	7 days after meetings	  	 1 electronic Word 

document

	4	  	Technical 
Requirement	  	 Milestone
Reports

[if funded]
	  	 Draft: 2 weeks following completion of procedure

Final: 2 weeks after receipt
 of SAIC comments
	  	 Draft: Word 
Document

Final: Signed PDF

	8	  	Technical 
Requirement	  	 Antigen

deliverables
	  	 2 weeks following
 completion of
requirement.
	  	 Sent to SAIC 
designee in

proper shipping

containers

  

	*	Days = Calendar days; SAIC shall provide comment within 1 week. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

7 

 Core B. Carrier Protein Production 

P.I. Pfenex, Inc. San Diego, CA 
 Project Summary 

The overall goal of the Core is to express and produce carrier proteins for conjugation to [*] discovered in Projects 1 and 2. Special emphasis will be on the
production of [*] containing strategically inserted [*] to serve as anchors for targeted attachment of [*] and [*]. We expect that such an immunogen with a focused [*] will have a better chance of eliciting neutralizing antibodies than the [*] with
its unpredictable host-dependent glycan shield. In order to eliminate any other [*], we will express [*] in a [*] protein expression system. Further we will incorporate [*] at the sites of [*] to enable targeted attachment of synthetic [*] at
correct sites. 
 Attempts to express [*] in E. coli has been difficult, generally resulting in production of insoluble material that refolds with
very poor yields. The Pfenex Expression TechnologyTM platform represents a new paradigm of microbial strain development that overcomes the slow iterative process of strain selection and high failure rates for protein production in E. coli.
Pfenex has developed a proprietary strain of P.fluorescens specifically as a protein production platform to enable rapid development of expression strains capable of expressing high titers of soluble, active protein. Using a combinatorial
matrix of expression plasmids and host strains, along with high throughput methods for growth and analysis of expression strain candidates, identification of a production strain and development of a first fermentation process can be achieved
rapidly. Importantly, yields of soluble protein of ~ 1 gram per liter can be achieved upon optimization of fermentations conditions. Initial expression studies (Aim1) will be done using the codon-optimized sequence of the [*] from the [*] as it
has been shown to express epitopes recognized by each [*]. Next (Aim2), we will express [*] incorporating [*] at positions of [*] attachment such as positions [*]. This will enable attached of synthetic [*] at specific locations on [*] as part of
Project 2. Subsequent studies will use [*], as required. 
 Core B Specific Aims 

Aim 1. Efficiently express select [*] proteins in a prokaryotic system to produce non-glycosylated carrier proteins for elicitation of enhanced [*]
responses 
 Codon optimized [*] genes will be cloned into [*] unique plasmids, which will be transformed into [*] unique host strain
backgrounds resulting in a total of [*] unique expression strains. Following the small scale expression, Pfenex will perform analytical testing on the product produced from each of the Expression Strains, including [*]. Furthermore, Pfenex will
scale up production and purification of selected strains and provide purified protein for Projects 1, 2, and 3. 
  

	 	1.1	Develop P.fluorescens strains that efficiently express [*] 

  

	 	1.2	Develop P. fluorescens strains for efficient production of [*] 

  

	 	1.3	Scale up and purifiy [*] from above aims to provide ~ 1 gram of each protein to Projects 1, 2 and 3 

  

	 	1.4	Produce ~ 1 gram of [*] for use as a carrier protein for Project 1 and for use as a control for experiments in Project 2 

Aim 2. Efficiently express select [*] proteins in Pseudomonas fluorescens to produce soluble [*] proteins containing [*]. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

1 

 Codon optimized DNA designed to insert [*] known to be critical for binding to[*] will be cloned
into [*] unique plasmids, which will be transformed into [*] unique host strain backgrounds resulting in a total of [*] unique expression strains. Following the small scale expression, Pfenex will perform analytical testing on the product produced
from each of the Expression Strains, including [*]. Emphasis will be placed on selection of strains that secrete high quantities of protein into the periplasmic space to facilitate purification. Three – five high-producer strains will be
selected for scale up production and purification to provide [*] for Projects 2 and 3. 
  

	 	2.1	Develop P.fluorescens strains that efficiently express [*] 

  

	 	2.2	Scale up and purify [*] from strains developed in Aim 2.1 to provide ~ 1 gram of protein to support Projects 2 and 3. 

Research Plan 
 Significance. The
development of a vaccine to prevent AIDS is the best hope for controlling the epidemic that has led to infection of more than 30 million people with the HIV-1 virus worldwide. A vaccine approach that reduces viral load would certainly be
beneficial, but one that elicits sterilizing immunity would be preferred. Conventional vaccine approaches based on delivery of HIV-1 envelope (Env) proteins or peptides derived from Env sequences have failed to generate broadly neutralizing
antibodies (bNAbs) to the virus, which mutates rapidly to escape from the immune response. Recently, [*] have been discovered from subjects in the [*]. Several of these antibodies, including [*] determinants alone or in the context of the [*]
protein. Importantly, these antibodies are even more potent (i.e., they neutralize HIV-1 at lower antibody concentrations) than other newly discovered [*]. Immunogens that elicit antibodies similar to the [*] could be ideal vaccine candidates. 

(b) Innovation. The HIV-1 Env is shrouded with oligomannose glycans that obscure potential neutralization sites and prevent the
elicitation of broad and potent immune responses. Partial removal of glycans has been shown to improve the immunogenicity of [*]. From a practical perspective, [*] are notoriously difficult to express in abundance in either mammalian or prokaryotic
systems. In mammalian expression systems, yields of only 10-20μg per liter are common, and in E. coli expression results mainly in the production of insoluble material that is difficult to refold. Furthermore,
glycosylation patterns in proteins derived from biological production systems are typically highly variable whereas using synthetic chemical methods we can obtain pure glycans in a manner that may be scaled for ultimate large scale production.

 Our overall goal is to discover and develop an [*] exposure and targeted synthetic glycan modifications to elicit broadly neutralizing
glycoprotein-specific immune responses. Specifically, we will employ the new broad and potent antibodies [*], which bind [*]. These sugar-binding antibodies require [*] and appear to require the [*] on the [*]. We plan to prepare vaccines that
contain a constrained synthetic glycan attached specifically to [*] at the site of native [*]. The critical innovation required to meet this goal is the production of a large quantity (~ 1 gram) of soluble [*]. The Pfenex Expression System has the
following unique properties that will ensure a high probability of success that will enable us to meet the above requirements: 
 Please list
attributes... 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 

 (c) Approach. 

Show steps involved in production of [*] as “preliminary data” to describe how you will approach the production of [*] 

It is expected that our approach will elicit an immune response to [*] as well as to protein epitopes normally concealed by endogenous glycans. We recognize
that this could have the mixed benefit of focusing the antibody response on the linked glycan while potentially diverting the immune response to non-neutralizing epitopes. However, efforts to eliminate non-neutralizing protein epitope by, for
example, eliminating V loops, has not proven to be beneficial in focusing the immune response on neutralizing epitopes. Rather than trying to limit induction of non-neutralizing epitope, our approach it to stimulate a robust antibody response to the
entire immunogen, especially to the glycans presented in the [*]. Glycoconjugate vaccines such as Prevnar (for the prevention of pneumococcal diseases) have been extremely successful in reducing invasive pneumococcal disease in humans despite
induction of strong immune responses to the carrier protein. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

3 

 

 
 SUBCONTRACT AGREEMENT 

Modification 07 
  

					
	 SUBCONTRACTOR:
  

Pfenex Inc.
	  	SUBCONTRACT #:	  	P010022290
	  	  
 MODIFICATION #:
	  	  
 07

			
	 ADDRESS:
  

10790 Roselle Street
 San Diego, CA 92121
	  	DPAS RATING:	  	Not Rated
	  	  
 TYPE:
	  	  
 FIRM FIXED

PRICE COMMERCIAL
 ITEMS (GOVERNMENT)

			
	 Period of Performance:
  

Sep 11, 2009 thru Sep 21, 2014
	  	 VALUE:
 FUNDED:
	  	 $4,055,873.00

$2,640,928.02

 The purpose of this modification is to extend the period of performance, at no additional cost, FROM
Sep 11, 2009 through Sep 21, 2011 TO Sep 11, 2009 through Sep 21, 2014. The total value and funding value remain unchanged at $4,055,873 and $2,640,928.02 respectively. The address for Pfenex, Inc. is revised to that shown above. 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown.

  

									
	PFENEX, INC.	 		 	SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Michael A. Younkins

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick Lucy
	 		 	Name:	 	 Michael A. Younkins

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

					
	Date:	 	 9/9/11
	 		 	Date:	 	 9/9/11

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 1 of 1 

 

 
 SUBCONTRACT AGREEMENT 

Modification 08 
  

					
	 SUBCONTRACTOR:
  

Pfenex Inc.
	  	SUBCONTRACT #:	  	P010022290
	  	  
 MODIFICATION #:
	  	  
 08

			
	 ADDRESS:
  

10790 Roselle Street, San Diego, CA 92121
	  	DPAS RATING:	  	Not Rated
	  	  
 TYPE:
	  	  
 FIRM FIXED PRICE COMMERCIAL

 
 ITEMS (GOVERNMENT)

			
	 Period of Performance:
  

Sep 11, 2009 thru Sep 21, 2014
	  	 VALUE:
 FUNDED:
	  	 $4,055,873.00

$2,863,328.02

 The purpose of this modification is to provide incremental funding in the amount of $222,400.00. As a result, the funding
value is increased FROM $2,640,928.02 BY $222,400.00 TO $2,863,328.02. The total value remains unchanged at $4,055,873.00. 
 Article 1.0
PRICE is modified to read as follows: 
 The total not-to-exceed PRICE of Subcontract No. P010022290 is $4,055,873.00 including profit. This
subcontract is incrementally funded for work to be performed through September 21, 2014. The total FUNDING of Subcontract No. P010022290 is $2,863,328.02 including profit. 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 

 

									
	PFENEX INC.	 		 	SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Michael A. Younkins

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick Lucy
	 		 	Name:	 	 Michael A. Younkins

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

					
	Date:	 	 09/29/2011
	 		 	Date:	 	 09/29/2011

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
 SUBCONTRACT AGREEMENT 

Modification 09 
  

					
	SUBCONTRACTOR:	  	SUBCONTRACT #:	  	P010022290
			
	Pfenex Inc.	  	MODIFICATION#:	  	09
			
	ADDRESS:	  	DPAS RATING:	  	Not Rated
			
	 10790 Roselle Street, San Diego, CA
	  	TYPE:	  	FIRM FIXED PRICE COMMERCIAL
	92121	  		  	  
 ITEMS (GOVERNMENT)

			
	Period of Performance:	  	VALUE:	  	$4,055,873.00
			
	 Sep 11, 2009 thru Sep 21, 2014
	  	 FUNDED
	  	 $3,135,328.02

 The purpose of this modification is to provide incremental funding in the amount of $272,000.00. As a result, the funding
value is increased FROM $2863,328.02 BY $272,000.00 TO $3,135,328.02. The total value remains unchanged at $4,055,873.00. 
 Article
1.0 PRICE is modified to read as follows: 
 The total not-to-exceed PRICE of Subcontract No. P010022290 is $4,055,873.00 including profit. This
subcontract is incrementally funded for work to be performed through September 21, 2014. The total FUNDING of Subcontract No. P010022290 is $3,135,328.02 including profit. 

All other Subcontract terms and conditions remain unchanged 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 

 

									
	PFENEX, INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Michael A. Younkins

	(Signature)	 		 	(Signature)
			
	 Patrick Lucy
	 		 	 Michael A. Younkins

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

					
	Date:	 	 11-17-11
	 		 	Date:	 	 11-17-2011

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	 Page 1 of 1

 

 
 SUBCONTRACT AGREEMENT 

Modification 10 
  

					
	SUBCONTRACTOR:	  	SUBCONTRACT #:	  	P010022290
			
	Pfenex Inc.	  	MODIFICATION #:	  	10
			
	ADDRESS:	  	DPAS RATING:	  	Not Rated
			
	10790 Roselle Street, San Diego, CA 92121	  	TYPE:	  	 FIRM FIXED PRICE COMMERCIAL

		  		  	  
 ITEMS (GOVERNMENT)

	 Period of Performance:
	  	VALUE:	  	$4,055,873.00 
	  
 Sep 11, 2009 thru Sep 21, 2014
	  	FUNDED:	  	$3,915,373.26

 The purpose of this modification is to provide incremental funding in the amount of $780,045.24. As a result, the funding
value is increased FROM $3,135,328.02 BY $780,045.26 TO $3,915,373.26. The total value remains unchanged at $4,055,873.00. 
 Article 1.0 PRICE is
modified to read as follows: 
 The total not-to-exceed PRICE of Subcontract No.P010022290 is $4,055,873.00 including profit. This subcontract is
incrementally funded for work to be performed through September 21, 2014. The total FUNDING of Subcontract No.P010022290 is $3,916,373.26 including profit. 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 

 

									
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Michael A. Younkins

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick Lucy
	 		 	Name:	 	 Michael A. Younkins

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

					
	Date:	 	 December 12, 2011
	 		 	Date:	 	 12/13/11

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	 Page 1 of 1

 

 
 SUBCONTRACT AGREEMENT 

Modification 11 
  

					
	SUBCONTRACTOR:	  	SUBCONTRACT #:	  	P010022290
			
	 Pfenex Inc.
 10790 Roselle
Street, San Diego, CA
 92121
	  	MODIFICATION #:	  	11
	  	  
 DPAS RATING:
	  	  
 Not Rated

	  	  
 TYPE:
	  	  
 FIRM FIXED PRICE

		
		  	COMMERCIAL ITEMS (GOVERNMENT)
	Period of Performance: Sep 11, 2009 thru Sep 21, 2014	  	 VALUE:
 FUNDED:
	  	 $4,171,178.75 

$4,030,679.01

 The purpose of this modification is to increase the total award value by $115,305.75 for additional work; Stage 5A/
Preliminary [*]. As a result of this modification, the total value is increased FROM $4,055,873.00 BY $115,305.75 TO $4,171,178.75. The total funded amount is increased FROM $3,915,373.26 BY $115,305.75 TO $4,030,679.01. 

Statements of Work entitled “[*], November 21, 2011, Subcontract Modification 11” are herein incorporated into and made part of Subcontract No.
P010022290. 
 Article 1.0 PRICE is modified to read as follows: 

The total not-to-exceed PRICE of Subcontract No. P010022290 is $4,171,178.75 including profit. This subcontract is incrementally funded for work to be
performed through March 21, 2014. The total FUNDING of Subcontract No. P010022290 is $4,030,679.01 including profit. 
 All other
Subcontract terms and conditions remain unchanged. 
 In witness whereof, the duly authorized representatives of Buyer and Seller have executed this
Subcontract Modification on the dates shown. 
  

									
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Michael A. Younkins

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick Lucy
	 		 	Name:	 	 Michael A. Younkins

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

					
	Date:	 	 12/21/11
	 		 	Date:	 	 1/3/12

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	 Page 1 of 1

 

 
 November 8, 2011 

Steve C. Huang, PhD, RAC, PMP 
 Project Manager 

Science Applications International Corporation (SAIC) 

5202 Presidents Court 
 Suite 110 

Frederick, MD 21703 
 Dear Steve, 

Please find enclosed Pfenex Inc.’s proposal in response to SAIC’s Request for Proposal regarding the Preliminary Formulation Development of rCSP.
The scope of work will be Contract Modification 11 to Subcontract #P010022290 related to SAIC Prime Contract # N01-AI-05421. The total Firm Fixed Price of this program in accordance with Statement of Work enclosed is $70,500 inclusive of materials
cost. 
 This proposal is valid for 120 days from today’s date. 

I look forward to working with you on this program. 
  

	
	Sincerely,
	
	/s/ Patrick Lucy

 Patrick Lucy 
 Vice President of
Business Development & Marketing 
 Pfenex Inc. 
 301
Newbury Street PMB #251 
 Danvers, MA 01923 
 Tel.
(978) 887-4971 
 PKL@Pfenex.com 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-1- 

 

 
 STATEMENT OF WORK 

Evaluation of Malaria CSP Expression in Pfenex Expression TechnologyTM 

and Process Manufacturing 

Malaria Vaccine Production and Support Services 

November 11, 2011 

Subcontract Modification 

Stage 5A: Preliminary Formulation of rCSP 
  

	 	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all of
the necessary services, qualified personnel, materials, equipment, facilities, and travel not otherwise provided under the terms of this agreement as needed for the production of additional filtered lysates, and purified full-length CSP expressed in
Pfenex Expression TechnologyTM. As part of this support, Pfenex shall be required to provide summary reports related to the preliminary formulation of rCSP. 

 

	 	2.	Technical Requirements 

  

	 	2.1.	Screen buffer Systems 

  

	 	2.1.1.	Pfenex shall evaluate at a minimum [*] that can accommodate concentrations of [*]. 

  

	 	2.1.1.1.	Components/pH in the buffer systems should be suitable for human use. 

  

	 	2.1.1.2.	The buffer systems may include, but are not limited to the following. 

  

									
	 No.
	  	 Buffer
	  	 pH
	  	 Tonicity

Modifier
	  	 Stabilizer

					
	 1
	  	[*]	  	[*]	  	[*]	  	[*]
					
	 2
	  	[*]	  	[*]	  	[*]	  	[*]
					
	 3
	  	[*]	  	[*]	  	[*]	  	[*]
					
	 4
	  	[*]	  	[*]	  	[*]	  	[*]
					
	 5
	  	[*]	  	[*]	  	[*]	  	[*]

  

	 	2.1.1.3.	Compatibility of the buffer systems and CSP shall be analyzed. The methods that may include, but are not limited to, [*]. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-2- 

 

 
  

	 	2.2.	Short term stability monitoring 

  

	 	2.2.1.	Upon selection of suitable buffer system(s) for [*], a short term stability shall be conducted to monitor the quality changes of [*] in the selected buffer systems. 

 

	 	2.2.2.	The short term stability shall include, but are not limited to, the following temperature and time points 

  

					
	 Stress
	  	Conditions	 	Time Point(s)
	 Temperature
	  	[*]	 	[*]

  

	 	2.2.3.	[*] quality in the selected buffer systems. 

  

	 	2.2.4.	At the minimum, one aliquot per temperature and per time point shall be assessed 

  

	 	2.2.4.1.	Testing methods for the CSP stability may include, but are not limited to, [*]. 

  

	 	2.2.5.	Upon SAIC’s request, Pfenex shall provide [*] in the selected buffer system and concentration to SAIC for further testing 

  

	 	2.3.	Final Report 

  

	 	2.3.1.	Pfenex shall issue a final report. 

 The report shall include an executive summary, detailed
description of methods including system suitability controls, list of all raw materials and their source, results, conclusions, inventory of reagents provided by SAIC, and all raw data in PDF format. 

 

	 	3.	Deliverables to SAIC 

  

									
	 Deliverable
	  	Requirement	  	Item	  	 Date
	  	 Form

	 1
	  	Reporting	  	Final Report	  	 Draft: 2 weeks following completion
  

Final: 2 weeks after receipt of SAIC comments
	  	 Draft: Word Document
  

Final: Signed Pdf

					
	 2
	  	Technical	  	rCSP	  	Upon SAIC’s request	  	Proper shipping condition

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-3- 

 

 
  
  

	 	4.	Cost Proposal 

 The pricing for the proposal shall be based upon commercial rates and is inclusive of
costs for supplies, materials and reports. The pricing is broken down as follows: 
 Total Price – $[*] 

Payment Terms – [*] upon delivery of final report. 

Labor – Approximately [*] hours 

Materials – $[*] 
 Timescale
– Approximately eight (8) weeks from commencement to issuance of final report 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-4- 

 

 
  
 November 21, 2011 

Steve C. Huang, PhD, RAC, PMP 
 Project Manager 

Science Applications International Corporation (SAIC) 
 5202
Presidents Court 
 Suite 110 
 Frederick, MD 21703 

Dear Steve: 
 Please find enclosed Pfenex Inc.’s proposal
in response to SAIC’s Request for Proposal regarding the Characterization of Fourteen (14) rCSP Monoclonal Antibodies. The scope of work will be Contract Modification 11 to Subcontract #P010022290 related to SAIC Prime Contract #
N01-AI-05421. The total Firm Fixed Price of this program in accordance with Statement of Work enclosed is $45,000 inclusive of materials cost. 
 This
proposal is valid for 120 days from today’s date. I look forward to working with you on this program. 
 Sincerely, 

/s/ Patrick Lucy 
 Patrick Lucy 

Vice President of Business Development & Marketing 

Pfenex Inc. 
 301 Newbury Street PMB #251 

Danvers, MA 01923 
 Tel. (978) 887-4971 

PKL@Pfenex.com 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  
 STATEMENT OF WORK 

Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM 

and Process Manufacturing 

Malaria Vaccine Production and Support Services 

November 21, 2011 

Subcontract Modification 

Stage 6A: Characterization of 14 rCSP monoclonal antibodies 
  

	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all of
the necessary services, qualified personnel, materials, equipment, facilities, and travel not otherwise provided under the terms of this agreement as needed for the production of additional filtered lysates, and purified full-length CSP expressed in
Pfēnex Expression TechnologyTM. As part of this support, Pfenex shall be required to provide summary reports related to the characterization of 14 of rCSP monoclonal antibodies (mAbs). 

 

	2.	Technical Requirements 

  

	 	2.1.	[*] 

  

	 	2.1.1.	Pfenex shall characterize the provided [*] for their applications [*] and [*]. 

  

	 	2.1.1.1.	In both [*] and [*], Pfenex shall screen [*] against the purified rCSP and its forced-degraded derivatives. 

  

	 	2.1.1.2.	For forced degradation, the purified rCSP shall be subjected to, but is not limited to, [*]. 

  

	 	2.1.1.3.	Pfenex shall capture forced degradation conditions at which stability of the product can be reflected by the use of certain mAbs in [*]. 

 

	 	2.1.1.4.	Forced-degraded derivatives of rCSP will also be analyzed by analytical methods that include, but is not limited to, [*]. 

  

	 	2.2.	Final Report 

  

	 	2.2.1.	Pfenex shall issue a final report. 

 The report shall include an executive summary, detailed
description of methods including system suitability controls, list of all raw materials and their source, results, conclusions, inventory of reagents provided by SAIC, and all raw data in PDF format. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  
  

	3.	Deliverables to SAIC 

  

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date
	  	 Form

					
	 1
	  	Reporting	  	Final Report	  	Draft: 2 weeks following completion Final: 2 weeks after receipt of SAIC comments	  	 Draft: Word Document
 Final: Signed
PDF

					
	 2
	  	Technical	  	rCSP	  	Upon SAIC’s request	  	Proper shipping condition

  

	4.	Cost Proposal 

 The pricing for the proposal shall be based upon commercial rates and is
inclusive of costs for supplies, materials and reports. The pricing is broken down as follows: 
 Total Price – $[*] 

Payment Terms – [*] upon delivery of final report. 

Labor – Approximately [*] – Included 

Timescale – Approximately six (6) weeks from commencement to issuance of final report 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  
 SUBCONTRACT AGREEMENT 

Modification 12 
  

					
	SUBCONTRACTOR:	  	SUBCONTRACT #:	  	P010022290
	  
 Pfenex Inc.

10790 Roselle Street, San Diego, CA
 92121
	  	  
 MODIFICATION #:
	  	  
 12

	  	  
 DPAS RATING:
	  	  
 Not Rated

	  	  
 TYPE:
	  	  
 FIRM FIXED PRICE

		  	  
 COMMERCIAL ITEMS (GOVERNMENT)

	 Period of Performance:

Sep 11, 2009 thru Sep 21, 2014
	  	  
 Modification Value:
	  	  
 $122,288.00

	  	  
 FUNDED:
	  	  
 $4,152,967.01

	  	Ceiling VALUE:	  	$4,612,816.75

 The purpose of this modification is to increase the ceiling value by $441,638.00 and funding value by $122,288.00 for
additional work as stated below. 
 Effective date of this modification is February 24, 2012. 

Pfenex shall be required to provide (i) gene synthesis and strain engineering of PfRh5 in pseudomonas fluorecens, (ii) optimize fermentation for 1 L
scale, (iii) purified 10mg protein from three selected clones, and (iv) produce research cell bank and conduct cell bank testing. 
 As a result
of this modification, the total ceiling value is increased FROM $4,171,178.75 BY $441,638.00 TO $4,612,816.75. The total funded amount is increased FROM $4,030,679.01 BY $122,288.00 TO $4,152,967.01. 

Statements of Work entitled “Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM And Process Manufacturing Malaria
Vaccine Production and Support Services, dated February 6, 2012 Subcontract Modification 12” are herein incorporated into and made part of Subcontract No. P010022290 and is attachment 1 to this modification 12. 

Article 1.0 PRICE is modified to read as follows: The total not-to-exceed Ceiling Value of Subcontract No. P010022290 is $4,612,816.75
including profit. This subcontract is incrementally funded for work to be performed through March 21, 2014. The total FUNDING of Subcontract No.P010022290 is $4,152,967.01 including profit. 

Article 1.3 INVOICES is modified to read as follows: 

Invoices shall contain the following information: subcontract number, subproject number, Stage #. Invoices may be mailed or emailed to: 

Science Applications International Corporation 

Attention: Carol Frishman 
 5202
Presidents Court, Suite 110 
 Frederick, Maryland 21703 

carol.c.frishman@saic.com 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 1 of 3

 

 
  
 Article 2.0 TECHNICAL AND
CONTRACTUAL POINTS OF CONTACT is modified to replace Michael Younkins with the following: 
 SAIC (BUYER): 

Contractual: Carol Frishman 
 Article
1.4 PAYMENT — is modified to add the following: 
  

	(a)	Original Subcontract Award: For each Stage of work there will be two invoices each totaling 50 % of the price for each Stage of Work, an initial invoice upon commencement of the Stage and a final invoice upon
acceptance of the final report for each Stage. 

 The following table shall be utilized for Milestone Invoice submission for Modification
12: 
  

							
	 Milestone
	  	 Payment
	  	 Amount
	  	 Duration

				
	Milestone 1: Strain Screening	  	 50% upon

commencement
	  	[*]	  	 Approximately 8

weeks from receipt

of synthetic genes

	  
 Milestone 1: Strain Screening
	  	  
 50% upon

delivery of report
	  	  
 [*]
	  
				
	Milestone 2 [OPTIONAL]: Fermentation Assessment of [*] in Pfēnex Expression TechnologyTM	  	 50% upon

commencement
	  	[*]	  	 Approximately 6

weeks from receipt

of written

authorization to

proceed

	  
 Milestone 2 [OPTIONAL]: Fermentation Assessment of
[*] in Pfēnex Expression TechnologyTM
	  	  
 50% upon

delivery of report
	  	  
 [*]
	  
				
	Milestone 2A [OPTIONAL]: Provide [*] pure PfRh5 protein from [*] selected [*] clones respectively to SAIC	  	  
 50% upon

commencement
	  	[*]	  	 Approximately 7

weeks from receipt

of written

authorization to

proceed*

	  
 Milestone 2A [OPTIONAL]: Provide [*] pure
[*] protein from [*] selected [*] clones respectively to SAIC
	  	  
 50% upon

delivery of report
	  	  
 [*]
	  
				
	Milestone 3 [OPTIONAL]: Preparation and Characterization of a P. fluorescens- [*] Research Cell Bank (RCB)	  	 50% upon

commencement
	  	[*]	  	 Approximately 4

weeks from receipt

of written

authorization to

proceed

	  
 Milestone 3 [OPTIONAL]: Preparation and Characterization of
a P. fluorescens- [*] Research Cell Bank (RCB)
	  	  
 50% upon

delivery of report
	  	  
 [*]
	  

  

	*	Duration for Milestone 2A will depend on expression and quality data of [*] from Milestone 2 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 2 of 3

 

 
  
 (b) Payment terms will be Net 45 days from date of
invoice. Upon receipt of invoice Buyer shall within five (5) business days review the invoice and determine if the invoice is acceptable. If Buyer reasonable deems the invoice unacceptable Buyer shall contact Seller and Seller shall reissue a
conforming invoice with a new date of invoice. If (1) Buyer does not pay on time or (2) Buyer’s financial responsibility becomes unsatisfactory (S&P rating below BBB- or Moody’s rating below Baa3) to Seller and Seller deems
itself insecure, Seller may accelerate the due date and demand immediate payment on any outstanding invoice for Product, or may require cash payments or satisfactory security for future deliveries and for payment of all sums owed under this
Agreement. Buyer agrees to pay all costs and expenses, including reasonable attorney’s fees, incurred by Seller in the collection of any sum payable by Buyer to Seller, or in the exercise of any remedy. Pfenex may charge Prime +2% on all
overdue amounts. 
 Article 17.0 ORDER OF PRECEDENCE — is modified to read as follows: 

The documents listed below are hereby incorporated by reference. In the event of an inconsistency or conflict between or among the provisions of this
Subcontract, the inconsistency shall be resolved by giving precedence in the following order: 
  

	 	1.	Attachment I: Statement of Work and Schedule dated February 6, 2012. 

  

	 	2.	Statements of Work and Schedules as follows: 

 Modifications - 6 dated 6/1/11, 5 dated 1/1/11, 4
dated 11/15/10, 2 dated 5/4/10 and original dated 5/11/11 respectively. 
  

	 	3.	Schedule A: Specific Terms and Conditions Form 9-932-072 (Rev. 9/25/06). 

  

	 	4.	Schedule B: U.S. Government Terms and Conditions, Part Ill — FAR Clauses Form 9-932-082 (Rev. 07/25/07). 

  

	 	5.	Attachment C (Enclosure 2; (Rev. 412009) Property Administration Requirements For Subcontractors With An Adequate System Or Requisite Internal Controls. 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 

 

									
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	/s/ Patrick Lucy	 		 	/s/ Carol Frishman
	  
	 		 	  

	(Signature)	 		 	(Signature)
					
	Name:	 	Patrick Lucy	 		 	Name:	 	Carol Frishman
		 	  
	 		 		 	  

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	Vice President of Business Development	 		 	Title:	 	Subcontracts Manager
		 	  
	 		 		 	  

					
	Date:	 	2/24/12	 		 	Date:	 	2/24/12
		 	  
	 		 		 	  

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 3 of 3

 Statement of Work 

Evaluation of [*] Expression in Pfēnex Expression TechnologyTM 

and Process Manufacturing 

Malaria Vaccine Production and Support Services 

May 20, 2013 

Subcontract Modification 
  

	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all of
the necessary services, qualified personnel, materials, equipment, and facilities for the full development of a manufacturing process for the [*] expressed from [*] clone using Pfēnex Expression TechnologyTM and technical transfer of
the process to a SAIC designated cGMP manufacturing facility with processing capabilities and equipment compatible with the upstream and downstream process developed by Pfenex. The process shall be suitable for a scale up, at a minimum, of a [*]
fermentation scale and follow-on purification, upon transfer. As part of this project, Pfenex is required to provide related meeting support, reports, and deliverables as listed in Table 1. 

 

	 	1.1.	SAIC will provide the following information and materials: 

  

	 	•	 	Background literature/references relating to [*]. 

  

	 	•	 	Additional [*] monoclonal antibodies (mAbs) and control Rh5, if required. 

  

	 	•	 	Shipping instructions for purified [*] protein and other materials. 

  

	2.	Technical Requirements 

 As a follow-on to the successful production, testing and
selection of a [*] expressing cell line under the original subcontract and Mod 12 which was composed of: (i)-Evaluation of [*] (Stage 1), (ii)-Fermentation assessment of [*] (Stage 2A/Mod 12) and (iv)-Preparation and characterization of
Pseudomonas-[*] (Stage 3); SAIC now requires Pfenex to develop a manufacturing process suitable for a scale up, at a minimum, of a [*] fermentation scale and follow-on purification for the SAIC selected clone [*] and technical transfer of the
process to a SAIC designated cGMP manufacturing facility with processing capabilities and equipment compatible with the upstream and downstream process developed by Pfenex. 
  

	 	2.1.	Stage 4: Fermentation Optimization of cell line [*] 

  

	 	2.1.1.	Pfenex shall apply computer-aided, statistically-based design of experiments (DoE) to examine fermentation parameters [*] expression. Design and execute 2-level fractional factorial experiments to screen up to five
(5) factors (e.g. pH and temperature) [*] expression in an 8-unit multiplex 1L bioreactor system. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 1 of 10 

 Please Note: Appropriate samples for yield determination and analysis will
be collected throughout the fermentation runs. 
  

	 	2.1.2.	Perform the appropriate analysis on selected pre- and post-induction samples taken from the fermentations. 

  

	 	2.1.3.	Use JMP statistics software to analyze the data. Based on the conclusions, design a confirmation round of experiments up to a total of [*] X 1L fermentations. 

 

	 	2.1.4.	Evaluate [*] titer and quality on selected samples utilizing ELISA and western blot analysis development from Stage 7 Product Specific Analytical Method Development. 

 

	 	2.1.5.	The optimized fermentation condition shall be confirmed in up to [*] scale per round. 

  

	 	2.1.6.	The optimized fermentation shall produce material which can be subsequently purified to meet product quality safety specifications required for human use when produced under cGMP conditions. 

 

	 	2.1.7.	A technical study report shall be issued following the completion of the work. 

  

	 	2.1.7.1.	Pfenex shall submit the optimized fermentation procedure/protocol to SAIC for review and approval. 

  

	 	2.1.7.2.	Document shall also contain, at a minimum, in process parameters examined, rational for parameters selected, and copies of the raw data. 

 

	 	2.2.	Stage 5: Purification Process Development 

  

	 	2.2.1.	Pfenex shall develop a cGMP ready downstream purification process. 

  

	 	2.2.2.	Pfenex shall perform up to six rounds of [*] fermentation runs to supply cell paste for the experiments outlined in this stage of work. 

 

	 	2.2.3.	Pfenex shall develop a downstream purification process based on lessons learned from Stage 2A ([*] purification strategy). 

  

	 	2.2.4.	Pfenex shall design and execute a fractional factorial design to optimize protein release and purity [*]. 

  

	 	2.2.5.	Pfenex shall evaluate efficiency (throughput, purity, recovery) of bulk separation of soluble and insoluble material by [*]. 

  

	 	2.2.6.	Pfenex shall develop [*] will permit the material [*] to be filtered through a [*]. 

  

	 	2.2.7.	Pfenex shall analyze samples taken throughout the primary recovery development for [*] yield and purity. 

  

	 	2.2.8.	Pfenex shall utilize the process intermediate from 2.2.7 to design and execute a resin screen (microtiter plate scale) for the primary capture chromatography step. Up to [*] will be screened for the best conditions for
capacity. The best two resins will be screened in a second round using up to [*] conditions to determine selectivity. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 2 of 10

	 	2.2.9.	Pfenex shall compare screening leads from 2.2.8 using test gradients and method scouting at small scale and rank performance with an emphasis on determining operating parameters (e.g., capacity, resolution, and yield)
for protein with that resin 

  

	 	2.2.10.	The primary column resin and associated conditions selected from 2.2.9 will be optimized further for chromatography scale up and implemented at pilot scale. 

 

	 	2.2.11.	Pfenex shall utilize the elution pool from 2.2.10 to develop and execute a resin screen for the second chromatography step. Up to [*] will be screened for the best capacity and selectivity. The best resin will be
screened in a second round using up to [*]. 

  

	 	2.2.12.	Pfenex shall compare screening leads from 2.2.11 using test gradients and method scouting at small scale and rank performance with an emphasis on determining operating parameters (e.g., capacity, resolution, and yield)
for protein with that resin. 

  

	 	2.2.13.	The second column resin and associated conditions selected from 2.2.12 will be optimized further for chromatography scale up and implemented at pilot scale. 

 

	 	2.2.14.	Pfenex shall utilize the elution pool from 2.2.13 to design and execute a resin screen for the polishing chromatography step. Up to eight resins will be screened for the best capacity and selectivity. The best resin
will be screened in a second round using up to 36 conditions for efficiency and selectivity. 

  

	 	2.2.15.	Pfenex shall compare screening leads from 2.2.14 using test gradients and method scouting at small scale and rank performance with an emphasis on determining operating parameters (e.g., capacity, resolution, and yield)
for protein with that resin. 

  

	 	2.2.16.	The polishing column resin and associated conditions selected from 2.2.12 will be optimized further for chromatography scale up and implemented at pilot scale. 

 

	 	2.2.17.	[*] from 2.2.16 will be buffer exchanged into the final drug substance buffer determined in Stage 6 using [*]. [*] parameters will be optimized to minimize processing time while maintaining product quality.

  

	 	2.2.18.	For each downstream unit operation, Pfenex shall conduct hold studies to determine process intermediate stability. 

  

	 	2.2.19.	Pfenex shall perform analysis during development that may include [*]. 

  

	 	2.2.20.	Pfenex shall perform a pilot scale integrated purification run to confirm scale-up parameters and overall process performance. 

  

	 	2.2.20.1.	Pfenex shall collect and analyze intermediate samples taken during the integrated run for protein yield, purity and contaminant profile. 

 

	 	2.2.20.2.	Pfenex shall provide [*] produced from the integrated run to SAIC or its designee. 

  

	 	2.2.20.3.	Pfenex shall perform analysis of integrated run final material that may include [*]. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 3 of 10

	 	2.2.21.	Pfenex shall submit the developed purification process procedures and protocols to SAIC for review and approval before moving forward to engineering run (Stage 8). 

 

	 	2.2.21.1.	Document shall also contain, at a minimum, processes examined, rational or processes selected, and copies of the raw data. 

  

	 	2.2.22.	Pfenex shall ship [*] generated during development to a SAIC designated facility; however, Pfenex may retain all or a portion of the material produced for subsequent studies. 

 

	 	2.3.	Stage 6: BDS Formulation Development 

  

	 	2.3.1.	With material generated from Stage 5 Purification Process Development, Pfenex shall screen and evaluate at a minimum [*] buffer systems that are compatible with [*]. 

 

	 	2.3.1.1.	Components/pH in the buffer systems should be suitable for human use and may include stabilizing excipients. 

  

	 	2.3.1.2.	Pfenex will measure compatibility of the buffer systems using SEC-HPLC and/or other stability indicating assays. 

  

	 	2.3.2.	Pfenex shall confirm the selected buffer systems to monitor quality changes of [*]. 

  

	 	2.3.3.	Pfenex shall perform a short-term stability monitoring of selected, suitable buffer systems(s) to monitor quality changes of [*] and/or other stability indicating assays. 

 

	 	2.3.3.1.	Short term stability monitoring shall include the following temperature and time points: 

  

					
	 Stress
	  	 Conditions
	  	 Time Point(s)

	Temperature	  	[*]	  	[*]

  

	 	2.3.3.2.	[*]. 

  

	 	2.3.4.	Upon SAIC’s request, Pfenex shall provide [*] in the selected buffer system and concentration to SAIC for further testing 

  

	 	2.3.5.	Pfenex shall issue a final report. The report shall include an executive summary, detailed description of methods including system suitability controls, list of all raw materials and their source, results, conclusions,
inventory of reagents provided by SAIC, and all raw data in PDF format. 

  

	 	2.4.	Stage 7: Product Specific Analytical Method Development  

  

	 	2.4.1.	Pfenex shall develop product specific in-process and final product analytical methods and provide standard operating procedures (SOPs) for each method. 

Please Note: Method qualification may be performed as optional. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 4 of 10

	 	2.4.2.	Pfenex shall establish acceptance criteria and specifications in consultation with SAIC, where applicable, that will be the basis for release and stability monitoring. The specifications shall be appropriate for a Phase
1 clinical product. 

  

	 	2.4.3.	For in-process testing of low purity fermentation and purification samples, the testing shall include: [*] analysis. 

  

	 	2.4.4.	For release testing of bulk drug substance, the testing shall include: [*] 

  

	 	2.4.5.	For characterization of bulk drug substance, the testing shall include: [*] 

  

	 	2.4.6.	Pfenex shall recommend and submit the developed analytical and characterization testing, including procedures, protocols, and their results, to SAIC for review and approval. 

 

	 	2.4.7.	(Optional) Analytical method qualification shall be performed on methods developed. 

  

	 	2.4.7.1.	Qualification protocols and report template shall be issued for review and approval 

  

	 	2.4.7.2.	Qualification report shall be issued and include data and summary tables. 

  

	 	2.5.	Stage 8: Engineering Run 

  

	 	2.5.1.	Pfenex shall perform a complete engineering run at the [*] scale to ensure reproducibility of previously drafted procedures. 

  

	 	2.5.2.	Pfenex shall develop master batch production records (BPRs) for the engineering run that covers all of upstream and downstream process, and identifies where the in-process tests occur and what volume is removed for
testing. SAIC will be provided copies of the master BPRs for review and approval prior to use. 

  

	 	2.5.3.	Pfenex shall submit the completed BPRs to SAIC upon the completion of the engineering run. 

  

	 	2.5.4.	Pfenex shall execute the release and characterization testing as accomplished in Stage 7 for the engineering run material. 

  

	 	2.5.5.	Pfenex shall set aside aliquots for the stability program described below, and ship the remaining [*] from the engineering run to a SAIC designated facility in aliquots to be determined at a later timepoint.

  

	 	2.5.6.	(Optional) Pfenex may perform additional engineering run(s) if required by SAIC 

  

	 	2.5.6.1.	Pfenex shall develop master batch production records (BPRs) for the engineering run that covers all of upstream and downstream process, and identifies where the in-process tests occur and what volume is removed for
testing. SAIC will be provided copies of the master BPRs for review and approval prior to use. 

  

	 	2.6.	Stage 9: Stability Program  

  

	 	2.6.1.	Pfenex shall conduct a non-GMP stability monitoring of the [*]. Pfenex shall submit the stability monitoring plans for the engineering run to SAIC for review and approval. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 5 of 10

	 	2.6.2.	The stability of purified [*] from the engineering run will be evaluated for stability at conditions [*]. 

  

									
	 Method/Test

–70°C, 5°C, 25°C/60% relative humidity (RH), 40°C/75% RH
	  	Initial
Testing
(T=0)	  	1 mo	  	2 mo	  	3 mo
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	
	[*]	  	X	  	X	  	X	  	
	[*]	  	X	  		  		  	X

  

	 	2.6.3.	Stability monitoring assessment shall include: [*] 

  

	 	2.6.4.	A stability report shall be submitted to SAIC at each stability timepoint and include, at minimum, assays utilized with associated SOP, test results in table format, conclusion, trending data, and copies of raw data.

  

	 	2.7.	Stage 10: Process Training and Transfer 

  

	 	2.7.1.	Pfenex shall train SAIC’s cGMP contract manufacture organization (CMO) on the manufacturing process and shall transfer the BPRs (master and completed) and analytical method SOPs. 

 

	 	2.7.2.	As part of the process training and transfer Pfenex shall conduct at least one successful training run. 

  

	 	2.7.3.	The process yield from the process training run shall be within acceptable scientific variation from the engineering run performed in Stage 8. 

 

	 	2.7.4.	The process training run shall demonstrate within acceptable scientific variation reproducibility as compared to Stage 8, in all up- and down-stream processes including growth rate in fermentation, quantity and quality
of Rh5 in lysate, in primary recovery, in each process step, and in final product. 

  

	 	2.7.5.	Pfenex shall provide to SAIC and to SAIC designated CMO the RCB and a full process transfer package with all information necessary for the transfer of the manufacturing process. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 6 of 10

	 	2.7.6.	The full process transfer package shall include the following items: 

  

	 	2.7.6.1.	Bill of materials and suggested suppliers 

  

	 	2.7.6.2.	Detailed fermentation and purification process procedures (master BPRs) 

  

	 	2.7.6.3.	Listing of instruments/equipment 

  

	 	2.7.6.4.	Detailed testing procedures (SOPs) 

  

	 	2.7.6.5.	Technical specification for the bulk drug substance 

  

	 	2.7.6.6.	Health/Safety/Environment assessment of all materials and process 

  

	 	2.7.6.7.	Detailed characterization of purified protein/buffer and intermediates 

  

	 	2.7.6.8.	Stability testing plan and final report 

  

	 	2.7.6.8.1.	Research cell bank growth parameters and technical information 

  

	 	2.7.6.8.2.	Construct expression information and test results 

  

	 	2.7.7.	The process transfer and associated training records for the transfer to the clinical CMO shall be well documented and be provided to SAIC in the final report. 

 

	 	2.8.	CMC Support 

  

	 	2.8.1.	Pfenex shall provide support in reviewing CMC sections and documents related to IND submission including details of the cloning and development of the expression strain [*]. 

 

	3.	Quality Requirements 

 In addition to the Quality Requirements stated in the SOW, Pfenex
shall execute a Quality Management Plan suitable for process development and technical transfer (see Section 10). 
  

	 	3.1.	Pfenex shall provide a scientific, technical, and administrative infrastructure to ensure quality control of all process development and technical transfer activities. 

 

	 	3.2.	The quality management plan shall include use of any materials, instruments/equipment, methods, procedures utilized in the process development and technical transfer. 

 

	 	3.3.	At a minimum, Pfenex shall ensure: 

  

	 	3.3.1.	Facilities in which SAIC’s materials are maintained in a safe and secure manner and allow limited access. 

  

	 	3.3.2.	Personnel have the necessary education and training in all procedures relevant to work assignments; training and qualifications are verified by leadership of Pfenex. 

 

	 	3.3.3.	SOPs will be used to document policies and procedures. SOPs will be version controlled and approved by key personnel. 

  

	 	3.3.4.	An effective tracking/tracing system or procedure is in place for all materials and equipment used in this contract. 

  

	 	3.3.5.	Equipment calibration and maintenance are performed as required and are documented. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 7 of 10

	 	3.4.	The Quality Management Plan shall govern Pfenex’s commitment to quality and ensure that procedures addressing the following requirements are in place. 

 

	 	3.4.1.	SOPs 

  

	 	3.4.2.	Document/version control 

  

	 	3.4.3.	Equipment maintenance and repair 

  

	 	3.4.4.	Training: adherence of staff to required schedules 

  

	 	3.4.5.	Data management 

  

	 	3.4.6.	Record management system 

  

	 	3.4.7.	Safety plan 

  

	 	3.4.8.	Asset tracking and management 

  

	 	3.4.9.	Building and facility monitoring 

  

	 	3.4.10.	Adherence to Federal or other applicable regulatory requirements appropriate for work on this contract 

  

	 	3.4.11.	Operational deviations and failures will be investigated through root cause analysis, which will be documented. 

  

	 	3.5.	Cold/frozen and controlled temperature storage chambers have continuous monitors with alarms or are monitored at least every 4 hours by security staff. Any deviations will be immediately reported to Pfenex staff.

  

	 	3.6.	Effective cold chain management practices are in place for the handling of materials, products and samples. 

  

	 	3.7.	Investigation are initiated upon incident discovery (excursion from written procedure, policy, or protocol). Upon request, copies results of investigations are submitted to SAIC for review. 

 

	 	3.8.	SAIC may schedule in-plant and other visits at Pfenex to audit quality of activities conducted in this contract. 

  

	4.	Record Management Requirements 

 Pfenex shall maintain a record management system
suitable for process development and technical transfer (see Section 10, Quality Management Plan). 
  

	 	4.1.	Pfenex shall have a record management system that permits detailed records to be made concurrently with the performances of each process development activity. 

 

	 	4.2.	Records and documents shall be created and maintained in a manner that allows version control, handling steps, tests, retests, investigations, data, and results. 

 

	 	4.3.	Record and document security systems shall be adequate to ensure confidentiality and proprietary information. Confidential or proprietary information shall be restricted to staff with a need for access and inspectors
from regulatory agencies. Records shall be readily accessible for inspection by authorized personnel from SAIC. 

  

	 	4.4.	Records and documents shall be maintained for a minimum of 5 years after the completion of process development and technical transfer. SAIC shall be contacted for disposal or transfer instructions at the end of a
records storage period or at the end of the subcontract POP. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 8 of 10

	 	4.5.	Electronic records shall be backed up daily on a separate server or network. Weekly backups shall be stored on an appropriate media, e.g., CD, tape, and stored off-site. 

 

	 	4.6.	Corrections or changes in a record shall be made in accordance with a quality monitoring procedures suitable for managing process development and technical transfer. 

 

	 	4.7.	Unless alternate agreements are made, all raw data and laboratory notebooks related to this subcontract shall be made available to SAIC upon request. 

 

	5.	Table 1. Deliverables to SAIC 

  

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	 Form

					
	1	  	Technical	  	[*] from process development	  	Within a week of completion	  	Sent to SAIC designee in proper shipping containers with a temperature monitor
					
	2	  	Technical	  	[*] from engineering run	  	Within a week of completion	  	Sent to SAIC designee in proper shipping containers with a temperature monitor
					
	3	  	Technical	  	Unused reagents provided by SAIC	  	Within 2 weeks of SAIC request	  	Sent to SAIC designee in proper shipping containers
					
	4	  	Technical	  	Optimized fermentation procedure and protocols	  	Within 3 week of completion	  	PDF or Word document
					
	5	  	Technical	  	Selected primary recovery method	  	Within 3 week of completion	  	PDF or Word document
					
	6	  	Technical	  	Purification process procedures and protocols	  	Within 3 week of completion	  	PDF or Word document
					
	7	  	Technical	  	Recommended analytical and characterization testing	  	Within 3 week of completion	  	PDF or Word document
					
	8	  	Technical	  	Master BPRs for the engineering run	  	2 weeks prior to initiation	  	PDF or Word document

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 9 of 10

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	 Form

					
	9	  	Technical	  	Master BPRs for the second engineering run, etc	  	2 weeks prior to initiation	  	PDF or Word document
					
	10	  	Technical	  	Completed BPRs for the engineering run	  	Within 3 week of completion	  	PDF or Word document
					
	11	  	Technical	  	Completed BPRs for the second engineering run, etc	  	Within 3 week of completion	  	PDF or Word document
					
	12	  	Technical	  	Stability monitoring plans for engineering run(s)	  	2 weeks prior to initiation	  	PDF or Word document
					
	13	  	Technical	  	stability reports	  	3 week following each indicated time point	  	PDF or Word document
					
	14	  	Technical	  	Full Process transfer package	  	4 weeks following completion of engineering run	  	PDF or Word document
					
	15	  	Reporting	  	Biweekly Meeting and minutes	  	Meeting as scheduled, minutes within a week of the meeting	  	Telecom
					
	16	  	Reporting	  	Monthly Reports	  	Due by the 8th of each month during the performance of work efforts	  	PDF or Word document
					
	17	  	Reporting	  	CMC Support	  	Final: 3 weeks after receipt of SAIC CMC sections provided for review	  	Draft: Word document

  

	*	Days = calendar days 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

			
	Page 10 of 10

 7A PRICE SHEET for Subcontract P010022290 

May 24, 2012 
 Pricing is based upon
commercial rates and is inclusive of costs for supplies, materials (except as noted) and reports. 
  

											
	 Stage 7A Activity
	  	Payment Terms
(50% upfront/50%
issuance of final
report)	 	  	Estimated
Labor
(hours)	  	Estimated
Materials
Costs	  	Estimated
Timescales
					
	 2.1.1 [*]
	  	$	[*]	  	  	[*]	  	[*]	  	3 weeks
					
	 2.1.2 [*]
	  	$	[*]	  	  	[*]	  	[*]	  	2 weeks
					
	 2.1.3 [*]
	  	$	[*]	  	  	[*]	  	[*]	  	5 weeks
					
	 2.1.4 [*]
	  	$	[*]	  	  	[*]	  	n/a	  	1 week
					
	 2.1.5-2.1.8 [*]
	  	$	[*]	  	  	[*]	  	n/a	  	3 weeks
					
	 2.1.9 [*]
	  	$	[*]	  	  	[*]	  	n/a	  	2 weeks

  

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

			
	Attachment 2 P010022290 Mod 13	  	Page 1 of 1

 

 
 SUBCONTRACT AGREEMENT P010022290 Modification 13 

 

					
	 SUBCONTRACTOR:
  

Pfenex Inc.
 10790 Roselle Street, San Diego,

CA 92121
	  	SUBCONTRACT #:	  	P010022290
	  	  
 MODIFICATION #:
	  	  
 13

	  	  
 DPAS RATING:
	  	  
 Not Rated

	  	  
 TYPE:
	  	  
 FIRM FIXED PRICE

	  	  
 COMMERCIAL ITEMS (GOVERNMENT)

	  
 Period of Performance:

 
 Sep 11, 2009 thru Sep 21, 2014
	  	  

  •    Modification Value:
	  	  
 $238,336.00

	  	  
 FUNDED:
	  	  
 $4,391,303.01

	  	  
 Ceiling VALUE:
	  	  
 $4,851,152.75

 The purpose of this modification is to increase the ceiling value and funding value by $238,336.00 for additional work
as stated below. 
 Effective date of this modification is June 15, 2012. 

As a result of this modification, the total ceiling value is increased FROM $4,612,816.75 BY $238,336.00 TO $4,851,152.75. The
total funded amount is increased FROM $4,152,967.01 BY $238,336.00 TO $4,391,303.01. 
 Statement of Work entitled
“Evaluation of Malaria CSP Expression in Pfenex Expression TechnologyTM And Process Manufacturing Malaria Vaccine Production and Support Services, dated May 24, 2012 Subcontract
Modification 13” is herein incorporated into and made part of Subcontract No. P010022290 as additional work and is attachment 1 to this modification 13. 

1.0 PRICE is modified to read as follows: The total not-to-exceed Ceiling Value of Subcontract No. P010022290 is $4,851,152.75 including profit. This
subcontract is incrementally funded for work to be performed through September 21, 2014. The total FUNDING of Subcontract No.P010022290 is $4,391,303.01 including profit. 

Each Stage 7A Activity will commence upon request of SAIC representative in writing only. Payments will be made in accordance with Article 1.4 of this
subcontract. 
 17.0 ORDER OF PRECEDENCE — is modified to read as follows: 

The documents listed below are hereby incorporated by reference. In the event of an inconsistency or conflict between or among the provisions of this
Subcontract, the inconsistency shall be resolved by giving precedence in the following order: 
  

	 	1.	Attachment 1: Statement of Work and Schedule dated May 24, 2012, Mod 13. 

  

	 	2.	Attachment 2: 7A Price Sheet 

  

	 	3.	Statements of Work and Schedules as follows: 

 Modifications -12 dated 2/6/12, 6 dated 6/1/11, 5
dated 1/1/11, 4 dated 11/15/10, 2 dated 5/4/10 and original dated 5/11/11 respectively. 
  

	 	3.	Schedule A: Specific Terms and Conditions Form 9-932-072 (Rev. 9/25/06). 

  

	 	4.	Schedule B: U.S. Government Terms and Conditions, Part III — FAR Clauses Form 9-932-082 (Rev. 07/25/07). 

  

	 	5.	Attachment C: (Enclosure 2; (Rev. 4/2009) Property Administration Requirements For Subcontractors With An Adequate System Or Requisite Internal Controls. 

All other Subcontract terms and conditions remain unchanged. 

 In witness whereof, the duly authorized representatives of Buyer and Seller have
executed this Subcontract Modification on data shown. 
  

													
	PFENEX INC	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	/S/ Patrick Lucy	 		 	/s/ Carol Frishman
	  
	 		 	  

	(Signature)	 		 	(Signature)
							
	Name:	 	Patrick Lucy	 	Date 6/20/12	 		 	Name:	 	Carol Frishman	 	Date 6/20/12
		 	  
	 		 		 	  

	(Type or Print)	 		 	(Type or Print)
							
	Title:	 	Vice President of Business Development	 		 		 	Title:	 	Subcontracts Administrator	 	
		 	  
	 		 		 	  

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  
 STATEMENT OF WORK 

Evaluation of Malaria CSP Expression in Pfenex Expression
TechnologyTM 
 And Process Manufacturing 

Malaria Vaccine Production and Support Services 

May 24, 012 

Subcontract Modification 13 
  

	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all of the necessary
services, qualified personnel, materials, equipment, facilities, and travel not otherwise provided under the terms of this agreement as needed for the production of additional filtered lysates, and purified [*] expressed in Pfenex Expression
TechnologyTM. As part of this support, Pfenex shall be required to provide summary reports related to the development and manufacturing process, other documentation as required in the
deliverables, bacterial cell lysates and reagent-[*] protein under specifications defined in Stage 7. Pfenex shall provide antigens, and reports and other documentation related to the development and manufacturing process, as required in the
deliverables (Table 1). Milestones in this subcontract modification include: 
 Table 1. Milestones for CSP 

 

					
	 Antigen
	  	 Milestones
	  	 Timeline

	rCSP	  	Stage 7A: [*]	  	7-10 weeks, followed by Report in 2 weeks

 SAIC will provide the following information and materials: 

 

	 	1.1.1.	Background literature/references relating to [*]. 

  

	 	1.1.2.	Additional [*] and control [*], if required. 

  

	 	1.1.3.	Shipping instructions for filtered lysates and purified [*] 

  

	2.	Technical Requirements 

  

	 	2.1.	Stage 7A: Provide improvements to [*] purification process for manufacture at large-scale (pilot) scale and provide rCSP purified material to SAIC’s Repository designate 

 

	 	2.1.1.	Pfenex shall investigate thawed lysate precipitation using centrifugation of thawed lysate to remove precipitation. 

  

	 	2.1.2.	Pfenex shall develop [*] to test for reduction of host cell protein levels to [*]. Note: SAIC shall decide on approval of Activity 2.1.3 pursuant to results from Activity 2.1.2. 

 

	 	2.1.3.	Pfenex shall incorporate a third chromatography step to reduce host cell protein levels to[*], pursuant to results from Activity 2.1.2. 

 

	 	2.1.4.	Pfenex shall perform buffer development to define acceptable deviation thresholds on key buffer formulations to better understand variability from preparation to preparation, and confirm buffers are robust, i.e. will
meet process specifications from lot to lot. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  
  

	 	2.1.5.	Pfenex shall incorporate final buffer formulation from Stage 5A Preformulation Development of [*] Drug Substance and confirm at large-scale purification. 

 

	 	2.1.6.	Pfenex shall perform up to [*] scale fermentations to generate cell paste to support large-scale purification efforts. Targeted expression titer ranges shall be [*]. 

 

	 	2.1.6.1	Whole broth samples will be analyzed for titer by [*]. 

  

	 	2.1.7.	Pfenex shall place in-process samples from the large-scale purification (Activity 2.1.5) on a short stability study to characterize hold times. The final [*] will be incorporated into Stage 8 Stability Program.

  

	 	2.1.8.	Pfenex shall ship the remaining purified [*] to SAIC’s repository designate. 

  

	 	2.1.9.	Pfenex shall issue a final report of Stage 7A efforts. 

  

	 	2.1.9.1	Pfenex shall refine master BPRs for the large-scale (pilot) development work that cover all downstream process and identified where procedures are modified, if any. SAIC will be provided copies of the master BPRs for
review and approval prior to use. 

  

	3.	Deliverables to SAIC 

  

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	 Form

					
	1	  	Project Management	  	Final Project Schedule	  	To be submitted within 1 week of kickoff meeting; schedule to be baselined within 3 weeks of award	  	1 electronic file, Preferably .mmp format
					
	2	  	Meeting Requirement	  	Meeting Agenda	  	1 day prior to regular meetings, 3 days prior to kickoff	  	1 electronic Word document or email
					
	3	  	Meeting Requirement	  	Meeting Summaries	  	7 days after meetings	  	1 electronic Word document
					
	4	  	Technical Requirement	  	7A Milestone Report	  	 Draft: 2 weeks following completion of procedure

Final: 2 weeks after receipt of SAIC comments
	  	 Draft: Word Document
 Final: Signed
PDF

					
	5	  	Technical Requirement	  	Antigen deliverables	  	2 weeks following completion of requirement	  	Sent to SAIC designee in proper shipping containers

  

	*	Days = Calendar days; SAIC shall provide comment within 1 week. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-2- 

 

 
  
 7A PRICE SHEET for Subcontract
P010022290 
 May 24, 2012 
 Pricing is
based upon commercial rates and is inclusive of costs for supplies, materials (except as noted) and reports. 
  

													
	 Stage 7A Activity
	  	Payment Terms
(50% upfront/
50% issuance of
final report)	 	  	Estimated Labor
(hours)	  	Estimated
Materials Costs	 	  	Estimated
Timescales
					
	 2.1.1 Precipitation Issues
	  	$	34,560	  	  	120	  	 	n/a	  	  	3 weeks
					
	 2.1.2 HCP method development
	  	$	14,824	  	  	48	  	$	1,150 (ELISA kit)	  	  	2 weeks
					
	 2.1.3 HCP Reduction by Chromatography
	  	$	86,400	  	  	300	  	$	17,250 (resins)	  	  	5 weeks
					
	 2.1.4 Buffer Development
	  	$	13,824	  	  	48	  	 	n/a	  	  	1 week
					
	 2.1.5-2.1.8 Large-scale (Pilot) demonstration
	  	$	77,208	  	  	216	  	 	n/a	  	  	3 weeks
					
	 2.1.9 Final Report
	  	$	11,520	  	  	40	  	 	n/a	  	  	2 weeks

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
 SUBCONTRACT AGREEMENT P010022290 Modification 14 

 

							
	SUBCONTRACTOR:	 	SUBCONTRACT #: 	 	P010022290
	  
 Pfenex Inc.

10790 Roselle Street, San Diego, CA
 92121
	 	  
 MODIFICATION #: 
	 	  
 14

	 	  
 DPAS RATING: 
	 	  
 Not Rated

	 	  
 TYPE:
	 	  
 FIRM FIXED PRICE

	 	  
 COMMERCIAL ITEMS (GOVERNMENT)

	 Period of Performance:
  

Sep 11, 2009 thru Sep 21, 2014
	 	  

•      Modification Value: 
	 	  

        $1,086,563.00

	 	  
 FUNDED: 
	 	  
 $5,477,866.01

	 	  
 Ceiling VALUE: 
	 	  
 $5,937,715.75

 The purpose of this modification is to increase the ceiling value and funding value for additional work as stated below. 

Effective date of this modification is July 31, 2012. 

As a result of this modification, the total ceiling value is increased FROM $4,851,152.75 BY $1,086,563.00 TO $5,937,715.75. The total
funded amount is increased FROM $4,391,303.01 BY $1,086,563.00 TO $5,477,866.01. 
 Statement of Work entitled
“Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM And Process Manufacturing Malaria Vaccine Production and Support Services June 22, 2012 Subcontract Modification” is herein
incorporated into and made part of Subcontract No. P010022290 as additional work and is attachment 1 to this modification 14. 
 1.0 PRICE is
modified to read as follows: The total not-to-exceed Ceiling Value of Subcontract No. P010022290 is $5,937,715.75 including profit. This subcontract is incrementally funded for work to be performed through September 21, 2014. The total FUNDING
of Subcontract No. P010022290 is $5,477,866.01 including profit. 
 This Milestone Activity will commence upon request of SAIC representative in writing
only. Payments for this modification 14 will be made in accordance with the schedule as outlined below. 
  

							
	 Milestone
	  	Invoicing	  	Amount	 
	 Milestone 1: Technology Transfer (including CMO Upfront Payments)
	  	Due upon execution of the
contract modification	  	$	864,209.00	  
	 Project Management Storage & Shipping
	  	Due upon Initiation of GMP
manufacturing run	  	$	222,354.00	  
		  		  	  
	  
	 
	 Total for modification 14 Activity
	  		  	$	1,086,563.00	  
		  		  	  
	  
	 

 ADDITIONAL TERMS AND CONDITIONS: 
  

	 	1.	SAIC is responsible for all regulatory and quality issues related to Mod 14/cGMP Manufacturing. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 1 of 2 

 

 
  
  

	 	2.	In the event SAIC shall be required to recall the Product because such SAIC Product may violate local, state or federal laws or regulations, or the laws or regulations of any applicable foreign government or agency, or
does not conform to the Specifications, or in the event that SAIC elects to institute a voluntary recall, withdrawal, field alert or similar action (collectively a “Recall”), SAIC shall be responsible for coordinating such Recall. SAIC
shall promptly notify Pfenex if the SAIC Product is the subject of a Recall and provide Pfenex with a copy of all documents relating to such Recall. Pfenex shall reasonably cooperate with Client in connection with any Recall and shall cause any of
its Subcontractors to do the same, at SAIC’s expense. SAIC shall be responsible for all of the costs and expenses of such Recall except to the extent caused by a Limited Latent Defect in which case Pfenex shall cause the CMO to reimburse SAIC
to that extent for its reasonable, direct and documented out of pocket expenses, up to an aggregate limit of $100,000 for all such Recall(s). 

  

	 	3.	If SAIC terminates Mod 14 then all unavoidable termination fees/costs incurred by Pfenex shall be reimbursed by SAIC. 

  

	17.0	ORDER OF PRECEDENCE — is modified to read as follows: 

 The documents listed below are hereby
incorporated by reference. In the event of an inconsistency or conflict between or among the provisions of this Subcontract, the inconsistency shall be resolved by giving precedence in the following order: 

 

	 	1.	Attachment I: Statement of Work and Schedule dated June 22, 2012, Mod 14. 

  

	 	2.	Statements of Work and Schedules as follows: 

 Modifications -13 dated 6/15/12, 12 dated 2/6/12,
6 dated 6/1/11, 5 dated 1/1/11, 4 dated 11/15/10, 2 dated 5/4/10 and original dated 5/11/11 respectively. 
  

	 	3.	Schedule A: Specific Terms and Conditions Form 9-932-072 (Rev. 9/25/06). 

  

	 	4.	Schedule B: U.S. Government Terms and Conditions, Part III — FAR Clauses Form 9-932-082 (Rev. 07/25/07). 

  

	 	5.	Attachment C: (Enclosure 2; (Rev. 4/2009) Property Administration Requirements For Subcontractors With An Adequate System Or Requisite Internal Controls. 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 

 

													
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Carol Frishman

	(Signature)	 		 	(Signature)
							
	Name:	 	Patrick Lucy	 	August 2, 2012	 		 	Name:	 	Carol Frishman	 	8/2/12
		 	  
	 		 		 	  

	(Type or Print)	 	Date	 		 	(Type or Print)	 	Date
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

			
	  
	 		 	  

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 2 of 2 

 STATEMENT OF WORK 

Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM 

And Process Manufacturing 

Malaria Vaccine Production and Support Services 

June 22, 2012 

Subcontract Modification 
  

	1.	Background 

 The National Institute of Allergy and Infectious Diseases, Division of Microbiology and
Infectious Diseases (DMID), directed Science Applications International Corporation [Malaria Vaccine Production and Support Services Program, prime contract NO1-A1-05421] to develop early-phase malaria vaccines. SAIC provides project and quality
management as well as regulatory support for DMID’s malaria vaccine development efforts. Under subcontract agreement (P010022290) with SAIC, Pfenex has developed a [*]. Currently, Pfenex has reached “Stage 9: Process Training and
Transfer” which will facilitate the cGMP manufacture, release, and stability monitoring drug substance (DS) for use in Phase 1 clinical trials at a third party contract manufacture organization (CMO). As part of the Stage 9 agreement, Pfenex
will coordinate with the CMO to perform the follow activities: 
  

	 	•	 	Pfenex shall train the Pfenex-selected CMO manufacturing and QC staff, as necessary, using the information in the Pfenex technology transfer package. 

 

	 	•	 	SAIC shall provide Pfenex selected CMO the working cell bank vials and WCB growth parameters and technical information 

  

	 	•	 	Pfenex shall provide Pfenex selected CMO a full process transfer package with all information necessary for the successful transfer of the manufacturing process operable and reproducible at a minimum of [*] fermentation
scale and shall include, but is not limited to, the following items: 

  

	 	•	 	Bill of materials and suggested suppliers 

  

	 	•	 	Detailed fermentation and purification process procedures (master BPRs) 

  

	 	•	 	Listing of instruments/equipment 

  

	 	•	 	Detailed testing procedures (SOPs) 

  

	 	•	 	Technical specification for the bulk drug substance (BDS or DS) 

  

	 	•	 	Health/Safety/Environment assessment of all materials and process 

  

	 	•	 	Detailed characterization of purified protein/buffer and intermediates 

  

	 	•	 	Construct expression information and test results 

  

	 	•	 	The process transfer and associated training records of CMO personnel for the transfer to the CMO shall be well documented and be provided to SAIC in the final report. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 To further the successful transfer and manufacture of the [*] from Pfenex to the CMO, SAIC herein requests Pfenex
to identify and subcontract a cGMP qualified CMO to perform the DS manufacture and release of [*], produced by production strain [*] for use in Phase 1 clinical trials. 
  

	2.	Period of Performance 

 The period of performance (POP) for this effort is upon approval of the change of
scope through September 2014. 
  

	3.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all necessary services,
qualified personnel, and travel as needed to conduct the CMO subcontract technical management & coordination, cGMP manufacture and release of [*]. 
  

	4.	Technical Requirement 

 Pfenex Project Management and SAIC shall create a Project Coordination Team (PCT)
that shall provide scientific, technical, and administrative oversight to ensure the efficient planning, initiation, implementation, and management of all activities carried out for the execution of Pfenex’s subcontract with the CMO. Details of
the roles and responsibilities of the SAIC and Pfenex team members are described in detail in Section 5, Project Management). Pfenex shall provide necessary ad hoc support to the CMO to ensure the success of all technical requirement
activities. Upon SAIC’s request, Pfenex shall arrange for SAIC’s visit and audit at the CMO for monitoring tech transfer, engineering run(s) and GMP production activities, as well as other any other Quality Assurance functions (see
Section 6, Quality for more details). 
 The technical requirement include the following milestones: 

Milestone 1: Technical transfer 

Milestone 2: Engineering runs (Optional) 

Milestone 3: GMP manufacture (Optional) 

Milestone 4: Testing and release of [*] at CMO (Optional) 

Milestone 5: Regulatory support (Optional) 
  

	 	4.1	Milestone 1: Technical transfer 

  

	 	4.1.1	Beyond the agreed upon tech transfer activities to be undertaken under the existing Stage 9 agreement, Pfenex shall provide management and coordinating activities, between SAIC, Pfenex and the selected CMO, for the
suitable scale [*] fermentation, process, and analytical methods transfer at the CMO. 

  

	 	4.1.1.1	The PCT (Project Coordination Team) shall ensure that all updates, changes, decisions, findings, and study reports at the CMO site are directly transferred to Pfenex and SAIC within 48 hours of receipt or notification.
SAIC shall be responsible for approval. 

  

	 	4.1.2	The PCT shall provide all necessary documents for approval of transfer analytical methods, fermentation, and purification process of rCSP to the selected CMO at 5 L-scale. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-2- 

	 	4.1.3	The tech transfer runs shall generate sufficient interim non-GMP reference material to be used in the analysis of the engineering run(s). 

 

	 	4.1.3.1	The interim reference standard (IRS) must pass the following tests: [*]. 

  

							
	 TESTS
	  	 SPECIFICATIONS

	Appearance	  	[*]	  		  	[*]
	Identification	  	A.	  	[*]	  	[*]
	  	B. 	  	[*]	  	[*]
	Protein content	  	[*]	  		  	[*]
	Purity	  	A.	  	[*]	  	[*]
	  	B. 	  	[*]	  	[*]
	  	C. 	  	[*]	  	[*]
	 Structural

characterization (for information only)
	  	A.	  	[*]	  	[*]
	  	B. 	  	[*]	  	[*]
	Safety	  	A.	  	[*]	  	[*]
	  	B. 	  	[*]	  	[*]
	  	C. 	  	[*]	  	[*]
	  	D.	  	[*]	  	[*]
	Potency	  	[*]	  		  	[*]

  

	*	Target specifications may be revised prior to the GMP run 

  

	 	4.1.3.2	The IRS shall be aliquoted into up to [*]. (Note: assuming > [*] concentration) 

  

	 	4.1.3.3	The IRS shall be placed on a 3-month stability program as outlined in the table below. 

  

									
	 Method/Test
	  	 Initial

Testing

(T=0)
	  	 1 month
	  	 2 month
	  	 3 month

	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  		  		  	
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X
	[*]	  	X	  	X	  	X	  	X

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-3- 

	 	4.1.4	The PCT shall provide SAIC QAD all reports documenting the success of the transfer of analytical methods, fermentation, and purification to Pfenex-selected CMO, including all materials, SOPs, and raw data generated in
the transfer. 

  

	 	4.1.4.1	PCT shall provide sufficient supporting evidence of the success of the transfer to SAIC QAD for approval. 

  

	 	4.1.4.2	PCT shall receive the go/no go decision from SAIC QAD before moving forward to the engineering runs. 

  

	 	4.2	Milestone 2: Engineering runs (Optional) 

  

	 	4.2.1	PCT shall provide management and coordinating activities, between SAIC, Pfenex and the selected CMO, for all engineering run activities 

 

	 	4.2.1.1	PCT shall ensure that all updates, changes, decisions, findings, and study reports at the CMO site are directly transferred to SAIC within 48 hours of receipt or notification 

 

	 	4.2.2	The PCT shall provide all reports documenting the success of the engineering runs, including all materials, SOPs, and raw data generated in the transfer to Pfenex and SAIC QAD. SAIC QAD is responsible for approval.

  

	 	4.2.3	Up to two successful [*] runs shall be performed that will be of sufficient quality to be utilized in GLP toxicity studies. 

  

	 	4.2.3.1	Unused cell paste from successful [*] fermentation runs shall be aliquoted into [*] batch sizes and stored in -80°C at Pfenex CMO, under agreed upon monitoring conditions. 

 

	 	4.2.3.2	One successful [*]-scale purification run shall be performed with each [*] fermentation run. Note: current process flow diagram of [*]-scale purification run is provided for budgetary purposes (Exhibit 1).

  

	 	4.2.3.3	Potency data is not necessary BEFORE proceeding to second engineering run or GMP run. A decision will be submitted to SAIC QAD for approval based on the process and analytical data. 

 

	 	4.2.4	The engineering run(s) shall generate interim sufficient quantity of non-GMP reference material to be used in future testing of GMP manufactured lots of [*]. 

 

	 	4.2.4.1	The reference standard must pass the assays designated as release and characterization tests as specified by the PCT for the GMP BDS lot. 

 

	 	4.2.4.2	The reference standard shall be aliquoted in up to [*] and stored frozen at [*]. (Note: assuming concentration of [*]) 

  

	 	4.2.4.3	The reference standard shall be placed on a 12-month stability program with real-time storage, accelerated conditions, and freeze/thaw cycles as outlined in the table below. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-4- 

	 	4.2.4.4	The stability tests to be performed at a minimum for all temperatures and conditions will be: [*]. 

  

							
	 Time Point
	  	 CSP Reference Standard Storage Temperature

	  	 £-65°C
	  	 5°C±3°C
	  	 40°C±2°C/

70%±5% RH*

	0 (lot release)	  	X	  	—	  	—
	1 Month	  	X	  	X	  	X
	2 Month	  	X	  	X	  	X
	3 Month	  	X	  	X	  	X
	6 Month	  	X	  	X	  	X
	9 Month	  	X	  		  	
	12 Month	  	X	  		  	
	1 Cycle Freeze/Thaw	  	X	  		  	
	2 Cycle Freeze/Thaw	  	X	  		  	
	3 Cycle Freeze/Thaw	  	X	  		  	

  

	*	RH, relative humidity 

  

	 	4.2.5	PCT shall provide sufficient supporting evidence of the success of the engineering runs to SAIC QAD, i.e., completed BPRs and testing results, for approval 

 

	 	4.2.6	PCT shall receive the go/no go decision from SAIC QAD before moving forward to the GMP manufacturing. 

  

	 	4.3	Milestone 3: GMP manufacture of DS (Optional) 

  

	 	4.3.1	If the second engineering run is successful and is performed with GMP-compliant documentation and quality, then that material shall be utilized as the deliverable for this milestone. CMO must address and resolve issues
identified by SAIC QAD in quality audit report prior to commencement of GMP production of BDS. 

  

	 	4.3.2	PCT shall provide management and coordinating activities, between SAIC, Pfenex and the selected CMO, for GMP run activities. 

  

	 	4.3.2.1	Upon SAIC’s request, Pfenex shall facilitate/arrange for SAIC QAD and/or other SAIC representatives, at SAIC’s expense, to conduct audits at the Pfenex-selected CMO to ensure all cGMP activities and associated
internal quality assurance (QA) and quality control (QC) review are compliant with U.S. Code of Federal Regulations Parts 210, 211, 600, and 610 and ICH Guidance on Quality of Biotechnological Products. 

 

	 	4.3.2.2	PCT shall ensure that all updates, changes, decisions, findings, and study reports at the CMO site are directly transferred to SAIC QAD within 48 hours of receipt or notification. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-5- 

	 	4.3.3	The master batch production records (MPRs) for the [*] cGMP run shall be provided to the PCT for review and approval. 

  

	 	4.3.4	At a minimum, one successful [*] GMP fermentation run shall be performed using the rPfCSP WCB. 

  

	 	4.3.4.1	Unused GMP cell paste will be aliquoted into 10 L batches in single-use closed bags, and will be stored at the Pfenex selected CMO facility in temperature monitored GMP storage locations (-80°C) under agreed upon
monitoring conditions. Temperature monitoring records will be provided by Pfenex to SAIC upon request. SAIC will review shipping records to verify cold chain is maintained. 

 

	 	4.3.5	Pfenex CMO shall perform successful [*]-scale purification(s) and provide 5 to 10 grams of purified GMP-grade CSP meeting the agreed upon specifications to SAIC or SAIC designated location. 

 

	 	4.3.5.1	Interim bulk materials generated in each purification cycle must meet interim release specification to allow pooling to produce final bulk drug substance material. 

 

	 	4.3.5.2	Interim release testing will include, but is not limited to the following, [*]. 

  

	 	4.3.6	Following PCT provided guidance, the drug substance (DS) shall be dispensed in aliquots suitable for long-term storage, release testing, and stability monitoring. 

 

	 	4.3.6.1	SAIC aliquot sizes and container closures are: 

  

	 	•	 	[*] 

  

	 	•	 	Stability Samples: Vial component figuration to be determined (Note: [*]) 

  

	 	4.3.6.2	PCT to approve bottle specifications and labels in advance of the fills. (Stability monitoring of GMP Bulk DS will be determined at a later stage and scope of work will be handled as a contract modification.)

  

	 	4.3.7	CMO will ship Bulk drug substance samples to SAIC Designee using pre-approved, qualified shipping vendors, under the agreed upon shipping configuration 

 

	 	4.3.8	The completed BPR shall be internally reviewed by the Pfenex CMO and then submitted to PCT and SAIC QAD for review. 

  

	 	4.4	Milestone 4: Testing and release of [*] DS at CMO (Optional) 

  

	 	4.4.1	All analytical methods to be used at the CMO for release testing shall be qualified, based on mutual agreement within the PCT and SAIC QAD. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-6- 

	 	4.4.2	The CoA, including a list of analytical methods and specifications as well as results shall be generated based upon an agreed upon testing plan. 

 

	 	4.4.3	The cGMP [*] DS shall be shipped to an SAIC-designated facility. 

  

	 	4.4.3.1	The CMO shall ensure the shipment will be at the required temperatures using a qualified shipping configuration for dry ice shipments with temperature monitoring. SAIC will be responsible for the review and approval of
material following shipping. 

  

	 	4.4.3.2	A material safety data sheet shall be prepared by Pfenex PCT and included in the shipment; duplicates of documents shall be provided to PCT and SAIC QAD. 

 

	 	4.4.4	Any remaining development- and manufacture-related materials, such as cell bank, unpurified lysate, and in-process product, shall be shipped to SAIC’s repository upon SAIC’s request. 

 

	 	4.4.5	PCT shall provide management and coordinating activities, between SAIC, Pfenex and the selected CMO, for release testing activities 

  

	 	4.4.5.1	PCT shall ensure that all updates, changes, decisions, findings, and study reports at the CMO site are directly transferred to SAIC QAD within 48 hours of receipt or notification. 

 

	 	4.5	Milestone 5: Regulatory support (Optional) 

  

	 	4.5.1	The PCT shall transfer from the CMO to Pfenex and SAIC QAD all supporting material for the submission of an IND application by providing Chemistry, Manufacturing, and Control documentation (21CFR312.23) required by
U.S. regulatory authorities. The supporting materials shall include, but are not limited to, the following: 

  

	 	4.5.1.1	A detailed description of all production materials, including their derivation and the analytical methodology used to characterize and release these materials. 

 

	 	4.5.1.2	A list of all raw materials, including source and methods to qualify their suitability for further manufacture. All animal-derived raw materials will be specifically identified, including details of country of origin.

  

	 	4.5.1.3	Analytical method development and /or qualification reports. 

  

	 	4.5.1.4	A detailed description of the production process, including test sample points for intermediate materials and the DS. 

  

	 	4.5.1.5	The DS labels including draft and final. 

  

	 	4.5.1.6	Master and executed BPRs. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-7- 

	 	4.5.1.7	Protocol (draft and final) for release testing of production materials and release of lots of DS, including descriptions of analytical methods and target specifications. 

 

	 	4.5.1.8	CoAs for production materials and the DS; a detailed DS lot production report. 

  

	 	4.5.1.9	Stability testing protocol (draft and final) for interim reference materials. 

  

	 	4.5.1.10	Out-of-specification (draft and final) investigational reports. 

  

	 	4.5.1.11	Control documentation for changes in analytical or manufacturing methods. 

  

	 	4.5.1.12	Letter of cross-reference for Pfenex’s CMO Drug Master File. 

  

	5.	Project Management 

  

	 	5.1	Pfenex shall appoint a Project Manager who shall provide effective communications with SAIC’s PM and Subcontract Administrator in order to properly execute the manufacture of rPfCSP DS at the CMO. SAIC shall
provide an equivalent PM who will coordinate the decisions with Pfenex that can affect scope, cost and schedule for work including testing, performed at the CMO. 

  

	 	5.2	SAIC and Pfenex Project Management shall create a Project Coordination Team (PCT) that shall provide quality, scientific, technical, and administrative oversight to ensure the efficient planning, initiation,
implementation, and management of all activities carried out for the execution of Pfenex’s subcontract with the CMO. 

  

	 	5.2.1	The PCT is responsible for: (1) monitoring the CMO’s technical progress, including the surveillance and assessment of performance and recommending to the SAIC Subcontracts Administrator changes in
requirements; (2) interpreting the SOW and any other technical performance requirements; (3) performing technical evaluation as required; (4) review invoices against technical work performed (5) performing technical inspections
and acceptances required by this subcontract; and (6) assisting in the resolution of technical problems encountered during performance. 

  

	 	5.3	SAIC and Pfenex PMs shall be responsible for: 

  

	 	5.3.1	Facilitate and coordinate the activities the PCT Team members 

  

	 	5.3.2	Project management and communications 

  

	 	5.3.3	Tracking, monitoring, and reporting on status and progress 

  

	 	5.3.4	Establishing and maintaining a risk register 

  

	 	5.3.5	Provide tracking and verification of expenditures 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-8- 

	 	5.3.6	Recommending modifications to project requirements and time lines, including projects undertaken by third-tier subcontractors 

  

	 	5.3.7	Providing all deliverables according to the Reporting Requirements and Subcontract Deliverables sections of an agreed upon SOW to the CMO 

 

	 	5.3.8	Scheduling and monitoring of all tests and/or work 

  

	 	5.3.9	Collection and reporting of results 

  

	 	5.4	Any changes in the SOW, POP, delivery schedule, costs incurred during the performance of this subcontract, or terms and conditions for the CMO shall be approved by the SAIC PM and Subcontracts Administrator prior to
execution. 

  

	 	5.5	The PCT, through Pfenex Project Management, shall direct the CMO to maintain an accurate inventory and package and transfer all remaining reagents purchased or provided through this subcontract to SAIC or a designated
repository. The inventory shall be provided as part of a monthly report. The materials, if applicable, will be transferred in a manner sufficient to preserve their respective cold chains. SAIC will determine who is responsible for making this
shipment and method used to maintain cold chain. 

  

	6.	Quality 

 SAIC is contractually responsible for assuring that the CMO maintains a Quality
System that ensures compliance with current Good Manufacturing Practices (cGMP) to ensure the product has the necessary safety, purity, identity and other quality attributes that are suitable for its intended use and that these efforts can be
duplicated by an independent laboratory based solely on the documentation provided from CMO. 
 The PCT shall be responsible for the
development and demonstration of suitability of contracted deliverables as well as providing reports and managing this project in a manner that meets scientific expectations of traceability and control. 

The SAIC Quality Assurance Director (QAD) will verify that all CMO quality systems are in place and maintained prior to the execution of the
sub-contracted GMP-related work effort and shall have access to all systems and documentation utilized for completion of this effort. All quality issues at the CMO shall be addressed prior to the execution of GMP-related work. Additionally, the SAIC
QAD has the authority for review and final sign-off for acceptance of deliverables. The SAIC QAD has direct communication with the CMO’s QA/QC counterparts. As required, communications may be formal and include official responses to SAIC QAD
audit reports, responses to deviations and associated investigation resolution documentation, or informal emails, teleconferences, and face-to-meetings. 

SAIC shall perform an award audit of the Pfenex selected CMO to determine its adequacy, assessing the materials, systems, equipment, facilities
and equipment to be utilized in the performance of product transfer, the engineering run and the cGMP manufacturing of the DS. Following the audit, SAIC shall provide a written report with stated findings and concerns to both CMO and Pfenex. SAIC
shall verify remedial actions are completed by the CMO before GMP-contracted activities are initiated. The CMO shall complete follow-up to issues or concerns 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-9- 

 
raised during quality audits as appropriate. SAIC is responsible for providing final approval of CAPA’s. SAIC QAD will provide on-going quality monitoring and oversight during the execution
of sub-contracted activities. SAIC expects to have a person in the plant, as needed, to provide appropriate quality oversight. 
  

	7.	Reporting Requirement 

 The PCT is responsible for monitoring quality, technical
performance and budgetary updates and advising the (SAIC and Pfenex) subcontract administrator(s) on programmatic requirements. Further, they are responsible for coordinating these requirements with the USG Project and Contract Officers. Therefore,
all communications and reports (technical and financial) from the CMO shall be sent directly to all PCT members (SAIC and Pfenex PMs) simultaneously in order allow unfettered access to all information that impacts technical and financial performance
and decision making. 
  

	8.	Subcontract Deliverables 

 Table 1 summarizes documents and other deliverables due to
SAIC at the indicated time points. 
  

									
	 Deliverable
	 	 Requirement
	 	 Item
	 	 Date
	 	 Form

	1	 	Technical	 	Reports (technology transfer and engineering runs)	 	 Draft: 3 weeks following completion of transfer run
  

Final: 2 weeks after receipt of SAIC comments
	 	PDF or Word document
	2	 	Technical	 	Remaining non-GMP [*] product (technology transfer and engineering runs) including cell paste interim reference material, and lysates	 	Within a week of completion	 	Sent to SAIC designee in proper shipping containers with a temperature monitor in each container
	3	 	Technical	 	cGMP master BPRs	 	 Draft: 4 weeks before initiation
  

Final: 2 weeks after receipt of SAIC comments
	 	PDF or Word document
	4	 	Technical	 	Completed rCSP cGMP BPRs	 	 Draft: 3 weeks following completion of 100 L cGMP run
  

Final: 2 weeks after receipt of SAIC comments
	 	PDF or Word document

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-10- 

									
	 Deliverable
	 	 Requirement
	 	 Item
	 	 Date
	 	 Form

	5	 	Technical	 	[*] along with associated raw data	 	 Draft: 3 weeks following completion of cGMP rPfCSP DS release testing

 
 Final: 2 weeks after receipt of SAIC comments
	 	PDF or Word document
	6	 	Technical	 	[*]	 	Within a week of completion	 	Sent to SAIC designee in proper shipping containers with a temperature monitor
	7	 	Technical	 	Remaining cGMP unpurified cell paste and or lysate	 	Maintain GMP chain	 	Stored at Pfenex CMO in proper GMP storage conditions
	8	 	Technical	 	Interim reports and a final stability report for the [*] stability monitoring	 	 Draft: 3 weeks following completion of each time point
  

Final: 2 weeks after receipt of SAIC comments
	 	PDF or Word document
	9	 	Reporting	 	Biweekly meeting and minutes	 	Meeting as scheduled, minutes within a week of the meeting	 	Teleconference
	10	 	Reporting	 	Monthly reports, including technical progress, and budgeting updates	 	Due by the 15th of each month during the performance of work efforts	 	PDF or Word document
	11	 	Technical	 	Regulatory support documents	 	 Draft: 3 weeks following completion of all activities
  

Final: 2 weeks after receipt of SAIC comments
	 	 Draft: Word document
 Final: Signed
Pdf

	12	 	Reporting	 	Inventory Tracking Report, including banked production materials, reagents, held intermediates and Drug Substance	 	Due by the 15th of each month during the performance of work efforts	 	PDF or Word document

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-11- 

 Exhibit 1 of SOW 

Pfenex Inc. Confidential 
  

	#	Step and Parameters 

 The process flow sheet is based on purifying 5 L fermentation and projected downstream
process after development 
  

							
	 In-Process Testing
	  	 
		  	Fermentation (Pseudomonas fluorescens)	  		  	
		  	 Inoculum - batch
 Seed broth volume

Fermentation time
	  	  
 0 6 L

~24 h
	  	
				
		  	Fermentation 2	  	i	  	
	1	  	 Production - high density fed-batch

Production broth volume
 Fermentation time

Expression Level
	  	  
  

10 L
 ~48 h

4 g/L                     3-4 g/L
	  	
				
		  	Cell Paste by batch centrifugation	  		  	
	2	  	 Production - high density fed-batch

Broth aliquot volume
 Relative Centrifugation Force

Centrifugation Temperature
 Centrifugation Time
	  	  
  
 1
L, cpy = 10
 15900 × g
 4°C

60 min
	  	
				
		  	Cell Reconstruction	  	i	  	Hold (-80°C)
	3	  	 Feed
 Paste Mass

Cycles Needed
 Equipment

Mix Time
 Dilution Buffer

Dilution buffer amount
 Total volume upon dilution

Step Time
 Step yield
	  	 Frozen (-80°C, Paste from step 3a
 2.8 kg
(equivalent to 5L broth)
 2
 Batch mixer

0.5 – 1 hr
 20mM tris, 2M area

11.2 L approximate
 14 L approximate

~1 hr
 100%
	  	

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

							
	 In-Process Testing
	  	 
				
	4	  	Cell Lysis	  	i     2C g (per cycle)	  	
		  	 Feed
 Equipment

Flush buffer
 Flush buffer amount

Homogenization parameter
 Lysate temperature

 
 Number of passes

Lysis time
 Step yield
	  	 14 L approximate from step 3
 Niro Soayi

2M urea, 20mM Tris, pH 8.2
 As needed

TBD (critical parameter)
 Codec to < 12°C with heat
exchanger at outlet)
 1 pass
 1.4 hr approximate (at ~ 0
L/hr)
 100%
	  	 20% cell lysate: pH, Cond
 Retain for
SDS-PAGE/CGE

		
	5	  	Dilution of 20% lysate to 10% solids 2C g (per cycle)
		  	 Feed
 Feed volume

Equipment
 Dilution buffer

Dilution buffer amount
 Total volume upon dilution

Pump rate
 Mix time

Step yield
	  	 Lysate from step 4
 14 L

6C L single use bag Sartorius Stedim
 2M urea, 20mM tris, PH 8

14 L approximate
 28 L approximate

8 L/min
 > 10 min

100%
	  	 10% cell lysate: pH, Cond
 Retain for
SDS-PAGE/CGE

				
	6	  	Disk-Stack Centrifugation	  	i     2C g (per cycle)	  	
		  	 Feed
 Feed volume

Feed Temp
 Equipment

G-force
 Flow rate
	  	 10% lysate from step 5
 28 L

15 – 26 °C
 Westfalia SC -6

15,000 g
 0.3 L/mh
	  	Centrate turbidity (HACH NTU as well as Althea equipment measurement)
		  	Q/S	  	8.10E-10 m/s	  	
		  	 Backpressure
 Discharge Interval

Discharge Volume
 Centrate Temp

 
 Step Time

Step yield
	  	 75-82 psi
 20 min

0.7 L
 <20°C, cooled by heat exchanger on the outlet

1.6 hrs
 88%
	  	
				
	7	  	Depth Filtration	  	i     16 g (per cycle)	  	
		  	 Feed
 Feed volume

Equipment
 Manufacturer

Part #
	  	 Centrate from Step 6
 24.64 L

Millistak+XOHC Depth Filter
 Millipore

MXOHC05=S1
	  	 Depth Filter Equilibration:
 pH,
cond

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-2- 

							
	 In-Process Testing
	  	 
		  	 Quantity
 Filter Area

Filter Loading
 Flowrate

Step time
 Step yield
	  	 1
 0.22 m2

112 L/m 2
 33 – 50 LM-I 0.12 – 0.18 l/min

1 hr, run in parallel with centrugation
 95%
	  	
				
	8	  	Sterile Filtration	  	i     17 g (per cycle)	  	
		  	 Feed
 Feed volume

Equipment
 Manufacturer

Part #
 Quantity

Filter Area
 Filter Loading

Flowrate
 Step Time

Step yield
	  	 Filtrate from Step 7, processed in-line
 24.64
L
 Sartobran P (0.45/0.2um)
 Sartorius

5.235307H9-OO-V
 1

0.20 m2
 123 L/m2

36-54 LMH 0.12-0.18 L/min
 N/A run in parallel with step 7

100%
	  	 Primary Recovery Filtrate: pH, cond
 Retain for
SDS-PAGE/CGE

				
	9	  	Freezing of CSP clarified cell culture	  	i           17 g (per cycle)	  	
		  	 Feed
 Feed Volume

Equipment
 Manufacturer

Part #
 Quantity

Step Time
 Step Yield
	  	 Filtrate from Step 8
 24.64 L

Sartorius Stedim Bags
 Sartorious

Celsius FFT 2L, Celsius FFT 12L
 4 of each part#

48-72hrs Specs TBD
 100%
	  	
				
	10	  	Thawing and filtration of CSP clarified cell culture	  	i           17 g (per cycle)	  	
		  	 Feed
 Thaw volume

Equipment
 Filter

Part #
 Quantity

Filter Area
 Filter Loading

Flowrate
 Thaw Time

Filtration Time
 Step time

Step yield
	  	 Filtrate from Step 8
 24 L

Water Bath @ 25°C
 TBD

TBD
 1

TBD       m2

TBD       L/m2

TBD       LMH
 < 4 hrs

TBD
 < 5 hrs

97%
	  	 Thawed Filtrate: pH, cond
 Retain for
SDS-PAGE/CGE

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-3- 

							
	 In-Process Testing
	  	 
				
	11	  	Primary Capture	  	i           16 g (per cycle)	  	
		  	 Feed
 Feed Volume

Resin
  

Resin Amount
 Equipment

Mode
 Capacity

Flow rate
 Bed height

Residence time
 Loading Ratio

Equilibration/wash buffer
 Washes

Elution buffer
 Elution

Product elution volume
 Strip

Clean, sanitize
 Cycles Needed

Process time
 Step yield

Step yield (vol)
	  	 Filtrate from step 10
 24 L approximate

Fracotgel TMAE HiCap (M), an ion exchange resin
 5.2 L
approximate
 20 cm column + 6 mm BioProcess skid
 Bind and
elute
 ~3 g/L resin estimated
 150
cm/H          47.1 L/h
 16.6 cm

7 min
 4.6 L of Feed per L of Resin

20mM Tris, 2M Urea, pH 6.1
 5 CV

20mM Tris, 2M Urea, 75 mM NaCL, pH 8.1
 3.5 CV with higher
NaCL
 3 CV estimated
 High salt g caustic
 Common industry practice

1
 5.4 hrs approximate

80% estimated
 15.7 L approximate
	  	 TMAE Eluate pH, Cond, osmo (?, as a way to validate adj. pri HCT load)

Retain for SDS-PAGE/CGE

				
	12	  	xxxxxxxxxxxxxxxx	  	i           16 g (per cycle)	  	
		  	 Xxxxxxxxxxxxxxxx

Xxxxxxxxxxxxxxxx

Xxxxxxxxxxxxxxxx

xxxxxxxxxxxxxxxx
	  	  
 xxxxxxxxxxxxxxxx
	  	  
 Elution Immediately Processed to Step 13

				
	13	  	Ceramic HA Chromatography	  	i           13 g	  	
		  	 Feed
 Feed Volume

Resin
 Resin Amount

Equipment
 Mode

Capacity
 Flow rate

Bed height
 Residence time
	  	 Filtrate from step 12
 15.7 L approximate

Ceramic Hydroxyapetite
 5.2 L approximate

20 cm column + 6 mm Bio Process skid
 Bind and clute

3 c/L resin estimated
 1511
cm/h        4/1 L/h
 16.6 cm

7 min
	  	 CHT Load: pH, cond, osmo (as way to validate adjustments)

Retain for SDS-PAGE/CGE
  

 
  
 Eluate: pH, cond,
endotoxin
 Retain for SDS-PAGE/CGE

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-4- 

							
	 In-Process Testing
	  	 
		  	 Loading Ratio
 Equiliberation/Wash 1 buffer

 
 Wash 1

Wash 2 Buffer
  

Wash 2
 Elution

Product elution volume
 Strip

Clean, Sanitize
 Process time

Step yield
 Step yield (vol)
	  	 3.00 L u/Feed per L of Resin
 1mM phosphate,
50mM HEPES, 2 M urea, 75mM Nacl, pH 7.5
 10 CV
 4mM phosphate,
50 mM HEPES, 2M urea, 75mM NaCL, pH
 5 CV
 3.5 CV win 50 mM
NaPO4
 3 CV estimated
 0.5M NaPO4

Common industry practice
 5.6 hrs practice

90% estimated
 16 L approximate
	  	
				
	14	  	Sterile Filtration	  	i           11.6 g	  	
		  	 Feed
 Filter

 
 Filter capacity

Step Time
 Step Yield
	  	 Filtrate from step 13
 Sartobran 0/15/0.2-um
sterilizing grace filter, 500 cm2
 313 L/m2 loading
 0.5
hrs
 99%
	  	  
 5235307H7-OO0A

(Sartorius Stedim)
 -500 cm2 filter

				
	15	  	Mild Reduction of CSP	  	i           11.4 g	  	
		  	 Feed
 Feed volume

Reductant
  

Reductant Concentration
 Reductant Volume

Final Colume, HA Eluate +
 Reductant Concentration

Equipment
 Temperature

Reduction Time
 Agitator

Agitator Rate
 Filter

Par. #
 Quantity

Filter Area
 Filter Loading

Flowrate
 Step time

Step Yield
	  	 HA Eluate from step 14
 16 L

DIthiothreitol crystals U.T. Baker #JT-F780-2)

10 mM
 0.0314
L          (-HA Eluate Volume/499
 15.68 L

20 mm
 50_ disposable
sted m bag
 15-25 LC
 12-1X rrs

Recirculation on with Perstatic Pump
 15-25% (v/vi per minute)

Sartobran P (0 45/0 2urm)
 5235307H7—OO-V

 
 0.05 m2

X1X 1/m2
 1-2 L/min

12 – 10 hrs
 99%
	  	  
 Pre-Reduction: A280, SEC, RR

Retain for SDS-PAGE/CGE
  

(Sartorius Stedim) -500 cm2 filter
  

Post-Reduction: a280, SEC,
RP, endotoxin
 Retain for
SDS-PAGE/CGE

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-5- 

							
	 In-Process Testing
	  	 
			
	16	  	TFF (Concentration and Buffer Exchange)	  	i           11.9 g Many parameters yet to be optimized
		  	 Feed
 Feed Volume

Membrane
 Membrane Loading

Number of membranes
 Equipment

 
 Pumprate
  

Exchange into
 Diafiltration

Diafiltration buffer
 Clean and sanitize

Ultrafiltration time
 Retentate volume

Step time
 Step yield
	  	 Filtrate from step 1C
 15.7 L approximate

16 m2, 6 k/a regenerated cellulose
 11.3 g/m2

2
 Peristatic pumas cassete holders pressure sensors

324 | MH (1 per m2 per min)
 5.4 L/min/m2

TED
 6 fold

144 L approximate
 Industry practice

Hrs approximate
 14 L approximate

5.0 hrs, including prep and clearing
 90%
	  	  
 Equilibration: pH, (endotoxin?)

 
  

[                    ]

-Pellicon 2, C-screen UF cassette
  

Retentate: A280, retain for SDS-PAGE/CGE

				
	17	  	Sterile filtration and bulk fill	  	i           10.2 g	  	
		  	 Feed
 Filter

Filter Area
 Filter Capacity

Step Time
 Step yield
	  	 Retentate from step 16
 Wilpak 2000 22um
sterilizing grade
 OV m2
 14 L/m2 loading

30 min
 99%
	  	 All BDS release testing as outlined in documentation
  

MPVL2GCA3 )EMD Millipore)
 - Millipak 200, 0.2 um

1000 cm2

		  		  	Grams per 6L cycle 10.1 g	  	

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-6- 

 

 
 SUBCONTRACT AGREEMENT P010022290 Modification 15 

 

							
	SUBCONTRACTOR:	 	SUBCONTRACT #: 	 	P010022290
	  
 Pfenex Inc.

10790 Roselle Street, San Diego, CA
 92121
	 	  
 MODIFICATION #: 
	 	  
 15

	 	  
 DPAS RATING: 
	 	  
 Not Rated

	 	  
 TYPE:
	 	  
 FIRM FIXED PRICE

	 	  
 COMMERCIAL ITEMS (GOVERNMENT)

	 Period of Performance:
  

Sep 11, 2009 thru Sep 21, 2014
	 	  

•      Modification Value: 
	 	  

        $311,000.00

	 	  
 FUNDED: 
	 	  
 $5,788,866.01

	 	  
 Ceiling VALUE: 
	 	  
 $6,248,715.75

 The purpose of this modification is to increase the ceiling value and funding value for additional work as stated below. 

Effective date of this modification is August 17, 2012. 

As a result of this modification, the total ceiling value is increased FROM $5,937,715.75 BY $311,000.00 TO $8,248,715.75. The total
funded amount is increased FROM $5,477,866.01 BY $311,000.00 TO $5,788,866.01. 
 Statement of Work entitled “Evaluation of
Malaria CSP Expression in Pfēnex Expression TechnologyTM And Process Manufacturing Malaria Vaccine Production and Support Services May 4, 2012 Subcontract Modification” is herein incorporated into and made
part of Subcontract No. P010022290 as additional work and is attachment 1 to this modification 15. 
 1.0 PRICE is modified to read as follows: The
total not-to-exceed Ceiling Value of Subcontract No. P010022290 is $6,248,715.75 including profit. This subcontract is incrementally funded for work to be performed through September 21, 2014. The total FUNDING of Subcontract No. P010022290 is
$5,788,866.01 including profit. 
 This Milestone Activity will commence upon request of SAIC representative in writing only. Payments for this modification
15 will be made in accordance with the schedule as outlined below. 
  

									
	 Milestone
	  	 Payment
	  	 Amount
	 	 	 Duration

	 [*] (Antigen 1) Milestone 2B
	  	50% upon
commencement	  	 	[*	] 	 	Approximately nine (9) weeks
	  	50% upon delivery of
report	  	 	[*	] 	 
	 [*] (Antigen 2) Milestone 28
	  	50% upon
commencement	  	 	[*	] 	 	Approximately seven (7) weeks
	  	50% upon delivery of
report	  	 	[*	] 	 
	 [*] (Antigen 2) Milestone 2C
	  	50% upon
commencement	  	 	[*	] 	 	Approximately two (2) weeks
	  	50% upon delivery of
report	  	 	[*	] 	 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 1 of 2 

 

 
  
 17.0 ORDER OF PRECEDENCE — is modified to
read as follows: 
 The documents listed below are hereby incorporated by reference. In the event of an inconsistency or conflict between or among the
provisions of this Subcontract, the inconsistency shall be resolved by giving precedence in the following order: 
  

	 	1.	Attachment I: Statement of Work and Schedule dated May 4 2012, Mod 15. 

  

	 	2.	Statements of Work and Schedules as follows: 

 Modifications -14 dated 6/22/2012, 13 dated
6/15/12, 12 dated 2/6/12, 6 dated 6/1/11, 5 dated 1/1/11, 4 dated 11/15/10, 2 dated 5/4/10 and original dated 5/11/11 respectively. 
  

	 	3.	Schedule A: Specific Terms and Conditions Form 9-932-072 (Rev. 9/25/06). 

  

	 	4.	Schedule B: U.S. Government Terms and Conditions, Part Ill — FAR Clauses Form 9-932-082 (Rev. 07/25/07). 

  

	 	5.	Attachment C: (Enclosure 2; (Rev. 4/2009) Property Administration Requirements For Subcontractors With An Adequate System Or Requisite Internal Controls. 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 

 

									
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Carol Frishman

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick
Lucy                                         date
8/31/12
	 		 	Name:	 	 Carol
Frishman                                     date
8/31/12

	(Type or Print)	 		 	(Type or Print)
					
	Title: 	 	 Vice President of Business Development
	 		 	Title: 	 	 Subcontracts Manager

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 2 of 2 

 STATEMENT OF WORK 

Evaluation of Malaria CSP Expression in Pfenex Expression
TechnologyTM 
 And Process Manufacturing 

Malaria Vaccine Production and Support Services 

May 4, 2012 

Subcontract Modification 
  

	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all of
the necessary services, qualified personnel, materials, equipment, facilities, and travel not otherwise provided under the terms of this agreement as needed for the proof-of-principle evaluation of expressing full-length and functional [*], suitable
for use with [*] in combination vaccines, utilizing Pfenex Expression TechnologyTM. Pfenex shall provide antigens, and reports and other documentation related to the development and
manufacturing process, as required in the deliverables (Table 1). Milestones in this subcontract modification include: 
 Table 1. Milestones for
CELTOS/TRAP 
  

			
	 Antigen
	  	 Milestones

	[*]
 (Antigen 1)
	  	Milestone 2B: [*] protein from 1 selected [*]
	[*]
 (Antigen 2)
	  	 Milestone 2B: Provide additional purification development to support Milestone 2A ([*] produced [*] expression strains to SAIC)

 
 Milestone 2C (OPTION): Endotoxin Reduction Development

  

	1.	SAIC will provide the following information and materials: 

  

	 	1.1.	Background literature/references relating to [*]. 

  

	 	1.2.	Suitable reference materials and sera relating to [*] if available. 

  

	2.	Technical Requirements 

  

	 	2.1.	Milestone 2B [*] to SAIC 

  

	 	2.1.1.	Pfenex shall screen different wash conditions on HIC column as well as TMAE HiCap, for separation of endotoxin from target varying factors such as pH, detergents, solvents, heat treatment, etc 

 

	 	2.1.2.	Pfenex shall confirm endotoxin reduction results observed in 2.1.1 and conduct small scale chromatography runs using conditions identified in 2.1.1. 

 

	 	2.1.3.	Pfenex shall perform additional fermentation runs in a 1L-scale high-cell density bioreactor as needed to support purification of CelTOS from [*]. 

 

	 	2.1.4.	Pfenex shall purify up to [*] protein ([*] purity by SDS-CGE) from strain [*] with acceptable endotoxin levels ([*]). 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	2.1.5.	Pfenex shall analyze the final purified protein and the filtered lysate using analytical methods including [*]. 

  

	 	2.1.6.	If the quality and purity of purified protein is deemed acceptable by SAIC for R&D non-clinical studies, Pfenex shall ship the resulting purified [*] protein (310 mg) to
SAIC. 

 Note: Pfenex will complete the activities as described and shall assume no risk in the ability to deliver the
10 mg of [*] protein. The completion of the activities described shall suffice in meeting the deliverable and will be deemed acceptable to issue an invoice for the final 50% of the price. 

 

	 	2.1.7.	Pfenex shall issue a final report of purification efforts. 

  

	 	2.1.8.	Report shall include an executive summary, brief description of methods, results and conclusions, inventory of reagents provided by SAIC, and raw data in PDF format. 

 

	 	2.2.	Milestone 2B ([*]): Provide additional purification development to support Milestone 2A ([*] protein from 3 selected [*] clones respectively to SAIC)  

Note: As part of Milestone 2A: Pfenex shall perform additional resin screening to identify chromatography media for primary capture and
secondary capture of TRAP. Pfenex shall perform additional fermentation runs in 1L-scale high-cell density bioreactor to support purification of [*] protein 
  

	 	2.2.1.	Pfenex shall conduct small scale chromatography runs using conditions identified in Milestone 2A and purify up to 10 mg of purified [*] protein from strains [*] with acceptable endotoxin levels ([*]). 

Note: Pfenex will complete the activities as described and shall assume no risk in the ability to deliver the [*] of [*] protein. The
completion of the activities described shall suffice in meeting the deliverable and will be deemed acceptable to issue an invoice for the final 50% of the price described in this contract modification and the final 50% of the price described in
Contract Modification 6 Antigen 2 Milestone 2A. 
  

	 	2.3.	Milestone 2C ([*]): Pfenex shall screen different wash conditions on selected chromatography media, for separation of endotoxin from target varying factors such as pH, detergents, solvents, heat
treatment, etc 

  

	 	2.3.1.	Pfenex shall confirm endotoxin reduction results observed in 3.2.2 and conduct small scale chromatography runs using conditions identified in 3.2.2. 

 

	 	2.3.2.	Pfenex shall analyze the final purified proteins and the filtered lysate using analytical methods including [*] 

  

	 	2.3.2.1	  

  

	 	2.3.3.	If the quality and purity of purified protein is deemed acceptable by SAIC for R&D non-clinical studies, Pfenex shall ship the resulting purified [*] protein (>10 mg) from 3 selected [*] clones to SAIC.

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-2- 

 Note: Pfenex will complete the activities as described and shall assume no risk in the
ability to deliver the [*] of [*]. The completion of the activities described shall suffice in meeting the deliverable and will be deemed acceptable to issue an invoice for the final 50% of the price described in this contract modification and the
final 50% of the price described in Contract Modification 6 Antigen 2 Milestone 2A. 
  

	 	2.3.4.	Pfenex shall issue a final report of purification efforts. 

  

	 	2.3.5.	Report shall include an executive summary, brief description of methods, results and conclusions, inventory of reagents provided by SAIC, and raw data in PDF format. 

 

	3.	Quality Requirements 

  

	 	3.1.	Pfenex shall maintain a Quality System that meets scientific expectations of traceability, reliability and control. Pfenex shall be responsible for the development and demonstration of suitability of contracted
deliverables as well as providing reports and managing this project in a manner that meets scientific expectations of traceability, reliability and control ensuring that the filtered whole cell lysate or periplasmic release extract and cell free
broth produced and analyzed in the developed process and assays have the quality, and identity they purport. 

  

	4.	Meeting and Conference Requirements 

 Unless an alternative directive is provided;
meeting, conference, and audit support shall include the following: 
  

	 	4.1.	Pfenex shall schedule a kickoff meeting via teleconference with SAIC within 7 days of award. The agenda shall be provided by Pfenex in advance. The purpose of the kickoff meeting is formal introduction of key staff and
project management, technical and contractual discussions, and initial action items required to initiate contract work. 

  

	 	4.2.	Pfenex shall participate in biweekly meetings and/or teleconferences with SAIC. Such meetings may include, but are not limited to, meetings to discuss the technical (e.g., assay designs and critical reagents), quality,
schedule, regulatory, and contractual aspects of the program and site visits to Pfenex’s facilities. All visits to Pfenex’s facility shall be prearranged. Pfenex shall be responsible for preparing meeting agendas and summaries. Meeting
minutes shall be captured by Pfenex and are due to SAIC within 7 days after the completion of a biweekly teleconference. 

  

	 	4.3.	Pfenex also shall be available for ad hoc support (e.g., phone calls and e-mails) to SAIC as required for project communications. 

  

	5.	Reporting Requirements 

  

	 	5.1.	Monthly Technical and Business Progress Report: A monthly TPR shall be submitted to the SAIC management point of contact by the eighth of each month during subcontract POP. 

 

	 	5.1.1.	The TPR shall cover the work accomplished as well as issues and proposed resolutions that occur during each reporting period. 

  

	 	5.1.2.	Each TPR also shall contain an updated monthly project management schedule to indicate work completed and any change in schedule. Deliverables shall be incorporated into the schedule. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-3- 

	 	5.2.	Reports should include an updated inventory log, and a notice of any temperature deviations of equipment storing SAIC material. The report shall also document any changes made to methods and procedures utilized for the
cloning and expression efforts. 

  

	 	5.2.1.	Report shall include invoicing information for work performed during each reporting period and anticipated work activities. 

  

	 	5.3.	Documentation to Support an IND or Amendment: Data generated under this subcontract may be incorporated into an FDA submission. Pfenex shall provide a list of relevant SOPs or other control, development and testing
documents as requested. 

  

	6.	Subcontract Deliverables 

  

	 	Table 2 summarizes documents and other deliverables due to SAIC at the indicated timelines. 

Table 2. Deliverables to SAIC 
  

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	 Form

	1	  	Project Management	  	Final Project Schedule	  	To be submitted within 1 week of kickoff meeting; schedule to be baselined within 3 weeks of award	  	1 electronic file, Preferably .mmp format
	2	  	Meeting Requirement	  	Meeting Agenda	  	1 day prior to regular meetings, 3 days prior to kickoff	  	1 electronic Word document or email
	3	  	Meeting Requirement	  	Meeting Summaries	  	7 days after meetings	  	1 electronic Word document
	4	  	Technical Requirement	  	Milestone Reports [If Funded]	  	Draft: 2 weeks following completion of procedure Final: 2 weeks after receipt of SAIC comments	  	Draft: Word Document Final: Signed PDF
	5	  	Technical Requirement	  	Antigen deliverables	  	2 weeks following completion of requirement.	  	Sent to SAIC designee in proper shipping containers

  

	*	Days = Calendar days; SAIC shall provide comment within 1 week. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-4- 

 

 
  
 SUBCONTRACT AGREEMENT P010022290
Modification 16 
  

					
	SUBCONTRACTOR:	  	 SUBCONTRACT #:
  
	  	P010022290
	 Pfenex Inc.
 10790 Roselle
Street, San Diego, CA
 92121
	  	 MODIFICATION #:
  
	  	16
	  	 DPAS RATING:
  
	  	Not Rated
	  	TYPE:	  	FIRM FIXED PRICE
		  	  
 COMMERCIAL ITEMS (GOVERNMENT)

	 Period of Performance:
  

Sep 11, 2009 thru Sep 21, 2014
	  	  

•    Modification
Value:            $-217,854.00***

	  	  
 FUNDED:
	  	  
 $5,571,012.01

	  	Ceiling VALUE:	  	$6,253,215.75

 The purpose of this modification is to correct the funding amount and add additional services in support of pre-clinical
development. 
 Effective date of this modification is September 21, 2012. 

As a result of this modification, the total ceiling value is increased FROM $6,248,715.75 BY $4,500.00 TO $6,253,215.75. The total funded
amount is decreased FROM $5,788,866.01 BY $217,854.00 TO $5,571,012.01. The ceiling value remains $6,253,215.75. 
 Statement of
Work entitled “Evaluation of Malaria CSP Expression in Pfēnex Expression TechnologyTM And Process Manufacturing Malaria Vaccine Production and Support Services September 14, 2012 Subcontract Modification
16” is herein incorporated into and made part of Subcontract No. P010022290 as additional work and is attachment 1 to this modification 16. 
  

	***	Funding is corrected as listed below: 

 Mod 14 funding corrected from $1,086,563.00 to $864,209.00 (less
$222,354.00) 
  

					
	 Mod 15
	  	$	311,000.00	  
	 Mod 16 for SOW 9/14/12
	  	+ $	4,500.00	  
		  	  
	  
	 
		  	$	1,179,709.00	  
		
	 Funding at Mod 13
	  	+ $	4,391.303.01	  
		  	  
	  
	 
	 Total amount funded all Mods
	  	$	5,571,012.01	  

 1.0 PRICE is modified to read as follows: The total not-to-exceed Ceiling Value of Subcontract No. P010022290 is
$6,253,215.75 including profit. This subcontract is incrementally funded for work to be performed through September 21, 2014. The total FUNDING of Subcontract No. P010022290 is $5,571,012.01 including profit. 

This Activity will commence upon request of SAIC representative in writing only. Payments for this modification 16 will be made in accordance with the
schedule as outlined below. 
 Payment of $4,500.00 due upon the initiation of testing of the vials. 

Delivery of Modification 16 is approximately two weeks from commencement. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 1 of 2

 

 
  
 17.0 ORDER OF PRECEDENCE — is modified to
read as follows: 
 The documents listed below are hereby incorporated by reference. In the event of an inconsistency or conflict between or among the
provisions of this Subcontract, the inconsistency shall be resolved by giving precedence in the following order: 
  

	 	1.	Attachment I: Statement of Work and Schedule dated September 14, 2012. 

  

	 	2.	Statements of Work and Schedules as follows: 

 Modifications — 16 dated September 14,
2012, 15 dated May 4 2012, 14 dated 6/22/2012, 13 dated 6/15/12, 12 dated 2/6/12, 6 dated 6/1/11, 5 dated 1/1/11, 4 dated 11/15/10, 2 dated 5/4/10 and original dated 5/11/11 respectively. 

 

	 	3.	Schedule A: Specific Terms and Conditions Form 9-932-072 (Rev. 9/25/06). 

  

	 	4.	Schedule B: U.S. Government Terms and Conditions, Part III — FAR Clauses Form 9-932-082 (Rev. 07/25/07). 

  

	 	5.	Attachment C: (Enclosure 2; (Rev. 4/2009) Property Administration Requirements For Subcontractors With An Adequate System Or Requisite internal Controls. 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 

 

									
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Carol Frishman

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick
Lucy                                         
   date 9/28/12
	 		 	Name:	 	 Carol
Frishman                                        
date 9/28/12

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 2 of 2

 

 
 September 14, 2012 

Carol C. Frishman 
 Subcontracts Administrator 

Health Solutions Business Unit 
 Science Applications
International Corporation 
 5202 Presidents Court, Suite 110 

Frederick, MD 21703 
 Dear Ms. Frishman, 

Please find enclosed Pfenex Inc.’s contract modification proposal for additional services in support of pre-clinical development of the circumsporozoite
protein (CSP). The specific activities are described in the statement of work below. This scope of work will be Contract Modification 16 to Subcontract #P010022290 related to SAIC Prime Contract # N01-AI-05421. If all options are exercised the total
Firm Fixed Price of this program in accordance with Statement of Work enclosed is $4,500 inclusive of materials. 
 This proposal is valid for 120 days from
today’s date. 
 We look forward to continuing to work with you on this program. 

 

	
	Sincerely,
	
	/s/ Patrick Lucy
	
	Patrick Lucy
	Vice President of Business Development
	Pfenex Inc.
	301 Newbury Street PMB #251
	Danvers, MA 01923
	Tel. (978) 887-4971
	PKL@pfenex.com

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-1- 

 

 
 STATEMENT OF WORK 

Evaluation of Malaria CSP Expression in Pfenex Expression TechnologyTM 

and Process Manufacturing 

Malaria Vaccine Production and Support Services 

September 14, 2012 

Subcontract Modification 16 
  

	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all of
the necessary services, qualified personnel, materials, equipment, facilities, and travel not otherwise provided under the terms of this agreement as needed for the preparation of vials containing diluent that will be used in support of pre-clinical
studies. 
  

	2.	Technical Requirements 

  

	 	2.1.	Pfenex will prepare vials containing meeting the following requirements: 

  

	 	2.1.1	Number: [*] 

  

	 	2.1.2	Formulation: [*] 

  

	 	2.1.3	Fill Volume: [*] 

  

	 	2.1.4	Vial Type: [*] 

  

	 	2.1.5	Container Closure: Screw cap 

  

	 	2.1.6	Label Description: Name (rCSP Dilution Buffer), Date, Manufacturer, Formulation, Expiration Date 

  

	 	2.1.7	Storage conditions: Following the completion of the filling and labeling exercise the vials will be stored at -80° C prior to shipment. In transit the vials will be shipped on dry ice. 

 

	 	2.1.8	SAIC will provide detailed shipping instructions when they would like the vials shipped to a designated location. 

  

	 	2.1.9	Specification: A Certificate of Analysis shall be provided and will include the following test results: pH, conductivity, osmolality and endotoxin (LAL) test results. 

 

	3.	Cost Proposal 

 The pricing for the proposal shall be based upon commercial rates and is inclusive of
costs for supplies and materials. The pricing is broken down as follows: 
 Total Price - $[*] 

Payment Terms – 100% due upon the initiation of testing of the vials. 

Time-scale – Approximately two (2) weeks from commencement. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

-2- 

 

 
  
 SUBCONTRACT AGREEMENT P010022290
Modification 17 
  

					
	SUBCONTRACTOR:	  	 SUBCONTRACT #:
  
	  	P010022290
	  
 Pfenex Inc.

10790 Roselle Street, San Diego, CA

92121
	  	 MODIFICATION #:
  
	  	17
	  	 DPAS RATING:
  
	  	Not Rated
	  	 TYPE:
  
	  	FIRM FIXED PRICE
		  	 COMMERCIAL ITEMS (GOVERNMENT)
  

	 Period of Performance:
  

Sep 11, 2009 thru Sep 21, 2014
	  	 •    Modification
Value:            $0
  

	  	FUNDED:	  	$5,571,012.01
	  	Ceiling VALUE:	  	$6,253,215.75

 The purpose of this modification is to correct the Milestone Chart as shown on Modification 14 to read as shown below. 

Effective date of this modification is October 9, 2012. 
  

							
	 Milestone
	  	 Invoicing
	  	Amount	 
	 Milestone 1: CMO Initiation
	  	 Due upon execution of the contract modification,
	  	$	293.831.06	  
	 Milestone 1a: Technology Transfer
	  	 Due upon execution of Tech Transfer
	  	$	570,377.94	  
	 Project Management Storage & Shipping
	  	 Due upon Initiation of GMP manufacturing run
	  	$	222,354.00	  
		  		  	  
	  
	 
	 Total for modification 14 Activity
	  		  	$	1,086,563.00	  
		  		  	  
	  
	 

 All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 

 

									
	PFENEX INC.	 		 	SCIENCE APPLICATION INTERNATIONAL CORPORATION
			
	 /s/ Patrick Lucy
	 		 	 /s/ Carol Frishman

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick
Lucy                                        date
9/20/12
	 		 	Name:	 	 Carol
Frishman                                date 9/20/12

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Manager

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 1 of 1

 

 
  
 SUBCONTRACT AGREEMENT P010022290
Modification 18 
  

					
	 SUBCONTRACTOR:
  

Pfenex Inc.

10790 Roselle Street, San Diego, CA

92121
	  	 SUBCONTRACT #:
  
	  	P010022290
	  	 MODIFICATION #:
  
	  	18
	  	 DPAS RATING:
  
	  	Not Rated
	  	 TYPE:
  
	  	FIRM FIXED PRICE
	  	 COMMERCIAL ITEMS
  
	  	(GOVERNMENT)
	 Period of Performance:
  

Sep 11, 2009 thru Sep 21, 2014
	  	 •    Modification
Value:            $590,522.25
  

	  	 FUNDED:
  
	  	$6,161,534.26
	  	Ceiling VALUE:	  	$6,253,215.75

 The purpose of this modification is to add incremental funding as shown below. (This is an increase in funding only and is not
for additional scope of work). 
 Effective date of this modification is May 21, 2013. 

The total funded amount is increased FROM $5,571,012.01 BY $590,522.25 TO $6,161,534.26. The ceiling value remains
$6,253,215.75. 
 1.0 PRICE is modified to read as follows: The total not-to-exceed Ceiling Value of Subcontract No. P010022290 is
$6,253,215.75 including profit. This subcontract is incrementally funded for work to be performed through September 21, 2014. The total FUNDING of Subcontract No. P010022290 is $6,161,534.26 including profit. 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 

 

									
	PFENEX INC.	 		 	SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
			
	 s/s Patrick Lucy
	 		 	 s/s Carol Frishman

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick
Lucy                                         
       date
	 		 	Name:	 	 Carol
Frishman                                        
        date

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Administrator

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 1 of 1

 

 
  
 SUBCONTRACT AGREEMENT P010022290
Modification 19 
  

					
	 SUBCONTRACTOR:
  

Pfenex Inc.

10790 Roselle Street, San Diego, CA

92121
	  	 SUBCONTRACT #:
  
	  	P010022290
	  	 MODIFICATION #:        19

 

	  	 DPAS RATING:
  
	  	Not Rated
	  	 TYPE:
  
	  	FIRM FIXED
	  	 PRICE COMMERCIAL ITEMS (GOVERNMENT)
  

	 Period of Performance:
  

Sep 11, 2009 thru Sep 21, 2014
	  	 •    Modification Value:

 
	  	$2,155,708.00
	  	TOTAL FUNDED:        $7,437,162.26
	  	Ceiling VALUE:	  	$8,408,923.75

 The purpose of this modification is to increase the ceiling value and funding value for additional work as stated below. 

Effective date of this modification is September 30, 2013. 

As a result of this modification, the total ceiling value is increased FROM $6,253,215.75 BY $2,155,708.00 TO $8,408,923.75. The
total funded amount is increased FROM $6,161,534.26 BY $1,275,628.00 TO $7,437,162.26. 
 Statement of Work entitled
“Evaluation of [*] Antigen Expression in Pfēnex Expression TechnologyTM and Process Manufacturing” and dated May 20, 2013 is herein incorporated into and made part of Subcontract No. P010022290 as additional work
and is attachment 1 to this modification 19. 
 1.0 PRICE is modified to read as follows: The total not-to-exceed Ceiling Value of Subcontract No.
P010022290 is $8,408,923.75 including profit. This subcontract is incrementally funded for work to be performed through September 21, 2014. The total FUNDING of Subcontract No. P010022290 is $7,437,162.26, including profit. 

This Milestone Activity will commence upon request of SAIC representative in writing only. Payments for this modification 19 will be made in accordance with
the schedule as outlined below. 
 It is understood Payment terms are 50% upon commencement of task and 50% upon acceptance of task draft final report which
includes results of a successful engineering run. A successful engineering run is defined as pilot scale execution of bench-scale process that does not experience any operator error and/or mechanical error that impacts the successful completion of
the run. The product quality from the engineering run needs to be comparable to that of the smaller scale runs and suitable for pre-clinical testing. Master batch records, along with process and analytical data will be outlined in the final Stage 8
report. 
 The estimated pricing for this proposal is inclusive of costs for labor, supplies, materials and reports. 

 

							
	 Stage
	  	Estimated
Timescale	  	Price	 
			
	 Stage 4: Fermentation Development
	  	8 weeks	  	$	200,200	  
			
	 Stage 5: Purification Development
	  	20 weeks	  	$	652,960	  
			
	 Stage 5 materials & service fees
	  		  	$	160,000	  
			
	 Stage 6: BDS Formulation Development
	  	4 weeks	  	$	103,796	  
	 Stage 7: Product-Specific Analytical Method SOP Development
	  	20 weeks	  	$	237,468	  

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 1 of 2

 

 
  

							
	 Stage
	  	Estimated
Timescale	  	Price	 
			
	 Stage 7 materials & service fees
	  		  	$	25,000	  
			
	 Stage 8: Engineering Run (ER)
	  	4 Weeks
 Assumes using
materials purchased
in Stage 5.
	  	$	221,760 per ER	  
	 Stage 9: Stability Study for material from Stage 8: Engineering Run
	  	16 weeks	  	$	263,648	  
	 Stage 10: Process Transfer and Training
	  	8 weeks	  	$	260,876	  
			
	 CMC Support
	  	3 weeks	  	$	30,000	  
		  		  	  
	  
	 
			
	 Total Price:
	  		  	$	2,155,708	  
		  		  	  
	  
	 

 17.0 ORDER OF PRECEDENCE – is modified to read as follows: 

The documents listed below are hereby incorporated by reference. In the event of an inconsistency or conflict between or among the provisions of this
Subcontract, the inconsistency shall be resolved by giving precedence in the following order: 
  

	 	1.	Attachment I: Statement of Work and Schedule dated May 20, 2013, Mod 19. 

  

	 	2.	Statements of Work and Schedules as follows: 

 Modifications -15 dated 5/4/12, 14 dated 6/22/12,
13 dated 6/15/12, 12 dated 2/6/12, 6 dated 6/1/11, 5 dated 1/1/11, 4 dated 11/15/10, 2 dated 5/4/10 and original dated 5/11/11 respectively. 
  

	 	3.	Schedule A: Specific Terms and Conditions Form 9-932-072 (Rev. 9/25/06). 

  

	 	4.	Schedule B: U.S. Government Terms and Conditions, Part III – FAR Clauses Form 9-932-082 (Rev. 07/25/07). 

  

	 	5.	Attachment C: (Enclosure 2; (Rev. 4/2009) Property Administration Requirements For Subcontractors With An Adequate System Or Requisite Internal Controls. 

All other Subcontract terms and conditions remain unchanged. 

In witness whereof, the duly authorized representatives of Buyer and Seller have executed this Subcontract Modification on the dates shown. 

 

									
	PFENEX INC.	 		 	SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
			
	  
	 		 	  

	(Signature)	 		 	(Signature)
					
	Name:	 	 Patrick
Lucy                                         
       date
	 		 	Name:	 	 Carol
Frishman                                        
        date

	(Type or Print)	 		 	(Type or Print)
					
	Title:	 	 Vice President of Business Development
	 		 	Title:	 	 Subcontracts Administrator

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 

	
	Page 2 of 2

 Statement of Work 

Evaluation of [*] Malaria Antigen Expression in Pfēnex Expression TechnologyTM 

and Process Manufacturing 

Malaria Vaccine Production and Support Services 

May 20, 2013 

Subcontract Modification 
  

	1.	Scope of Work 

 Independently and not as an agent of SAIC, Pfenex shall furnish all of
the necessary services, qualified personnel, materials, equipment, and facilities for the full development of a manufacturing process for the [*] clone using Pfēnex Expression TechnologyTM and technical transfer of the process to a
SAIC designated cGMP manufacturing facility with processing capabilities and equipment compatible with the upstream and downstream process developed by Pfenex. The process shall be suitable for a scale up, at a minimum, of a [*] scale and follow-on
purification, upon transfer. As part of this project, Pfenex is required to provide related meeting support, reports, and deliverables as listed in Table 1. 
  

	 	1.1.	SAIC will provide the following information and materials: 

  

	 	•	 	Background literature/references relating to Rh5. 

  

	 	•	 	Additional [*], if required. 

  

	 	•	 	Shipping instructions for [*] and other materials. 

  

	2.	Technical Requirements 

 As a follow-on to the successful production, testing, and
selection of a [*] line under the original subcontract and Mod 12 which was composed of: (i)-Evaluation of Rh5 expression (Stage 1), (ii)-Fermentation assessment of Rh5 (Stage 2), (iii)-Rh5 purification (Stage 2A/Mod 12) and (iv)-Preparation and
characterization of [*] (RCB) (Stage 3); SAIC now requires Pfenex to develop a manufacturing process suitable for a scale up, at a minimum, of a [*] scale and follow-on purification for the SAIC selected clone [*] and technical transfer of the
process to a SAIC designated cGMP manufacturing facility with processing capabilities and equipment compatible with the upstream and downstream process developed by Pfenex. 
  

	 	2.1.	Stage 4: Fermentation Optimization of cell line [*] 

  

	 	2.1.1.	Pfenex shall apply computer-aided, statistically-based design of experiments (DoE) to examine fermentation parameters for [*] expression. Design and execute 2-level fractional factorial experiments to screen up to five
(5) factors (e.g. pH and temperature) for [*] expression in an 8-unit multiplex 1L bioreactor system. 

 Please
Note: Appropriate samples for yield determination and analysis will be collected throughout the fermentation runs. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 1 of 10 

	 	2.1.2.	Perform the appropriate analysis on selected pre- and post-induction samples taken from the fermentations. 

  

	 	2.1.3.	Use JMP statistics software to analyze the data. Based on the conclusions, design a confirmation round of experiments up to a total of 32-40 X 1L fermentations. 

 

	 	2.1.4.	Evaluate Rh5 titer and quality on selected samples utilizing ELISA and western blot analysis development from Stage 7 Product Specific Analytical Method Development. 

 

	 	2.1.5.	The optimized fermentation condition shall be confirmed in up to three rounds at 3 X 20L scale per round. 

  

	 	2.1.6.	The optimized fermentation shall produce material which can be subsequently purified to meet product quality and safety specifications required for human use when produced under cGMP conditions. 

 

	 	2.1.7.	A technical study report shall be issued following the completion of the work. 

  

	 	2.1.7.1.	Pfenex shall submit the optimized fermentation procedure/protocol to SAIC for review and approval. 

  

	 	2.1.7.2.	Document shall also contain, at a minimum, in process parameters examined, rational for parameters selected, and copies of the raw data. 

 

	 	2.2.	Stage 5: Purification Process Development 

  

	 	2.2.1.	Pfenex shall develop a cGMP ready downstream purification process. 

  

	 	2.2.2.	Pfenex shall perform up to six rounds of [*] working volume) fermentation runs to supply cell paste for the experiments outlined in this stage of work. 

 

	 	2.2.3.	Pfenex shall develop a downstream purification process based on lessons learned from Stage 2A (Rh5 research-grade purification strategy). 

 

	 	2.2.4.	Pfenex shall design and execute a fractional factorial design to optimize protein release and purity [*]. 

  

	 	2.2.5.	Pfenex shall evaluate efficiency (throughput, purity, recovery) of bulk separation of [*]. 

  

	 	2.2.6.	Pfenex shall develop centrifugation, clarification, and filter train that will permit the material containing Rh5 [*]. 

  

	 	2.2.7.	Pfenex shall analyze samples taken throughout the primary recovery development for Rh5 yield and purity. 

  

	 	2.2.8.	Pfenex shall utilize the process intermediate from 2.2.7 to design and execute a resin screen (microtiter plate scale) for the primary capture chromatography step. Up to [*] resins will be screened for the best
conditions for capacity. The best two resins will be screened in a second round using up to [*] to determine selectivity. 

  

	 	2.2.9.	Pfenex shall compare screening leads from 2.2.8 using test gradients and method scouting at small scale and rank performance with an emphasis on determining operating parameters (e.g., capacity, resolution, and yield)
for protein with that resin 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 2 of 10 

	 	2.2.10.	The primary column resin and associated conditions selected from 2.2.9 will be optimized further for chromatography scale up and implemented at pilot scale. 

 

	 	2.2.11.	Pfenex shall utilize the elution pool from 2.2.10 to design and execute a resin screen for the second chromatography step. Up to [*] will be screened for the best capacity and selectivity. The best resin will be
screened in a second round using up to [*] for efficiency and selectivity. 

  

	 	2.2.12.	Pfenex shall compare screening leads from 2.2.11 using test gradients and method scouting at small scale and rank performance with an emphasis on determining operating parameters (e.g., capacity, resolution, and yield)
for protein with that resin. 

  

	 	2.2.13.	The second column resin and associated conditions selected from 2.2.12 will be optimized further for chromatography scale up and implemented at pilot scale. 

 

	 	2.2.14.	Pfenex shall utilize the elution pool from 2.2.13 to design and execute a resin screen for the polishing chromatography step. Up to [*] will be screened for the best capacity and selectivity. The best resin will be
screened in a second round using up to [*] for efficiency and selectivity. 

  

	 	2.2.15.	Pfenex shall compare screening leads from 2.2.14 using test gradients and method scouting at small scale and rank performance with an emphasis on determining operating parameters (e.g., capacity, resolution, and yield)
for protein with that resin. 

  

	 	2.2.16.	The polishing column resin and associated conditions selected from 2.2.12 will be optimized further for chromatography scale up and implemented at pilot scale. 

 

	 	2.2.17.	Purified Rh5 from 2.2.16 will be buffer exchanged into the final drug substance buffer determined in Stage 6 using tangential flow filtration (TFF). TFF parameters will be optimized to minimize processing time while
maintaining product quality. 

  

	 	2.2.18.	For each downstream unit operation, Pfenex shall conduct hold studies to determine process intermediate stability. 

  

	 	2.2.19.	Pfenex shall perform analysis during development that may include [*]. 

  

	 	2.2.20.	Pfenex shall perform a pilot scale integrated purification run to confirm scale-up parameters and overall process performance. 

  

	 	2.2.20.1.	Pfenex shall collect and analyze intermediate samples taken during the integrated run for protein yield, purity and contaminant profile. 

 

	 	2.2.20.2.	Pfenex shall provide purified Rh5 produced from the integrated run to SAIC or its designee. 

  

	 	2.2.20.3.	Pfenex shall perform analysis of integrated run final material that may include [*]. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 3 of 10 

	 	2.2.21.	Pfenex shall submit the developed purification process procedures and protocols to SAIC for review and approval before moving forward to engineering run (Stage 8). 

 

	 	2.2.21.1.	Document shall also contain, at a minimum, processes examined, rational for processes selected, and copies of the raw data. 

  

	 	2.2.22.	Pfenex shall ship purified Rh5 generated during development to a SAIC designated facility; however, Pfenex may retain all or a portion of the material produced for subsequent studies. 

 

	 	2.3.	Stage 6: BDS Formulation Development 

  

	 	2.3.1.	With material generated from Stage 5 Purification Process Development, Pfenex shall screen and evaluate at a minimum [*] that are compatible with Rh5. 

 

	 	2.3.1.1.	Components/pH in the buffer systems should be suitable for human use and may include stabilizing excipients. 

  

	 	2.3.1.2.	Pfenex will measure compatibility of the buffer systems using SEC-HPLC and/or other stability indicating assays. 

  

	 	2.3.2.	Pfenex shall confirm the selected buffer systems to monitor quality changes of rRh5 using SEC-HPLC and SDS-PAGE. 

  

	 	2.3.3.	Pfenex shall perform a short-term stability monitoring of selected, suitable buffer systems(s) to monitor quality changes of Rh5 using SEC-HPLC and/or other stability indicating assays. 

 

	 	2.3.3.1.	Short term stability monitoring shall include the following temperature and time points: 

  

					
	 Stress
	  	 Conditions
	  	 Time Point(s)

	Temperature	  	-70°C; 5°C; 25°C; 40C	  	Day 0, 1, 2

  

	 	2.3.3.2.	Repeated freeze/thaw stress in 3-cycles. 

  

	 	2.3.4.	Upon SAIC’s request, Pfenex shall provide Rh5 in the selected buffer system and concentration to SAIC for further testing 

  

	 	2.3.5.	Pfenex shall issue a final report. The report shall include an executive summary, detailed description of methods including system suitability controls, list of all raw materials and their source, results, conclusions,
inventory of reagents provided by SAIC, and all raw data in PDF format. 

  

	 	2.4.	Stage 7: Product Specific Analytical Method Development 

  

	 	2.4.1.	Pfenex shall develop product specific in-process and final product analytical methods and provide standard operating procedures (SOPs) for each method. 

Please Note: Method qualification may be performed as optional. 

 

	 	2.4.2.	Pfenex shall establish acceptance criteria and specifications in consultation with SAIC, where applicable, that will be the basis for release and stability monitoring. The specifications shall be appropriate for a Phase
1 clinical product. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 4 of 10 

	 	2.4.3.	For in-process testing of low purity fermentation and purification samples, the testing shall include: [*]. 

  

	 	2.4.4.	For release testing of bulk drug substance, the testing shall include: [*], endotoxin, and suitable process specific assays such as detection of impurities. 

 

	 	2.4.5.	For characterization of bulk drug substance, the testing shall include: [*]. 

  

	 	2.4.6.	Pfenex shall recommend and submit the developed analytical and characterization testing, including procedures, protocols, and their results, to SAIC for review and approval. 

 

	 	2.4.7.	(Optional) Analytical method qualification shall be performed on methods developed. 

  

	 	2.4.7.1.	Qualification protocols and report template shall be issued for review and approval 

  

	 	2.4.7.2.	Qualification report shall be issued and include data and summary tables. 

  

	 	2.5.	Stage 8: Engineering Run 

  

	 	2.5.1.	Pfenex shall perform a complete engineering run at the 20 L (10 L w/v) scale to ensure reproducibility of previously drafted procedures. 

 

	 	2.5.2.	Pfenex shall develop master batch production records (BPRs) for the engineering run that covers all of upstream and downstream process, and identifies where the in-process tests occur and what volume is removed for
testing. SAIC will be provided copies of the master BPRs for review and approval prior to use. 

  

	 	2.5.3.	Pfenex shall submit the completed BPRs to SAIC upon the completion of the engineering run. 

  

	 	2.5.4.	Pfenex shall execute the release and characterization testing as accomplished in Stage 7 for the engineering run material. 

  

	 	2.5.5.	Pfenex shall set aside aliquots for the stability program described below, and ship the remaining purified Rh5 from the engineering run to a SAIC designated facility in aliquots to be determined at a later
timepoint. 

  

	 	2.5.6.	(Optional) Pfenex may perform additional engineering run(s) if required by SAIC 

  

	 	2.5.6.1.	Pfenex shall develop master batch production records (BPRs) for the engineering run that covers all of upstream and downstream process, and identifies where the in-process tests occur and what volume is removed for
testing. SAIC will be provided copies of the master BPRs for review and approval prior to use. 

  

	 	2.6.	Stage 9: Stability Program 

  

	 	2.6.1.	Pfenex shall conduct a non-GMP stability monitoring of the purified Rh5. Pfenex shall submit the stability monitoring plans for the engineering run to SAIC for review and approval. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 5 of 10 

	 	2.6.2.	The stability of purified Rh5 from the engineering run shall be evaluated for stability at conditions of -70°C, 2°C–8°C, 25°C/60% relative humidity (RH), and 40°C/75% RH at month-0, 1,2, and 3.
Note: T=0 initial testing is covered in Stage 8: Engineering Run. 

  

									
	 Method/Test

-70°C, 5°C, 25°C/60% relative humidity (RH), 40°C/75% RH
	  	Initial
Testing
(T=0)	  	1 mo	  	2 mo	  	3 mo
	 [*]
	  	X	  	X	  	X	  	X
	 [*]
	  	X	  	X	  	X	  	X
	 [*]
	  	X	  	X	  	X	  	X
	 [*]
	  	X	  	X	  	X	  	X
					
	 [*]
	  	X	  	X	  	X	  	X
	 [*]
	  	X	  	X	  	X	  	X
	 [*]
	  	X	  	X	  	X	  	X
	 [*]
	  	X	  	X	  	X	  	X
	 [*]
	  	X	  	X	  	X	  	X
	 [*]
	  	X	  	X	  	X	  	X
	 [*]
	  	X	  	X	  	X	  	X
	 [*]
	  	X	  	X	  	X	  	
	 [*]
	  	X	  	X	  	X	  	
	 [*]
	  	X	  		  		  	X

  

	 	2.6.3.	Stability monitoring assessment shall include: pH, SDS-PAGE/CGE, RP-HPLC, SE-HPLC, peptide mapping by mass spectrometry, intact mass, capillary isoelectricfocusing (CIEF), circular dichroism, Intrinsic fluorescence.

  

	 	2.6.4.	A stability report shall be submitted to SAIC at each stability timepoint and include, at minimum, assays utilized with associated SOP, test results in table format, conclusion, trending data, and copies of raw data.

  

	 	2.7.	Stage 10: Process Training and Transfer 

  

	 	2.7.1.	Pfenex shall train SAIC’s cGMP contract manufacture organization (CMO) on the manufacturing process and shall transfer the BPRs (master and completed) and analytical method SOPs. 

 

	 	2.7.2.	As part of the process training and transfer Pfenex shall conduct at least one successful training run. 

  

	 	2.7.3.	The process yield from the process training run shall be within acceptable scientific variation from the engineering run performed in Stage 8. 

 

	 	2.7.4.	The process training run shall demonstrate within acceptable scientific variation reproducibility as compared to Stage 8, in all up- and down-stream processes including: growth rate in fermentation, quantity and
quality of Rh5 in lysate, in primary recovery, in each process step, and in final product. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 6 of 10 

	 	2.7.5.	Pfenex shall provide to SAIC and to SAIC designated CMO the RCB and a full process transfer package with all information necessary for the transfer of the manufacturing process. 

 

	 	2.7.6.	The full process transfer package shall include the following items: 

  

	 	2.7.6.1.	Bill of materials and suggested suppliers 

  

	 	2.7.6.2.	Detailed fermentation and purification process procedures (master BPRs) 

  

	 	2.7.6.3.	Listing of instruments/equipment 

  

	 	2.7.6.4.	Detailed testing procedures (SOPs) 

  

	 	2.7.6.5.	Technical specification for the bulk drug substance 

  

	 	2.7.6.6.	Health/Safety/Environment assessment of all materials and process 

  

	 	2.7.6.7.	Detailed characterization of purified protein/buffer and intermediates 

  

	 	2.7.6.8.	Stability testing plan and final report 

  

	 	2.7.6.8.1.	Research cell bank growth parameters and technical information 

  

	 	2.7.6.8.2.	Construct expression information and test results 

  

	 	2.7.7.	The process transfer and associated training records for the transfer to the clinical CMO shall be well documented and be provided to SAIC in the final report. 

 

	 	2.8.	CMC Support  

  

	 	2.8.1.	Pfenex shall provide support in reviewing CMC sections and documents related to IND submission including details of the cloning and development of the expression strain CS672-3057. 

 

	3.	Quality Requirements 

 In addition to the Quality Requirements stated in the SOW, Pfenex
shall execute a Quality Management Plan suitable for process development and technical transfer (see Section 10). 
  

	 	3.1.	Pfenex shall provide a scientific, technical, and administrative infrastructure to ensure quality control of all process development and technical transfer activities. 

 

	 	3.2.	The quality management plan shall include use of any materials, instruments/equipment, methods, procedures utilized in the process development and technical transfer. 

 

	 	3.3.	At a minimum, Pfenex shall ensure: 

  

	 	3.3.1.	Facilities in which SAIC’s materials are maintained in a safe and secure manner and allow limited access. 

  

	 	3.3.2.	Personnel have the necessary education and training in all procedures relevant to work assignments; training and qualifications are verified by leadership of Pfenex. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 7 of 10 

	 	3.3.3.	SOPs will be used to document policies and procedures. SOPs will be version controlled and approved by key personnel. 

  

	 	3.3.4.	An effective tracking/tracing system or procedure is in place for all materials and equipment used in this contract. 

  

	 	3.3.5.	Equipment calibration and maintenance are performed as required and are documented. 

  

	 	3.4.	The Quality Management Plan shall govern Pfenex’s commitment to quality and ensure that procedures addressing the following requirements are in place. 

 

	 	3.4.1.	SOPs 

  

	 	3.4.2.	Document/version control 

  

	 	3.4.3.	Equipment maintenance and repair 

  

	 	3.4.4.	Training: adherence of staff to required schedules 

  

	 	3.4.5.	Data management 

  

	 	3.4.6.	Record management system 

  

	 	3.4.7.	Safety plan 

  

	 	3.4.8.	Asset tracking and management 

  

	 	3.4.9.	Building and facility monitoring 

  

	 	3.4.10.	Adherence to Federal or other applicable regulatory requirements appropriate for work on this contract 

  

	 	3.4.11.	Operational deviations and failures will be investigated through root cause analysis, which will be documented. 

  

	 	3.5.	Cold/frozen and controlled temperature storage chambers have continuous monitors with alarms or are monitored at least every 4 hours by security staff. Any deviations will be immediately reported to Pfenex staff.

  

	 	3.6.	Effective cold chain management practices are in place for the handling of materials, products and samples. 

  

	 	3.7.	Investigation are initiated upon incident discovery (excursion from written procedure, policy, or protocol). Upon request, copies results of investigations are submitted to SAIC for review. 

 

	 	3.8.	SAIC may schedule in-plant and other visits at Pfenex to audit quality of activities conducted in this contract. 

  

	4.	Record Management Requirements 

 Pfenex shall maintain a record management system
suitable for process development and technical transfer (see Section 10, Quality Management Plan). 
  

	 	4.1.	Pfenex shall have a record management system that permits detailed records to be made concurrently with the performances of each process development activity. 

 

	 	4.2.	Records and documents shall be created and maintained in a manner that allows version control, handling steps, tests, retests, investigations, data, and results. 

 

	 	4.3.	Record and document security systems shall be adequate to ensure confidentiality and privacy of proprietary information. Confidential or proprietary information shall be restricted to staff with a need for access and
inspectors from regulatory agencies. Records shall be readily accessible for inspection by authorized personnel from SAIC. 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 8 of 10 

	 	4.4.	Records and documents shall be maintained for a minimum of 5 years after the completion of process development and technical transfer. SAIC shall be contacted for disposal or transfer instructions at the end of a
records storage period or at the end of the subcontract POP. 

  

	 	4.5.	Electronic records shall be backed up daily on a separate server or network. Weekly backups shall be stored on an appropriate media, e.g., CD, tape, and stored off-site. 

 

	 	4.6.	Corrections or changes in a record shall be made in accordance with a quality monitoring procedures suitable for managing process development and technical transfer. 

 

	 	4.7.	Unless alternate agreements are made, all raw data and laboratory notebooks related to this subcontract shall be made available to SAIC upon request. 

Table 1. Deliverables to SAIC 
  

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	 Form

	1	  	Technical	  	Purified Rh5 from process development	  	Within a week of completion	  	Sent to SAIC designee in proper shipping containers with a temperature monitor
	2	  	Technical	  	Purified Rh5 from engineering run	  	Within a week of completion	  	Sent to SAIC designee in proper shipping containers with a temperature monitor
	3	  	Technical	  	Unused reagents provided by SAIC	  	Within 2 weeks of SAIC request	  	Sent to SAIC designee in proper shipping containers
	4	  	Technical	  	Optimized fermentation procedure and protocols	  	Within 3 week of completion	  	PDF or Word document
					
	5	  	Technical	  	Selected primary recovery method	  	Within 3 week of completion	  	PDF or Word document
	6	  	Technical	  	Purification process procedures and protocols	  	Within 3 week of completion	  	PDF or Word document
	7	  	Technical	  	Recommended analytical and characterization testing	  	Within 3 week of completion	  	PDF or Word document
					
	8	  	Technical	  	Master BPRs for the engineering run	  	2 weeks prior to initiation	  	PDF or Word document

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 9 of 10 

									
	 Deliverable
	  	 Requirement
	  	 Item
	  	 Date*
	  	 Form

	9	  	Technical	  	Master BPRs for the second engineering run, etc	  	2 weeks prior to initiation	  	PDF or Word document
					
	10	  	Technical	  	Completed BPRs for the engineering run	  	Within 3 week of completion	  	PDF or Word document
	11	  	Technical	  	Completed BPRs for the second engineering run, etc	  	Within 3 week of completion	  	PDF or Word document
	12	  	Technical	  	Stability monitoring plans for engineering run(s)	  	2 weeks prior to initiation	  	PDF or Word document
	13	  	Technical	  	stability reports	  	3 week following each indicated time point	  	PDF or Word document
	14	  	Technical	  	Full Process transfer package	  	4 weeks following completion of engineering run	  	PDF or Word document
	15	  	Reporting	  	Biweekly Meeting and minutes	  	Meeting as scheduled, minutes within a week of the meeting	  	Telecom
	16	  	Reporting	  	Monthly Reports	  	Due by the 8th of each month during the performance of work efforts	  	PDF or Word document
					
	17	  	Reporting	  	CMC Support	  	Final: 3 weeks after receipt of SAIC CMC sections provided for review	  	Draft: Word Document

  

	*	Days = Calendar days 

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

Page 10 of 10 

 

 
 October 29, 2013 

Pfenex Inc. 
 10790 Roselle Street 

San Diego, CA 92121 
  

	Attention:	Patrick Lucy, Vice President of Business Development and Marketing 

  

	Subject:	Modification No. 20 

  

	Reference:	(a) SAIC Subcontract P010022290 

 Dear Mr. Lucy: 

In 2012, SAIC, Inc. announced plans to separate into two independent, publicly-traded companies. This separation was approved by the SAIC Board of
Directors and will occur on 28 September 2013. The legacy company (SAIC, Inc.) will operate under the name Leidos, Inc., and will continue to use the original Home Office CAGE Code and DUNS Number. 

Therefore, this unilateral modification, effective 28 September 2013, to Reference (a) Subcontract is issued to amend “Science Applications
International Corporation” (SAIC) to “Leidos, Inc.”. All references in the Reference (a) Subcontract to “SAIC” are hereby amended to “Leidos.” 

 

	
	Sincerely,
	
	 s/s Carol Frishman

	
	Carol Frishman
	Subcontracts Administrator | Leidox, Inc.
	Phone: 240-529-0438
	Carol.c.frishman@leidos.com

  
 [*] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
 Page 1 of 1 

The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or 

privileged material. If you received this in error, please contact the sender and delete the material from any computer.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]